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The cadre of small molecule metabolites in a cell, aka the “metabolome,” is the final 
output of the genome and ultimate determinant of cell phenotype (DNA → RNA → 
protein → metabolite → phenotype). In addition to a genetic contribution, the 
metabolome is conditioned by diet, lifestyle and composition of the microbiome - 
ultimately determining health vs. disease status. Therefore, the profiling of small 
molecule levels using mass spectrometry-based metabolomic analyses can contribute 
significantly to our understanding of disease processes, enable confident molecular 
diagnoses, monitor the efficacy of therapies, and serve many other biomedical 
applications. Here, we discuss applications and considerations for the use of targeted 
and untargeted metabolite profiling using mass spectrometry.  This topic is presented 
in the context of three independent research studies, described herein. First, we 
describe the use of targeted metabolomics to characterize the endocannabinoid system 
in a mouse model of alcohol “binge” drinking. We show that anandamide, one of the 
primary endogenous agonists of the cannabinoid receptor, along with several other 
endocannabinoids, increase in response to acute alcohol withdrawal. Further, we 
consider the biological significance of these observations. Second, we describe the use 
of mass spectrometry-based untargeted metabolite profiling and stable isotope tracing 
for defining metabolic perturbations that occur in the setting of sporadic amyotrophic 
lateral sclerosis (sALS), considering discoveries made with patient-derived skin 
fibroblasts. Using a multiomic approach, this study identifies and characterizes a 
  
distinct subgroup of sALS patients, possessing fibroblasts that are typified by 
enhanced transsulfuration pathway activity and glucose hypermetabolism. We 
speculate that this sALS patient subclass will prove to be selectively responsive to 
anti-oxidant therapies and therefore a recognition of this patient subclass may allow 
for the future establishment of personalized medicines. Finally, we discuss efforts to 
characterize solute carrier 25 (SLC25) family mitochondrial transporters using 
CRISPR knockout cell lines and a heterologous bacterial overexpression system-based 
protocol. These studies utilize mass spectrometry and stable isotope-labeled 
compounds in attempt to recognize potential biological substrates for these 
transporters.
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INTRODUCTION: MASS SPECTROMETRY-BASED 
METABOLOMICS 
 
Metabolomics: small molecules, big deal 
Metabolomics, or metabolite profiling, seeks to survey diverse small molecules 
in a biological sample for changes in relative abundances. Importantly, small molecule 
levels are the most direct determinant of phenotype in biological systems, 
distinguishing physiology from pathophysiology [Aretz et al. 2016]. For this reason, 
the study of the ebbs and flows of metabolite abundances is crucial for furthering our 
understanding of practically all normal and abnormal biological processes. However, 
metabolomic analyses present unique challenges - unlike DNA, RNA and proteins that 
are built of a defined set of repeating elements, metabolite structures and their physical 
properties are extremely varied, incompletely defined, and turnover can be rapid [de 
Koning et al. 1992; Lu et al. 2017]; the Human Metabolome Database (HMDB) 
includes >8000 known detected compounds and >80,000 compounds that are 
predicted [Wishart et al. 2018].  This makes the isolation, detection and interpretation 
of abundances for these important biological players a distinctly complicated task, 
explaining why access to this knowledge has only recently become accessible. Indeed, 
over the past few years, technological advances have enabled remarkable ability to 
quantify metabolites with ever-increasing ease, accuracy and sensitivity and have 
pushed metabolomics to the forefront of next-generation research [Beger et al. 2016]. 
Mass spectrometry is a powerful analytical tool for metabolism-centered 
biomedical research and clinical application that has gained considerable prominence 
and capabilities over the past decade (Figure I.1).  
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Figure I.1. Interest in and use of mass spectrometry metabolomics is growing 
rapidly. Number of publications per year containing “mass spectrometry” 
and “metabolomics” in the title or abstract are shown (PubMed). 
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Mass spectrometry detection relies on the ionization of compounds and 
quantification as ion counts, based on mass-to-charge ratio (m/z). The ability to 
quantify metabolite abundances using mass spectrometry in either a targeted or 
untargeted manner provides for both hypothesis-testing and hypothesis-generation. In 
this Introduction, I discuss the current state of mass spectrometry-based metabolite 
profiling (aka metabolomics), considering sample preparation, liquid chromatography 
first-dimension separations, data collection, data analysis and data interpretation. I will 
also discuss related topics, such as stable isotope tracing, multi-omic data integration 
and next-generation MS applications/methods. In the three chapters that follow this 
Introduction, I will describe research applications that include the use of both targeted 
and untargeted metabolite profiling, highlighting examples of the triumphs and 
challenges of mass spectrometry-based metabolite profiling strategies in biomedical 
research. 
 
Metabolite extraction and sample preparation for metabolomics analysis 
 Once the overall experiment design for a metabolomic study has been 
established, the next step in experimental workflow is to define an appropriate sample 
preparation strategy (Figure I.2). Metabolite profiling is extremely versatile and can be 
performed on a variety of samples for a vast number of purposes, ranging from 
environmental toxicology to cancer biomarker discovery [Bundy et al. 2009; Armitage 
et al. 2014]. For biomedical research, metabolites are most often harvested for analysis 
from biological fluids (e.g. urine, plasma, CSF), tissue biopsies (e.g. skin, liver, 
kidney) and cells grown in culture. 
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Metabolites of interest are commonly extracted from a relevant biological 
source using a suitable solvent and disruption method. For biofluids, samples can 
generally be directly diluted into a suitable solvent, diluting interfering salts and 
precipitating insoluble proteins/DNA, then centrifuged and analyzed using liquid 
chromatography(LC)-coupled mass spectrometry [Vuckovic et al. 2012; Vuckovic et 
al. 2013]. We employ this simple methodology for plasma metabolomics in Chapter 2 
and show sufficient metabolite coverage for comparison with cell extract-derived 
metabolite findings. The relatively slow LC component of LC/MS-based profiling can 
sometimes be omitted and replaced by direct flow-injection of sample extracts for MS-
only analysis. Alternatively, more complicated metabolite enrichment protocols, such 
as solid phase extraction (SPE), may be required for detection of particular metabolites 
of interest [Dettmer et al. 2007]. 
For analysis of adherent cells grown in culture, culture media is commonly 
removed by aspiration, and cells are then washed sequentially with a buffer (e.g. 
phosphate-buffered saline; PBS), to limit metabolite carry-over from culture medium, 
and ddH2O, to reduce salt levels that otherwise diminish MS sensitivity. In an 
experiment comparing the efficacy of 1, 2 or 3 rapid water washes, I determined that 2 
rapid water washes is optimal for reducing ion suppression while providing for 
reproducible detection of a broad array of endogenous metabolites (Figure I.3). Often, 
ice cold buffer and water are used to slow metabolism during the process of metabolite 
extraction, although the effects of cold-shock on cell metabolism warrants 
consideration [Lu et al. 2017; Wittmann et al. 2004; Wellerdiek et al. 2009]. 
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Regardless, cold wash steps should be as swift as possible in order to both 
rapidly quench metabolism and minimize the potential cell-leakage of otherwise 
informative metabolites. 
Following all cell-wash steps, metabolites can be extracted by scrape-
harvesting cells in a suitable solvent, often water with an organic solvent or a mixture 
of organic solvents (e.g. 80:20 methanol:water). Dettmer et al. explored the use of 
various extraction solvents with adherent mammalian cells and determined that ultra-
cold 80:20 methanol:water maximizes overall metabolite yields [Dettmer et al. 2011]. 
Cold extraction solvents, to quench metabolism, or hot solvents, to denature proteins 
can alternatively be employed for metabolomic sample preparation [Dettmer et al. 
2011; Sellick et al. 2010; Hiller et al. 2007; Winder et al. 2008]. Consistent with these 
findings, I employ -70°C 80% methanol as an extraction solvent for untargeted 
metabolomics experiments unless application-specific knowledge dictates otherwise 
(e.g. to assess changes in the abundance of specific lipid classes). Depending on the 
cell/tissue type, a disruption method may be additionally needed for efficient 
extraction of metabolites of interest. Cell/tissue extraction methods may include 
vortexing, cycles of free/thaw, sonication, and bead-beating. In any case, care must be 
taken to maintain a low temperature during extraction and to minimize processing 
time in order to limit potential metabolite degradation. Cell debris and precipitated 
proteins are removed from sample extracts by centrifugation. 
For metabolomic analysis of tissues, tissue are dissected, minced and flash-
frozen in either liquid nitrogen, or dry ice/acetone. Various homogenization 
techniques can be subsequently employed, but stainless steel bead-beating is 
commonly use (as herein) as an efficient technique that allows multiple samples to be 
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extracted simultaneously [Beckonert et al. 2007; Römisch-Margl et al. 2012; Wu et al. 
2008; Want et al. 2013]. The method and duration of homogenization for metabolomic 
sample preparation is tissue-dependent. For example, brain tissue, which is relatively 
soft, requires far less physical force for effective disruption than kidney, a relatively 
connective tissue-rich tissue. After metabolite extraction, remaining debris and 
precipitated protein/DNA can be effectively pelleted and removed by centrifugation. 
Depending on the specific metabolite profiling application, sample pre-
treatment can be performed using techniques that include liquid-liquid extraction, 
solid phase extraction, and electromigration [Raterink et al. 2014]. These methods can 
serve to enrich the metabolites of interest by diminishing contaminant levels or 
isolating compound classes of specific interest. With SPE, for example, metabolite 
extracts are exposed to a resin that selectively retains certain classes of molecules 
(such as hydrophobic lipids on a C18 resin), allowing for the removal of salts and 
other impurities that may interfere with MS data acquisition. Notably, these strategies 
can only be employed if specific compounds with similar properties are of interest and 
not in a completely untargeted experiment. The benefits of increased purity and 
metabolite enrichment should be weighed against the required time and expense and 
effect on the integrity of samples for analysis. As I show in subsequent Chapters 1-3, 
further purification is often not necessary to quantify relative abundances of a diverse 
array of metabolites in biosamples. 
As noted above, metabolite extracts must often be concentrated to increase the 
detection of compounds that are either present in relatively low abundance, or which 
ionize poorly. To address this potential analytical limitation, metabolite extracts are 
often dried using a vacuum centrifuge or lyophilizer [Lu et al. 2017]. This also allows 
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samples to be normalized by varying reconstitution volumes (e.g. based on protein or 
DNA content) to correct for variation in cell number or tissue mass. Toward this end, 
samples are reconstituted in a suitable solvent for injection into the LC/MS analytical 
system. The degradation of sample metabolites (yielding new non-biologically-derived 
metabolites) is a key concern at this step. If a metabolite of interest is known to be 
sensitive to sample dry-down, this sample preparation step will obviously need to be 
avoided. Regardless, samples from all treatment groups must be directly comparable 
and prepared in an identical manner. Ideally, following data analysis, metabolites of 
interest should be confirmed to not be artifacts of sample dry-down. 
 
Chromatography 
 Chromatography is often employed as a first-dimension metabolite separation 
approach prior to electrospray ionization for MS-based analyte quantification. There 
are two primary reasons for a chromatography front end. First, it attenuates ionization-
related issues, such as ion suppression and enhancement, thereby increasing MS 
detection sensitivity and reducing data variation. Metabolites compete for charge 
during the ionization process and, therefore, separating metabolites based on 
chromatographic retention time (RT) increases the extent to which metabolites enter 
the MS system for detection [Annesley 2003; Jessome et al. 2006; Furey et al. 2013]. 
Second, although mass spectrometers have achieved impressive resolution 
capabilities, metabolites with sufficiently similar or identical masses (in the case of 
structural isomers) cannot be discerned based on m/z alone. In these cases, 
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chromatographic retention time adds another dimension for confident compound 
identification [Jang et al. 2018]. 
 There are two major types of chromatography used in combination with MS, 
liquid chromatography (LC) and gas chromatography (GC), which both have 
advantages and disadvantages. GC can be used for separation of volatile compounds, 
or those which can be chemically derivitized to be made volatile. It is highly 
reproducible, including reproducible fragmentation that leads to easier compound 
identification using available databases (e.g. NIST). However, derivatization to 
produce volatile compounds can be time consuming and can lead to confounding 
factors, such as incomplete conversion or generation of multiple species for a given 
metabolite. Also, the requirement of volatilization means that GC-MS is suitable for 
fewer compounds and therefore results in more limited coverage [Theodoridis et al. 
2012]. 
 LC-MS, on the other hand, is suitable for the separation and detection of far 
more compounds and is therefore widely used for metabolite profiling. Although 
sample run times can be relatively long (usually 20-40 min) and ion suppression is a 
technical concern, samples do not require derivatization, which simplifies sample 
preparation and increases coverage capabilities. In terms of LC, there are two general 
resin types used in the columns, hydrophobic or “reversed-phase” (RP), and 
hydrophilic, or “normal phase.” These chromatographic matrices are complimentary in 
that they retain molecule with opposite biophysical properties. RPLC columns retain 
relatively hydrophobic species, with low to moderate polarity, whereas normal phase 
columns preferably retain charged metabolites with high polarity. Unfortunately, no 
one extraction/chromatography method is sufficient to study all species and samples 
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can be run using both types of columns for greatest metabolite coverage. RPLC has a 
distinct advantage in that salts are not retained on these columns, avoiding salt-
mediated interferences with MS detection. Depending on the compound(s) of interest, 
this can diminish the sample preparation requirement for sample desalting, and even 
eliminate the need for a water wash that can be stressful for cells [Lu et al. 2017]. 
However, many of the most important intermediary metabolites are highly polar 
compounds (e.g., nucleotide di- and tri-triphosphates, TCA cycle intermediates, amino 
acids, etc.), requiring hydrophilic chromatography for adequate separation prior to MS 
analysis [Theodoridis et al. 2012; Gika et al. 2014; Spagou 2010]. Notably, nucleotide 
di- and tri-triphosphates can alternatively be detected by RPLC using an ion pairing or 
derivatization approach, but there are drawbacks to each [Lu et al. 2010]). For this 
reason, the studies described herein generally use normal phase chromatography on 
silica hydride resin with rapid and efficient washing for hydrophilic metabolite 
detection and relative quantification. This single approach provides good coverage, 
with chromatographic separation relative quantification of key metabolic 
intermediates and even of many weakly hydrophilic compounds. Lastly, organic acids 
and bases, the metal chelator EDTA and other mobile phase additives are often used to 
enhance the ionization and separation of positively- and negatively-charged 
metabolites [Yanes et al. 2011; Gao et al. 2005]. 
 
Targeted vs. untargeted 
 Mass spectrometry-based metabolomics can be done in a targeted or 
untargeted manner. In targeted metabolomics, abundances of structurally known 
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compounds (defined by a specific m/z and RT database entry) are relatively 
quantified. If absolute quantification is required for a more limited array of 
metabolites, a triple quadrupole mass spectrometer can be used in multiple-reaction-
monitoring mode, providing optimal sensitivity of specific compounds/transitions that 
are defined by the data acquisition method - this can enable the quantification of 
hundreds of metabolites in biologically-complex mixtures [Lu et al. 2008; Roberts et 
al. 2012; Zhou et al. 2012]. Notably, this method must first be developed, and LC-MS 
instrument parameters optimized, using pure standards for all analytes of interest. 
Specific methods can be produced for optimized detection of classes of compounds or 
metabolite members in pathways of interest. This approach was employed herein for 
the lipid analyses described in Chapter 1. Commercially available, ready-to-go triple-
quad LC-MS methods can be purchased for detection of certain compound classes 
(e.g. Biocrates AbsoluteIDQ® p180 or p400 HR). 
 If some or all metabolites of interest in a given experiment are undefined, an 
untargeted MS detection approach is warranted. Towards this end, a high-resolution 
mass spectrometer is employed to rapidly scan and record abundances for all 
detectable small molecules within a defined m/z range of interest (e.g., 50-1000 Da in 
studies described in Chapters 2 and 3) [Lu et al. 2017; Gika et al. 2014; Zhou et al. 
2012]. 
Data acquired in an untargeted manner can be analyzed in a targeted manner, 
taking advantage of a pre-established m/z and RT database, or analyzed in an 
untargeted manner, by extracting ion counts (relative abundance) for m/z values at 
specific retention times [Lu et al. 2008]. Advanced software (e.g. Agilent MassHunter 
Profinder) is available to extract this information, with user defined parameters/filters, 
  
13 
 
 
 
in an automated manner. In the latter case, structurally-undefined feature abundances 
are quantified as ion counts for a given m/z at a specific RT, surveying thousands of 
features. Differentially-expressed features of sufficient interest can then be 
subsequently identified structurally based on observed MS/MS fragmentation patterns, 
as compared with MS/MS fragmentation of pure chemical standards or predictions. 
 
Metabolite identification 
 One of the most challenging aspects of untargeted metabolomic studies can be 
the confident specification of structural identities for observed features. Indeed, 
features of interest that are not already included in the labs existent metabolite 
databases will often necessitate the challenging process of de novo structure 
elucidation. As a first pass, a molecular formula generator can be used to limit 
possible empirical formulae for a given feature based strictly on the accurate mass 
observed (where highest MS resolution provides greatest confidence in formula 
assignments). Considering accurate mass and isotope spacing, the feature can also be 
searched against a number of available databases (e.g. METLIN) for possible hits 
[Sana et al. 2008]. These searches can yield tentative identities, but often lead to an 
excess of structural possibilities. For manual structural elucidation, MS/MS 
fragmentation must be performed and compared with fragmentation patterns produced 
from a reference standard or a theoretical, in-silico fragmentation algorithm. Here, 
fragmentation spectra can be obtained for a compound over a range of defined 
collision energies (for collision–induced dissociation). If sufficient and clean 
fragmentation data is obtained, the fragments can be interpreted by a skilled mass 
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spectrometrist/chemist to obtain a putative structure [Rathahao-Paris et al. 2016]. 
MS/MS fragmentation databases (e.g. METLIN) are now available and can be 
searched to at least gain helpful insight into structure, but results may require 
additional confirmatory evidence. Unfortunately, fragmentation can vary based on 
analytical conditions and collision cell geometry, so conditions and MS 
instrumentation used for database creation would be most optimal for potential 
structure assignment. In Chapter 3, I describe the successful use of de novo MS/MS 
fragmentation coupled with METLIN MS/MS database matching to confirm the 
identity of betaine. However, there are often no convincing MS/MS database structure 
match for an unknown compound of interest [Rathahao-Paris et al. 2016]. In silico 
fragmentation spectra are also available for many compounds, although these are less 
reliable than those established using pure reference standards. In the end, all of this 
information can be used together by the mass spectrometrist to attempt to confidently 
elucidate the structure of an unknown compound [Dunn et al. 2013]. A major 
limitation of de novo structure assignment is that the compound concentration and 
ionization efficiency need to be sufficient to obtain an informative fragmentation 
spectra inasmuch as MS2 fragment signals are significantly lower than that of the 
original metabolite. In cases of MS/MS signal insufficiency, a strategy would be to 
inject more concentrated samples or greater volumes of sample for analysis. 
 MS/MS fragmentation runs can include hundreds of compounds for 
simultaneous analysis. However, to obtain the best data, fragmentation of compounds 
with overlapping RT should ideally be performed separately – this allows scan time to 
be dedicated to a single compound. Also, different compounds will likely require 
different parameters for optimal fragmentation and target-specific optimization of 
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MS/MS may be required. Auto MS/MS is now available for facile untargeted 
fragmentation data acquisition. Here, m/z’s are selected for fragmentation when the 
signal reaches a specific ion abundance threshold, facilitating the fragmentation of 
bona fide molecular features rather than noise. Auto MS/MS is a promising new 
instrument capability that is anticipated to become increasingly effective with the 
development of improved algorithms and MS instrumentation. 
 Advances in the process of identifying unknown features, including enhanced 
instrument performance, database breadth and applicability, fragmentation prediction 
algorithms, interpretive software and unique methods to gain structure-related 
information (such as retention time prediction algorithms [Cao et al. 2015] or the use 
of in-source MS-only fragmentation for structural elucidation assistance [Godzien et 
al. 2015; Seitzer et al. 2018]), are likely to be key contributors to enhancing the speed, 
usability and efficacy of metabolomics in the future. 
 
Stable isotope tracing 
 Stable isotope tracing coupled with mass spectrometry detection is a powerful 
tool for understanding active metabolism of a biological system [Jang et al. 2018]. 
Stable heavy isotopes are atoms that contain one or more additional neutrons, which 
provide an increase in mass that can be readily tracked using mass spectrometry. 
Stable isotopes are naturally abundant on earth with a specific frequency and do not 
radioactively decay, as opposed to unstable radioisotopes. Stable heavy isotopes that 
are useful for metabolic tracing are present in nature at significantly lower abundance 
than a primary (‘light’) isotope. Importantly, compounds can be chemically 
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synthesized that contain heavy labeled atoms at specific positions for metabolic 
tracing experiments. These species (or isotopologues) are biologically and 
biophysically identical to the light isotope versions, but are readily distinguished using 
MS. Tracing experiments can therefore be performed, where the temporal fate of 
heavy-labeled atoms are mapped. For example, heavy [13C]-labeled glucose can be fed 
to cells in culture, followed by the harvest of metabolites and analysis of 13C-
incorporation into glycolytic intermediates. By comparing two groups, a perturbation 
in glycolysis could be confirmed by detecting differential 13C-glucose trafficking into 
downstream metabolites. Multiple time points can be used to obtain detailed 
information about the metabolic flux of glucose (or other metabolites of interest) as a 
function of time. 
As opposed to simple metabolite profiling, which provides a snapshot of 
abundances of compounds, isotope tracing provides key information about reaction 
rates and metabolite origin/fate, and is integral for probing molecular mechanisms of 
metabolic perturbations [Zamboni et al. 2015; Johnson et al. 2016]. In Chapter 2, we 
effectively utilize stable isotope tracing with both [13C]-glucose and [13C]-glutamate to 
show increased glucose and transsulfuration metabolism in skin fibroblast cells grown 
from a newly-recognized subgroup of patients with sporadic amyotrophic lateral 
sclerosis (sALS). In Chapter 3, [DU]-choline is successfully used to show decreased 
choline-derived betaine in a cell line with a knockout in a functionally undefined 
mitochondrial transporter protein (SLC25A40). Later in Chapter 3, I take advantage of 
the ability of MS to distinguish heavy labeled compounds from their light counterparts 
to detect newly transported 2-oxoglutarate, glycine and aspartate. Many isotopically 
labeled compounds are commercially available with a defined isotopic enrichment, 
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enabling metabolic tracer studies. However, uncommon or difficult-to-produce 
compounds may not be available and are certain to be expensive.  
 
Data processing, normalization, analysis, interpretation and visualization 
 The most challenging aspect of untargeted metabolite profiling can be the data 
analysis and interpretation. As mentioned above, m/z features at specific retentions 
times are extracted from the acquired MS spectral data using software that filters, 
extracts and aligns feature peaks across samples in a recursive manner. Users must 
make decisions regarding optimal parameter and filter decisions for data analysis. For 
statistical and ease-of-interpretation reasons, it is important to avoid extracting low-
abundance noise (or impossible to interpret metabolites) from the acquired MS data. 
Automated integration of chromatograms (i.e., assessment of ion abundance vs. time) 
affords a facile relative abundance readout in terms of ion counts, but can be 
inaccurate (especially for compounds with low abundance with closely neighboring 
peaks or RT shifts) and confident abundance data often requires time-consuming 
manual curation. As discussed in more detail below, many, if not most, features do not 
correspond to bona fide cellular metabolites, but instead arise as in-source fragments 
or adducts of a given metabolite created as an MS ionization artefact [Xu et al. 2015; 
Brown et al. 2009; Lu et al. 2017]. Unfortunately, determining which m/z features are 
authentic biological metabolites, rather than in-source artefacts, can be challenging 
and can confound confident metabolite identification [Vinaixa et al. 2016]. Methods 
have been produced to try and automatically identify and group features that are 
related (and even to attempt to use the information to assist in structural elucidation 
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[Seitzer et al. 2018]). I have used a simple method based on RT similarity (in-source 
changes, such as fragments, adducts or multimers have the same RT) and abundance 
correlation between samples (in-source fragments should generally have the same 
relative abundance between samples) to identify and remove putative fragments. In 
one example, by using stringent parameters of ±0.03 min RT and sample abundance 
Pearson correlation >0.95 for fragment identification, I was able to algorithmically 
remove 29% of features as likely in-source compounds (Figure I.4). This makes the 
statistical analysis of remaining features more accurate (i.e., multiple measurements of 
the same compound are removed from consideration) and provides a clearer picture of 
the actual number of individual statistically significant compounds for data 
interpretation. Notably, removed in-source generated features are not discarded, but 
instead utilized to determine which peak is likely the parent metabolite, as well as to 
gain information for structure assignment or confirmation. 
As mentioned above, samples are typically normalized prior to MS data 
acquisition (e.g. based on protein content) to control for variations in cell number or 
tissue quantity in extracts. However, a second normalization is often required to 
control for post-reconstitution variability in metabolite detection, such as changes in 
MS instrument sensitivity, LC drifts in retention time, and time-dependent sample 
degradation. Such normalization is generally essential for large, multi-day or multi-
instrument experiments. In any case, to minimize bias in data acquisition, MS samples 
are routinely analyzed in a staggered order (e.g. disease, control, disease, control, etc.) 
so that potential batch effects are minimized.   
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Figure I.4. Features produced in-source can be algorithmically identified. Excerpts 
from a list of features (sorted by RT) identified in an untargeted analysis are shown. 
Highlighted are two groups of features where multiple in-source compounds 
(fragments, adducts and multimers, denoted with a 1) corresponding to the same parent 
compound (denoted with a 0) were algorithmically labeled. A 1 was assigned to a 
feature with a RT of ±0.03min and had a Pearson correlation (among the 72 samples) 
of 0.95 or greater with any other feature. In the comparison, the feature with lower 
average abundance was assumed to be produced in source and assigned a 1 (the 
feature with higher average abundance was assumed to be the parent compound and 
assigned a 0). In this example, this analysis identified 219 features out of 747 as in-
source (~29%).  
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One normalization technique that is often employed is to normalize based on a 
continually re-analyzed quality control (QC) sample, created from a mixture of the 
experimental samples, which is aliquoted, frozen and repeatedly analyzed at regular 
intervals (i.e. every 6-10 runs). Abundances for each individual metabolite can then be 
normalized based on the abundance in flanking quality control sample LC-MS runs 
[Kamleh et al. 2012; Chen et al. 2014]. In Chapter 2, we demonstrate the use of this 
technique to compare samples analyzed on the mass spectrometer over the course of 
one month. 
A common normalization method for targeted MS analyses is to normalize to a 
heavy isotope-labeled internal standard that is added to each sample. However, heavy 
labeled compounds are not always available (or can be expensive). An array of 
internal standards with various retention times have been used to correct for 
compounds across an LC-MS run [Sysi-Aho et al. 2007]. Unfortunately, compounds 
are so diverse that this approach is not robust for the detection of many compounds, 
where it can suppress biological variation, and certainly cannot be utilized for 
untargeted experiments [De Livera et al. 2012]. 
Other methods of normalization are data-driven methods, which generally 
normalize based on the array of metabolite abundances within each sample and can 
range from median fold change or quantile normalization to complex machine learning 
algorithm-based normalization [Ejigu et al. 2013; van den Berg et al. 2006; Shen et al. 
2016; Wu et al. 2016; De Livera et al. 2015; Karpievitch et al. 2014]. For any 
experiment with samples being run at different times or on different machines a robust 
data normalization strategy must be selected during the experiment design phase to 
ensure the ability to effectively compare all the samples. 
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After the feature abundances have been obtained and normalized, the data is 
analyzed based on the goals of the experiment either using data science tools (e.g. R, 
Matlab) or metabolomics-specific applications (e.g. Agilent Mass Profiler 
Professional, MetaboAnalyst). These can include basic tests of statistical significance 
or advanced machine learning applications [Hendriks et al. 2011]. Interpretation and 
visualization of complex metabolomics results can be challenging. Often, pathway 
enrichment analyses (e.g. metabolite set enrichment analysis and pathway topology 
analysis) and are employed to connect individual metabolic difference and highlight 
perturbations in a more global way (these pathways become good candidates for stable 
isotope tracing experiments) [Johnson et al. 2016; Xia et al. 2010; Xia et al. 2011; Xia 
et al. 2016; Brown et al. 2016; Chen et al. 2015]. Multiple metabolite perturbations are 
generally visualized in heatmaps or pathway/metabolic maps [Sugimoto et al. 2012], 
as we do in Chapter 2 for transsulfuration-related compounds. In the end, an 
orthogonal approach to confirm metabolomics results should be employed, if possible. 
 
New applications and methods  
Mass spectrometry-based metabolomics is a rapidly growing field and new 
applications and methodologies are continuously being developed. Unique approaches 
to solving many of the challenges (e.g. data normalization or improving 
chromatography for greater metabolite coverage) are being explored in individual labs. 
Many times, the application of the newest approaches requires specialized 
instrumentation or in-depth understanding of advanced statistical/computational 
concepts. However, those new approaches that are most promising eventually gain 
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mainstream interest and are broadly incorporated into the research of a number of 
metabolomics laboratories. Three relatively recent and advanced uses of metabolomics 
which further highlight its powerful, developing capabilities are multi-omics, mass 
spectrometry imaging of small molecules and single cell metabolomics. 
As the name implies, a multi-omic analysis integrates data from at least two 
different ‘omics (metabolomics, transcriptomics, proteomics, genomics) experiments 
to provide an even more insightful and encompassing understanding of the topic under 
study. Combining the different ‘omic datasets (e.g. making connections between 
metabolites and RNA) and performing a shared pathway interpretation is challenging, 
but tools to assist with integration and interpretation of these data are continually 
being developed [Chong et al. 2018]. In Chapter 2 we use metabolomics and 
transcriptomics in a multi-omic analysis to help characterize a subgroup of sALS 
patient fibroblasts. In the coming years, the continued work into the integration of 
different ‘omics data is likely to provide far deeper and multi-layer insight in diverse 
research endeavors. 
Another metabolomics application that has recently become feasible due to 
enhanced instrumentation is mass spectrometry imaging. In MS imaging, metabolite 
abundances can be sequentially obtained across a sample surface (such as an unfixed 
tissue cryosection). Matrix-assisted laser desorption/ionization (MALDI), where a 
laser is used to ionize metabolites from the sample provides the most common source 
for metabolite-on-tissue ionization. The spatial resolution of this ionization technique 
and the detection sensitivity of mass spectrometers is now sufficiently high to obtain 
single cell resolution metabolomics data [Hansen et al. 2018; Wang et al. 2017; 
Kompauer et al. 2016; Balluff et al. 2018]. This can be collected across a sample 
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surface (e.g. a brain slice) to obtain information about the relative abundance and 
distribution of compounds across the tissue section. This developing field is likely to 
add significantly to our understanding of endogenous-location-specific metabolism in 
a myriad of biological samples types. 
An additional cutting-edge application in metabolomics is single cell 
metabolomics. Again, methodological and instrumentation-related improvements have 
begun to make the detection of metabolites from single cells possible. Generally, 
single cells from a population are isolated using various techniques, such as 
micropipettes or microfluidic devices, and metabolites from individual cells are 
sequentially ionized by various methods, such as by MALDI or by directly trapping 
and spraying a live cell using an electrospray ionization tip [Emara et al. 2017]. This 
developing technology will continue the expansion of research related to the study of 
single cells from primarily RNA transcript level to the level of cellular small molecule 
metabolism.  
 
Conclusion 
 In summary, mass spectrometry-based global metabolite profiling is a 
powerful tool that serves to both generate and test novel hypotheses in biomedical 
research. Advances in MS instrumentation, chromatographic separations, data 
acquisition and statistical and computational/bioinformatic analyses are continuing to 
expand the use of MS-based metabolomics as a powerful tool in the armamentarium of 
biomedical researchers. Judicious selection of metabolite extraction techniques, 
chromatography and MS detection platforms now enable the detection of thousands of 
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metabolite with greatly disparate structures, biophysical properties and biological 
functions. 
Researchers must be careful, however, when designing and implementing 
experiments in order to ensure the collection of informative data and avoid possible 
pitfalls. Since there are no universally-accepted methodologies as yet, sample 
preparation protocols must be established in each laboratory to ensure reproducibility 
and to minimize common confounding factors, such as ion suppression. 
Due to the extremely large number of detectable features and undefined 
inventory of resident biomolecules, unique issues arise. These include confident 
feature identification as a bottleneck and the potential to over fit data (i.e. the curse of 
dimensionality), requiring both diligence and expertise on the part of experimenters. 
However, these challenges are clearly surmountable and metabolomics analysis, as 
utilized in the subsequent chapters, offers a powerful tool for small molecule-centered 
research. 
 In the next three chapters I discuss a number of applications of mass 
spectrometry-based metabolomics. Many of the topics considered in this Introduction 
are explicitly or implicitly explored and applied. In Chapter 1, I discuss the 
endocannabinoid system in the context of acute withdrawal from binge alcohol 
drinking and use targeted RPLC-MS methodology to detect multiple N-acyl 
ethanolamine family endocannabinoids in mouse brain samples. In Chapter 2, I 
provide an example of the use of aqueous normal phase LC-MS unbiased metabolite 
profiling to generate and test a hypothesis regarding sALS. Specifically, we identify a 
previously unrecognized subgroup of sALS patient fibroblasts that are defined by a 
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unique metabotype. We use stable isotope tracing and a multi-omics analysis to 
confirm the hypothesis and further characterize the metabolic perturbations of this 
novel sALS subgroup. Finally, in Chapter 3, I seek to utilize MS-based targeted and 
untargeted small molecule detection in research focused on characterizing the function 
of members of the SLC25 family of mitochondrial transporter proteins. 
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CHAPTER ONE* 
 
BLOCKADE OF ALCOHOL ESCALATION AND 
“RELAPSE” DRINKING BY PHARMACOLOGICAL FAAH 
INHIBITION IN MALE AND FEMALE C57BL/6J MICE 
 
INTRODUCTION 
 
The endocannabinoid (eCB) system consists of cannabinoid receptors (CB1 
and CB2) and endogenous cannabinoids (including anandamide [AEA] and 2-
arachidonoyl glycerol). Pharmacological blockade of CB1 receptors reduces alcohol 
drinking in mice [Arnone et al. 1997], decreases alcohol intake and the motivation to 
consume alcohol [Colombo et al. 1998; Gallate and McGregor 1999] and blocks 
alcohol seeking in rats [McGregor et al. 2005], suggesting that the eCB/CB1 system is 
involved in the positive reinforcing properties and consumption of alcohol. In 
addition, mice lacking CB1 have reduced alcohol drinking or preference [Hungund et 
al. 2003; Wang et al. 2003; Naassila et al. 2004], and alcohol-induced reward [Houchi 
et al. 2005]. Together, the increased eCB/CB1 activity is likely to promote alcohol 
intake during early stages of alcohol drinking by potentiating acute alcohol reward 
[Manzanares et al. 1999]. In apparent contrast, eCB/CB1 signaling deficiency occurs 
after chronic alcohol exposure and protracted withdrawal, which may promote alcohol 
                                                          
* Reprinted by permission from [RightsLink Permissions Springer Nature Customer Service Centre 
GmbH]: [Springer Nature][PSYCHOPHARMACOLOGY][BLOCKADE OF ALCOHOL 
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INHIBITION IN MALE AND FEMALE C57BL/6J MICE, YAN ZHOU,  BENJAMIN I 
SCHWARTZ,  JOANNA GIZA,  STEVEN S GROSS,  FRANCIS S LEE,  MARY JEANNE 
KREEK], [© SPRINGER-VERLAG GMBH GERMANY 2017] (2017) 
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intake through a negative reinforcement mechanism. Several findings support this 
notion: [1] down-regulation of CB1 expression and function is observed during 
protracted alcohol withdrawal [Mitrirattanakul et al. 2007; Varodayan et al. 2016]; [2] 
in humans, in vivo imaging studies find decreased CB1 availability in heavy-drinking 
alcoholics that persists into abstinence [Hirvonen et al. 2013; Ceccarini et al. 2014]; 
and [3] alcohol dependent patients have lowered AEA levels in plasma during recent 
abstinence [Mangieri et al, 2009]. 
The AEA-dependent signaling has been shown to be regulated by the enzyme 
involved in its catabolism, fatty acid amide hydrolase (FAAH) [Cravatt et al. 1996, 
2001]. Several lines of evidence have demonstrated that AEA is involved in the 
behavioral effects of alcohol: inhibition or genetic deletion of FAAH, with resultant 
increases in AEA levels [Cravatt et al. 2001], increases alcohol consumption and 
preference [Basavarajappa et al. 2006; Blednov et al. 2007]. The FAAH C385A 
polymorphism (with increased eCB activity due to impaired FAAH function) has been 
reported to be associated with increased alcohol abuse and dependency [e.g., Sipe et 
al. 2002; Sloan et al. 2017], and consistently, we found that the knock-in mice with the 
human FAAH C385A polymorphism had increased alcohol consumption [Zhou et al. 
2016], with decreased anxiety-like behavior [Dincheva et al. 2015]. 
Withdrawal from alcohol is associated with increased stress responsivity and 
persistent negative affective symptoms, such as anxiety and depression, the severity of 
which are closely associated with alcohol relapse susceptibility [Koob & Kreek 2007]. 
eCBs exert prominent modulatory influence on the extended amygdala and 
corticostriatal circuits, and stress exposure disrupts eCB-enriched regions that 
participate in emotional control [Serrano et al. 2012; Dincheva et al. 2015; Morena et 
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al. 2016]. Specifically, the relatively deficient eCB function is associated with 
increased anxiety and depression, and as such, impaired eCB activity may contribute 
to the negative affective states and increased stress responsivity that underlie negative 
reinforcement mechanisms driving alcohol drinking by dependent individuals and that 
contribute to alcohol relapse following periods of abstinence [Parsons & Hurd, 2015]. 
Pharmacologic and genetic manipulations (knockout or knock-in) of FAAH have been 
implicated in anxiolytic and anti-depressive behaviors [Bortolato et al. 2007; Gunduz-
Cinar et al. 2013; Kathuria et al. 2003; Moreira et al. 2008; Carnevali et al. 2015]. 
However, there is no study on FAAH inhibitors in rodent models with alcohol 
withdrawal from high intake, though FAAH inhibition decreases anxiety-like 
behaviors that are present during alcohol withdrawal [Cippitelli et al. 2008]. 
Our hypothesis is that enhanced eCB signaling by FAAH inhibition opposes 
the effect of alcohol withdrawal driving alcohol escalation and “relapse” drinking. In 
this study, therefore, we first investigated whether a selective FAAH inhibitor 
URB597 alters voluntary alcohol drinking in mice during acute (1 day) withdrawal 
from chronic (3-week) intermittent access (IA) alcohol drinking, to explore its 
potential for development as a therapeutic agent for alcoholism. In the IA model, the 
mice had access to alcohol drinking for 3 weeks in a two-bottle choice paradigm with 
alcohol drinking every other day, and the mice developed high alcohol consumption 
(15-25 g/kg/day). Thus, chronic IA mice constitute an appropriate animal model for 
studying voluntary alcohol drinking, as they display rapid escalation of high alcohol 
intakes [Hwa et al. 2011] and develop the alcohol deprivation effect (ADE, modeling 
the relapse episodes that occur in human alcoholics) [Zhou et al. 2017]. Consequently, 
we determined the pharmacological effects of URB597 in an ADE model, which 
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allows for access to alcohol after 1 week of withdrawal. For comparison, we compared 
the effect of URB597 in the drinking-in-the-dark (DID) model, which allows for 
limited access (4 h/day) with low intake (<5-6 g/kg/day) [Rhodes et al. 2005], and 
models “binge” drinking to the point of intoxication. Finally, we assessed the eCB 
system at a biochemical level in the IA model, by measuring relative abundances of 
AEA, other N-acyl ethanolamide (NAE) lipids and of FAAH protein after chronic IA 
and acute (1 day) or long-term (1 and 2 weeks) withdrawal, providing a dynamic 
profile of the eCB system in response to chronic alcohol IA consumption and 
subsequent withdrawal. 
 
MATERIALS AND METHODS 
 
1. Animals. Male adult C57BL/6J (B6) mice (8 weeks of age) were obtained from The 
Jackson Laboratory (Bar Harbor, ME, USA) and housed in a temperature-controlled 
room (21 ºC). Mice were placed on a 12-hour reverse light-dark cycle (lights off at 
7:00 am) upon arrival, and acclimated for a week prior to testing. During the first day 
of testing (i.e., session 1), all mice were 9 weeks of age. Mice were individually 
housed in ventilated cages fitted with steel lids and filter tops and given ad libitum 
access to food and water. Animal care and experimental procedures were conducted 
according to the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources Commission on Life Sciences 1996), and were 
approved by the Institutional Animal Care and Use Committee of the Rockefeller 
University. 
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2. Materials. FAAH inhibitor URB597 (Cyclohexylcarbamic acid 3’-
[aminocarbonyl]-[1,1’-biphenyl]-3-yl ester) and selective CB1 antagonist AM251 
[Tocris Inc., Bristol, UK] were dissolved in 1% DMSO plus physiological saline and 
in 5% Cremophor in physiological saline, respectively. Alcohol solutions (7.5%, 15% 
and 30% v/v) were prepared from 190 proof absolute ethyl alcohol (Pharmco-AAPER, 
Brookfield, CT, USA) and dissolved in tap water. Sucrose and saccharin [Sigma-
Aldrich Inc., St. Louis, MO, USA) were diluted in tap water. Optima liquid 
chromatography-mass spectrometry (LC/MS) grade acetonitrile [Fisher Scientific, 
Pittsburgh, PA, USA] was used for metabolite extractions and liquid chromatography. 
Deuterated anandamide standard was purchased from Cayman Chemical [Ann Arbor, 
Michigan, USA]. 
3. Procedures. 
3.1 Chronic Intermittent Access (IA). This model of alcohol drinking in 
C57BL/6J mice has been widely used for several years by many laboratories [e.g., 
Hwa et al. 2011; Zhou et al. 2017] (Table 1.1). 
3.1.1. The 3-week IA model. Mice had access to alcohol drinking in their home 
cages for 3 weeks. Food and water were available at all times in this two-bottle choice 
paradigm with chronic alcohol exposure every other day. This IA model was similar to 
earlier protocols [e.g., Hwa et al. 2011], with our modifications [Zhou et al. 2017]: At 
the time when the mice started individual housing (1 week before the experiments), 
the original water bottles were exchanged for those with sipper tubes to acclimate the 
mice to the sipper tubes (without ball bearings). Starting at 3 hours after lights off 
(10:00 am), both the water and alcohol (7.5%, 15% or 30%) solution sipper tubes were 
placed on their home cages. 
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Week 1 Week 2 Week 3 1-day withdrawal (day 22) 
IA 
24-h alcohol vs 
water 
IA 
24-h alcohol vs 
water 
IA 
24-h alcohol vs 
water 
Single URB597 with 
AM251 
24-h alcohol vs water 
Table 1.1. The 3-week chronic intermittent access (IA) alcohol drinking model 
(15% alcohol vs. water, 24 hours) every other day with selective FAAH inhibitor 
URB597, CB1 antagonist AM251 or their combination. 
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These sipper tubes were 10-ml pipettes that were cut at both ends, sealed with 
a rubber stopper, and fitted with a stainless steel straight sipper tubing. The sipper 
tubing contained a ball bearing at the end to prevent alcohol leakage. The left ⁄ right 
position of the tubes was randomly set to avoid the development of side preference. 
The alcohol pipettes were refilled with fresh alcohol solution, and left for 24 hours 
before being replaced with the water tubes. Alcohol solutions were prepared fresh 
every 48 hours by mixing alcohol with tap water to reach the appropriate (v ⁄ v) 
alcohol concentration. Body weights were recorded every 2 days. Alcohol and water 
intake values were recorded after 4, 8 and 24 hours of alcohol access in the drinking 
days (to the nearest 0.1 ml). These data were used to calculate consumed alcohol 
intake (i.e., g ⁄ kg) and relative preference for alcohol (i.e., alcohol intake ⁄ total fluid 
intake). 
Mice exposed to the 2-bottle “alcohol vs. water” choice regimen every other 
day rapidly acquired alcohol drinking behaviour, and subsequently daily alcohol 
intake rose to levels averaging approximately 15-20 g/kg/day after 3 weeks with 15% 
alcohol, with a high preference ratio above 0.8-0.9. This 3-week voluntary IA alcohol 
exposure was found to give rise to blood alcohol concentrations (BAC) around 0.50 - 
0.63 mg/ml, which were within the range required to produce specific psycho-
pharmacological effects [Hwa et al. 2011; Zhou et al. 2017]. 
The mice randomized as the vehicle-treated and drug-treated groups had 
matched body weight and similar alcohol intake 24 hours before the test day. The drug 
dissolved in vehicle was administered by an experimenter, blinded to the treatments 
given to the experimental groups. 
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3.1.2. Single, acute administration in the 3-week IA model. After 1 day of 
withdrawal, alcohol (7.5%, 15% or 30% concentrations) was presented 30 min after a 
single injection of URB597 (0.125, 0.25, 0.5, or 1 mg/kg in 1% DMSO, i.p.) or 
vehicle, and then alcohol and water intake values were recorded (Table 1.1). The 
URB597 doses chosen (0.125-1 mg/kg) were based on the literature [Blednov et al. 
2007; Manwell et al. 2009]. 
In this experiment, we also tested the effect of URB597 at 0.5 mg/kg after 1 
day of withdrawal in female mice exposed to 3 weeks of IA. We did not observe any 
sex differences in the effects of URB597 after either single or repeated administration 
in the following experiments, suggesting that the estrous cycle and associated 
hormones might not be important factors in the response to these treatments in 
females. 
Lastly, we used selective CB1R antagonist AM251 to pharmacologically block 
the CB1R to confirm that the URB597 effects were mediated via CB1R. Mice were 
pretreated with AM251 (0.1 mg/kg) in 5% Cremophor plus saline (i.p.) 30 min before 
one URB597 (0.5 mg/kg) or vehicle (1% DMSO) injection 30 min before the drinking 
test. The AM251 dose chosen (0.1 mg/kg) was based on our recent study [Zhou et al. 
2016]. 
3.2 Chronic (3-week) drinking-in-the-dark (DID) (Table 1.2). This model of 
alcohol drinking in C57BL/6J mice has been widely in use by many laboratories [e.g., 
Rhodes et al. 2005].  In this one-bottle paradigm, alcohol exposure was every day, and 
alcohol drinking was measured during 4 hours of alcohol access. 
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Week 1 Week 2 Week 3 1-day withdrawal (day 22) 
 
4-h alcohol 
 
4-h alcohol 
 
4-h alcohol 
Single URB597 
4-h alcohol 
Table 1.2. The 3-week chronic alcohol drinking-in-the-dark (DID) model (15% 
alcohol, 4 hours) every day with selective FAAH inhibitor URB597. 
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This chronic DID model was similar to earlier protocols [Rhodes et al. 2005], 
with our modifications [Zhou et al. 2017]; The procedures were identical to the above 
IA with the following exceptions: Starting at 3 hours after lights off (10:00 am), the 
water bottle was replaced with one 10-ml alcohol (15%) pipette, and left for 4 hours 
before being replaced with the water bottle. Alcohol intake values were recorded after 
4 hours of alcohol access every day (to the nearest 0.1 ml). These data were used to 
calculate alcohol intake (i.e., g ⁄ kg). After 3 weeks of DID, the mice assigned to the 
vehicle-treated and URB597-treated groups with matched body weight had similar 
15% alcohol intake 1 day before the test day. The URB597 doses (0.25 and 0.5 mg/kg) 
were chosen based on the results of the above IA alcohol study. On the test day (20 
hours of withdrawal), alcohol (15% concentration) was presented 30 min after a single 
injection of URB597 or vehicle. Control groups: mice experienced DID for 3 weeks, 
and received one vehicle injection (1% DMSO, i.p.) before the 4-h drinking test. Test 
groups: mice experienced DID for 3 weeks, and received one URB597 injection (0.25 
or 0.5 mg/kg in 1% DMSO, i.p.) before the test. 
3.3. Sucrose (caloric reinforcer) and saccharin (non-caloric reinforcer) 
drinking. With 0.5 mg/kg URB597 (the most effective dose tested for reducing alcohol 
intake), we further tested the specificity of the action of URB597 on alcohol intake 
using sucrose or saccharin drinking behavior after single, acute administration in 
alcohol naïve mice or following the IA. The URB597 dose was chosen also based on 
the literature for sucrose drinking tests (0.1-1 mg/kg) [Bortolato et al. 2007; 
Rademacher & Hillard, 2007]. The sucrose or saccharin preference test in mice is 
sensitive to the function of brain rewarding systems and is widely used to measure the 
expression of anhedonia after chronic stress [Lim et al. 2012] and during alcohol 
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abstinence [Pang et al. 2013]. In the following experiments, 15% alcohol IA exposure 
was identical to those in the above experiment as described in section 3.1.1. After 3 
weeks of IA, the alcohol tube was switched to sucrose for 3 sessions with stable 
intakes. The mice assigned to the vehicle-treated or URB597-treated groups had 
similar sucrose intake 24 hours before the test day. On the test day (after 8 days of 
alcohol withdrawal), sucrose (2% or 4%) and water intake values were recorded after 
4, 8 and 24 hours of sucrose access. In parallel separate experiments, saccharin 
drinking (0.1% or 0.2%) was tested after 3 weeks of IA with an identical procedure.   
3.3.1. Single, acute administration of URB597 on sucrose or saccharin 
drinking after 3-week IA. A single i.p. injection of URB597 (0.5 mg/kg) in 1% DMSO 
or vehicle was given 30 min before the sucrose and saccharin were presented. Mice 
were assigned to one of two treatment groups: vehicle as control and URB597. 
3.3.2. Single, acute administration of URB597 on saccharin drinking in 
alcohol-naïve mice. The procedures were identical to the above, except the mice were 
exposed to saccharin or sucrose only (after 3 training sessions). 
3.4. The alcohol deprivation effect (ADE) after 1-week withdrawal from 3-
week IA (Table 1.3). Similar to the above, mice were given access to 15% alcohol and 
water for 24 h, and then received 24-h access to alcohol on alternating days for 3 
weeks.  
In the baseline session, 15% alcohol and water intake values were recorded at 
4, 8 and 24 hours after 3 weeks of IA. The alcohol bottles were then removed from the 
cages leaving the mice with access to food and water ad libitum. 
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Week 1 Week 2 Week 3 Week 4 Day 30 
IA 24-h 
alcohol vs 
water 
IA 24-h 
alcohol vs 
water 
IA 24-h alcohol vs 
water 
Baseline (BL) 
1-week 
withdrawal 
5 repeated 
URB597 
Single 
URB597 
ADE 
Table 1.3. The alcohol deprivation effect (ADE) model after 1-week withdrawal 
from a 3-week chronic intermittent access (IA) drinking (15% alcohol vs. water) 
with selective FAAH inhibitor URB597. 
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After 7 days of withdrawal, the alcohol (30%) bottles were presented to the 
mice 3 hours after the dark cycle and the alcohol and water intake values were 
recorded at 4, 8 and 24 hours in the ADE session. In the following two experiments, 
we also tested the effect of URB597 at 0.5 mg/kg in female mice with the ADE model. 
3.4.1. Single, acute administration in the ADE model. The mice assigned to the 
vehicle-treated or URB597-treated groups had similar alcohol intake in the baseline 
session. Control groups: mice received one vehicle injection (1% DMSO, i.p.) before 
the ADE test after 1-week withdrawal; and Test groups: mice received one URB597 
injection (0.5 mg/kg in 1% DMSO, i.p.) before the ADE test after 1-week withdrawal. 
Then, alcohol was presented 30 min after URB597 or vehicle injection, and then 
alcohol and water intake values were recorded after 4, 8 and 24 hours of alcohol 
access. The URB597 dose chosen (0.5 mg/kg) was based on the above IA 
experiments. 
3.4.2. Repeated administration in the ADE model. In the following 
experiments, alcohol exposure procedure was identical to the above experiment in 
section 3.4.1, with the following exceptions: mice received 5 consecutive 
administrations of vehicle or URB597 (0.5 mg/kg) during the 1-week withdrawal. On 
the ADE test day, alcohol (15%) was presented 1 day after the last URB597 injection, 
and then alcohol and water intake values were recorded after 4, 8 and 24 hours of 
alcohol access. 
3.5. N-Acyl Ethanolamide (NAE) extraction for mass spectrometry (MS) 
quantification. 
3.5.1. Brain tissue collection and extraction. Alcohol exposed and control 
(water) male mice from the 3-week chronic IA model were sacrificed by decapitation 
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in the following groups: No alcohol withdrawal (immediately following the last day of 
alcohol exposure), 1-day withdrawal, 1-week withdrawal, and 2-week withdrawal. 
Brain regions (nucleus accumbens [NAc], prefrontal cortex [PFC], basolateral 
amygdala [BLA] and cerebellum) were dissected and frozen on dry ice within 1 
minute of sacrifice. Brain regions from two mice were combined for each sample to 
ensure sufficient sample size. 
NAEs were extracted from brain tissue using a protocol adapted from a 
previously described method [Patel et al. 2003]: Stainless steel bead-beating beads 
were added to the Eppendorf tubes containing brain tissue. 400µL of acetonitrile 
(ACN) was added to the samples. 1µL of 1ng/µL deuterated anandamide ([2H8]AEA) 
was added as an internal standard (IS). Bead beating homogenization was performed 
using a TissueLyser II bead beater (Qiagen) for 1 minute at 30/s frequency. Samples 
were maintained on dry ice until homogenization, after which they were kept on ice. 
Homogenates were centrifuged in a table top centrifuge cooled to 4°C at maximum 
speed for 10 min to pellet brain tissue. The supernatant was removed to a new 
Eppendorf and brain tissue was homogenized twice more in 400µL ACN to ensure 
complete extraction of NAEs. Supernatants were combined and stored overnight at -
20°C to precipitate particulates. Remaining brain tissue protein pellets were stored at -
80°C until protein quantification. Brain extracts were centrifuged at max speed for 10 
min and supernatants were removed to a new Eppendorf. Extracts were dried under 
vacuum in a vacufuge, reconstituted in 500 µL ACN to remove metabolites from the 
side of the tube and dried again. Dried extracts were stored at -80°C until 
reconstitution for mass spectrometry. 
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3.5.2. Protein quantification. Remaining protein pellets from brain tissue 
homogenization were dried under vacuum in a vacufuge and dissolved in 0.2N NaOH 
at 95°C and protein content was determined using standard Bio-Rad Bradford protein 
quantification protocol. 
3.5.3. Liquid chromatography-mass spectrometry (LC-MS) NAE 
quantification. Dried brain extracts were reconstituted to the equivalent of 1µL 70% 
ACN in water per 100µg protein to correct for differences in brain tissue size. The 
relative abundances of NAEs were determined by liquid chromatography-electrospray 
ionization mass spectrometry using a 1290 Infinity LC system (Agilent Technologies) 
coupled to a 6460 Triple Quadrupole Mass Spectrometer (Agilent Technologies). 
Metabolites were separated on a ZORBAX SB-Aq Rapid Resolution reversed-phase 
column (2.1 X 100mm, 1.8 micron) using mobile phase A (deionized water, 1% ACN, 
1mM ammonium formate, 0.1% formic acid) and mobile phase B (ACN, 1% 
deionized water, 1mM ammonium formate, 0.1% formic acid). Samples were eluted 
using the following gradient (Table 1.4): 
NAEs were detected in positive ion mode. Standard multiple reaction 
monitoring methodology was employed for detection of anandamide (m/z 348.3 → 
62.1; retention time = 4.8 min), deuterated anandamide (m/z 356.3 → 62.1; retention 
time = 4.8 min), palmitoyl ethanolamide (m/z 300.3 → 62.1; retention time = 5.5 min) 
and oleoyl ethanolamide (m/z 326.3 → 62.1; retention time = 6.2 min). 
3.5.4. MS data analysis. MS data was extracted and integrated using Agilent 
Technologies Masshunter Quantitative Analysis software. 
  
  
49 
 
 
 
  
Time (min) A [%] B [%] Flow [mL/min] 
0 65 35 0.4 
0.5 65 35 0.4 
0.6 45 55 0.4 
10 45 55 0.4 
10.1 0 100 1 
13.1 0 100 1 
13.2 65 35 0.4 
16.2 65 35 0.4 
Table 1.4. LC gradient used to separate NAEs. A: deionized water, 1% ACN, 1mM 
ammonium formate, 0.1% formic acid, B: ACN, 1% deionized water, 1mM 
ammonium formate, 0.1% formic acid. 
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Raw ion count abundances were then normalized as follows: internal standard 
([2H8]AEA) abundances were normalized by multiplying by
 
𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
 
to correct for different reconstitution volumes. These normalized IS abundances were 
then used to normalize the raw abundances by multiplying by 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 [2H8]AEA abundance
𝑠𝑎𝑚𝑝𝑙𝑒 [2H8]AEA abundance
 to correct for handling error. [2H8]AEA was used as the IS 
for all NAEs with the assumption that physical properties of the compounds are 
similar. 
3.6. Western Blot. Alcohol exposed and control (water) male mice from the 3-
week chronic IA model were sacrificed by decapitation in the following groups: water 
control, 1-day withdrawal, 1-week withdrawal, and 2-week withdrawal. Prefrontal 
cortex was dissected and frozen on dry ice within 1 minute of sacrifice, and the tissue 
from two mice were combined for each sample to ensure sufficient sample size. Tissue 
lysates were prepared in lysis buffer containing 1% NP-40, 1% Triton, 10% Glycerol, 
1% protease and phosphatase inhibitors (Calbiochem, San Diego, USA) in 1x buffered 
saline on ice. Samples were triturated and spun down at 12,000 rpm for 10 min at 4°C. 
Supernatants were collected and protein concentration measured by Bradford (Bio-
Rad, Hercules, USA). Proteins were resolved by SDS–PAGE electrophoresis using 
ready NuPAGE 10% Bis-Tris gel (Invitrogen, Carlsbad, USA) and probed as 
previously described (Dincheva et al. 2015) using anti-FAAH (1:500). Secondary 
HRP-conjugated antibodies were used at 1:3000 (Santa Cruz, Dallas, USA). 
4. Data analysis. We performed power analyses to determine the number of mice 
required to provide statistically significant results, based on the levels of differences 
seen previously [Zhou et al. 2016, 2017], and predicted that these studies require 6-8 
animals per group. In the experiments with URB597, alcohol intake, water intake, 
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total fluid and preference ratio differences between the different groups were analyzed 
using two-way ANOVA with repeat measures for treatment (vehicle vs drug) and for 
time (0-4h, 5-8h, vs 9-24h interval) in each sex (Figure 1.1).  For dose response 
analysis on URB597, group differences for alcohol intake and preference ratios at the 
4-hour recording time were analyzed using one-way ANOVA for treatments with 
different doses (Figure 1.2). In the experiments with URB597 with 7.5 and 30% 
alcohol, alcohol intake and preference ratio differences across the different groups 
were analyzed using two-way ANOVA for treatment (vehicle vs drug) and for 
concentration (7.5% vs 30%) (Table 1.5).  In the experiments with URB597 
combination with AM251, alcohol intake and preference ratio differences across the 
different groups were analyzed using one-way ANOVA for different treatments 
(Table 1.6). 
In the experiments with URB597 with 0.2 and 0.4% saccharin, saccharin 
intake and preference ratio differences across the different groups were analyzed using 
two-way ANOVA for treatment (vehicle vs drug) and for concentration (0.2% vs 
0.4%) (Figure 1.3). In the ADE experiments, alcohol intake differences across the 
different groups were analyzed using two-way ANOVA for treatment (vehicle vs 
drug) and for session (baseline vs ADE) in each sex, with testing our a priori 
hypothesis that there was an ADE based on the published findings [e.g., Vengeliene et 
al. 2014; Zhou et al. 2017] (Figures 1.4, 1.5). For NAE quantification, abundance 
differences between water and alcohol groups were analyzed using a two-tailed 
Student’s t-test followed by Bonferroni post-hoc tests (Figure 1.6) or one-way 
ANOVA with different time-points (Figure 1.7). All the ANOVA analysis was 
followed by Newman-Keuls post-hoc tests. 
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 7.5% Alcohol 30% alcohol 
 Vehicle  
(n = 6) 
0.5 mg/kg URB 
(n = 6) 
Vehicle  
(n = 6) 
0.5 mg/kg 
URB 
(n = 6) 
Intake, g/kg 3.6± 0.45  2.7 ± 0.40  11 ± 0.24 ++ 4.7 ± 0.81 ** 
Preference ratio 0.75 ± 0.05 0.76 ± 0.08 0.70 ± 0.08 0.40 ± 0.06 ** 
Table 1.5. Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) on 
7.5% or 30% alcohol intake and preference ratio at 4 hours in male mice after 1 
day of withdrawal from 3-week chronic intermittent access (IA) alcohol drinking. * 
p<0.05 or ** p<0.01 vs. vehicle control at the same alcohol concentration, and ++ 
p<0.01 vs. vehicle group at 7.5% alcohol. 
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 Vehicle + 
vehicle (n = 8) 
Vehicle + URB 
(n = 6) 
AM251 + 
vehicle (n = 7) 
AM251 + URB 
(n = 6) 
Intake, 
g/kg 
5.6 ± 0.65  3.6 ± 0.41 *  5.1 ± 0.25 4.8 ± 0.41 + 
Preference 0.81 ± 0.07 0.55 ± 0.04 * 0.82 ± 0.05 0.74 ± 0.04 ++ 
Table 1.6. Pretreatment with selective CB1R antagonist AM251 (0.1 mg/kg) blocks 
the effect of single, acute URB597 (URB, 0.5 mg/kg) on reducing 15% alcohol 
drinking in male mice after 4 hours of alcohol access. * p<0.05 vs. vehicle + vehicle 
control; + p<0.05 or ++ p<0.01 vs. vehicle + URB. 
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The accepted level of significance for all tests was p < 0.05.  All statistical 
analyses were performed using Statistica (version 5.5, StatSoft Inc, Tulsa, OK). 
 
RESULTS 
 
1. Single, acute administration of URB597 reduced alcohol (but not sucrose) 
intake and preference after 1 day of withdrawal from chronic IA. 
1.1. Single, acute URB597 at 0.5 mg/kg reduced 15% alcohol intake and 
preference in male and female mice. In male mice, for intake, two-way ANOVA with 
repeat measure revealed a significant effect of URB597 treatment [F (1, 13) = 4.6, 
p<0.05], and post hoc analysis showed that the URB597-treated males had less intake 
than the vehicle-treated ones at 4 hours [p<0.01] (Figure 1.1A). In comparison to the 
vehicle controls, 0.5 mg/kg URB597 reduced mean alcohol intake by 40-60% after 4 
hours, associated with a compensatory increase in water intake (resulting in virtually 
unchanged total fluid intake [Table S1.1]). For preference ratio at this dose, two-way 
ANOVA with repeat measure revealed a significant interaction between URB597 
treatment and time interval [F (1, 26) = 6.2, p<0.01], and post hoc analysis showed 
that the URB597-treated males had less preference than the vehicle-treated ones at 4 
hours [p<0.05] (Figure 1.1B).  
In this experiment, we also tested the effect of URB597 at 0.5 mg/kg in female 
mice after 3 weeks of IA, and URB597 had a similar reducing effect on alcohol intake 
and preference. As no significant sex difference in the effects of URB597 was found 
(Table S1.2), the female data are presented separately (Figures 1.1C, 1.1D). For 
intake, two-way ANOVA with repeat measure revealed a significant effect of 
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URB597 treatment [F (1, 14) = 4.8, p<0.05], and post hoc analysis showed that the 
URB597-treated females had less intake than the vehicle-treated ones at 4 hours 
[p<0.05] (Figure 1.1C). For preference ratio, two-way ANOVA with repeat measure 
revealed a significant effect of URB597 treatment [F (1, 14) = 8.6, p<0.05], and the 
URB597-treated females had less preference than the vehicle-treated ones at both 0-4 
and 5-8 hour intervals [p<0.01 for both, post hoc analysis] (Figure 1.1D).  
1.2. Dose-response of URB597 in male mice. At the 4-hour time point, the full-
dose response of single, acute URB597 administration (0, 0.125, 0.25, 0.5 and 1 
mg/kg) in terms of 15% alcohol intake and preference is presented in Figure 1.2. For 
intake (Figure 1.2A), one-way ANOVA revealed a significant effect of URB597 [F 
(4, 28) = 9.6, p<0.001], and post hoc analysis showed that: (1) in comparison with the 
vehicle group, the URB597-treated males had less intake than the vehicle-treated ones 
at 0.25, 0.5 and 1.0 mg/kg doses [p<0.05, p<0.01 and p<0.05, respectively]; and (2) 
the reductions at 0.5 mg/kg was greater than the one at 0.125 mg/kg [p<0.05]. For 
preference ratio (Figure 1.2B), one-way ANOVA revealed a significant effect of 
URB597 [F (4, 28) = 5.4, p<0.005], and post hoc analysis showed that (1) in 
comparison with the vehicle group, the URB597-treated males had less preference 
than the vehicle-treated ones at both 0.5 and 1.0 mg/kg doses [p<0.01 and p<0.05, 
respectively]; and (2) the reduction at 0.5 mg/kg was greater than the one at 0.125 
mg/kg and 0.25 mg/kg [p<0.05 for both].  
1.3. Single, acute URB597 (0.5 mg/kg) reduced 30% (but not 7.5%) alcohol 
intake and preference in male mice. 
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 Figure 1.1. Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) on 
15% alcohol intake and preference ratio in male (A and B, n=7-8) and female (C and 
D, n=8) mice after 1 day of withdrawal from 3-week chronic intermittent access 
alcohol drinking. Alcohol and water intake values were recorded after 4, 8 and 24 
hours of alcohol access. * p<0.05 and **p<0.01 vs. vehicle control at the same time 
point. 
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Figure 1.2. Dose responses of single, acute administration of URB597 (URB, 0, 
0.125-1 mg/kg) on reducing 15% alcohol intake (A) and preference ratio (B) in male 
mice (n=6-7) after 1 day of withdrawal from 3-week chronic intermittent access 
alcohol drinking. Data were collected at the 4-hour time point on the testing day and 
are expressed as a percentage of alcohol intake in vehicle-treated mice.  * p<0.05 or 
** p<0.01 vs. control (URB597 at 0 mg/kg), and + p<0.05 vs. 0.125 or 0.25 dose. 
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For alcohol intake after 4 hours (Table 1.5), two-way ANOVA revealed a 
significant effect of URB597 treatment [F (1, 20) = 7.5, p<0.05], alcohol 
concentration [F (1, 20) = 14.6, p<0.005], and a significant interaction between 
URB597 and alcohol concentration [F (1, 20) = 4.7, p<0.05]. Post hoc analysis 
showed that: (1) the URB597-treated males had less intake than the vehicle-treated 
ones at 30% concentration [p<0.01]; and (2) without URB597 treatment, mice had 
more intake at 30% concentration than at 7.5% [p<0.01]. For preference ratio, two-
way ANOVA revealed a significant effect of URB597 treatment [F (1, 20) = 4.9, 
p<0.05], concentration [F (1, 20) = 8.2, p<0.01], and a significant interaction between 
URB597 and concentration [F (1, 20) = 5.5, p<0.05]. Post hoc analysis showed that 
the URB597-treated mice had less preference than the control ones at 30% 
concentration only [p<0.01]. 
1.4. Pretreatment with selective CB1R antagonist AM251 (0.1 mg/kg) blocked 
the effect of acute URB597 (0.5 mg/kg) on reducing 15% alcohol drinking in male 
mice. One-way ANOVA revealed a significant effect of URB597 treatment [F (3, 23) 
= 5.1, p<0.01], and post hoc analysis showed that the URB597-treated males had less 
intake than the vehicle-treated ones [p<0.05]. Although pretreatment with AM251 at 
0.1 mg/kg alone had no effect on alcohol drinking per se, it blunted the effect of 
URB597 at 0.5 mg/kg on alcohol drinking during 4 hours [p<0.05] (Table 1.6). For 
preference ratio, one-way ANOVA revealed a significant effect of URB597 treatment 
[F (3, 23) = 5.2, p<0.01], and post hoc analysis showed that (1) the URB597-treated 
males had less preference than the vehicle-treated ones [p<0.05]; and (2) although 
pretreatment with AM251 at 0.1 mg/kg alone had no effect on preference ratio per se, 
it blunted the reducing effect of URB597 [p<0.01]. 
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A 
2% sucrose Vehicle (n = 6) 0.5 mg/kg URB (n = 6) 
Intake, g/kg  1.69 ± 0.14  2.10 ± 0.26  
Preference 0.89 ± 0.04 0.94 ± 0.02 
B 
4% sucrose Vehicle (n = 6) 0.5 mg/kg URB (n = 6) 
Intake, g/kg 7.10 ± 0.98   7.70 ± 0.70  
Preference 0.94 ± 0.02 0.93 ± 0.02 
Table 1.7. No effect of single, acute administration of URB 597 (URB, 0.5mg/kg) on 
2% (A) and 4% (B) sucrose intake and their preference ratio in male mice after 4 
hours of sucrose access. 
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  1.5. No effects of single, acute URB597 (0.5 mg/kg) on sucrose intake and 
preference in male mice. As alcohol is a caloric reinforcer, the specificity of the action 
of URB597 on alcohol intake was tested after single, acute administration of 0.5 
mg/kg URB597 on sucrose (caloric reinforcer) drinking in mice after chronic IA. In 
these experiments, the chronic 15% alcohol exposure procedures were identical to 
those in the above experiments. After 3 weeks of chronic IA, the alcohol tube was 
switched to sucrose for 3 sessions over 6 days, with stable intake observed. The male 
mice assigned to the vehicle- or URB597-treated groups had similar sucrose intake 24 
hours before the test day. URB597 had no significant effect on either intake or 
preference at 2% (Table 1.7A) or 4% (Table 1.7B) sucrose concentration. Further, in 
alcohol-naïve male mice (n = 6), there was no effect of 0.5 mg/kg URB597 on 4% 
sucrose intake (control mice: 7.5 ± 0.77 g/kg; URB597 mice: 7.7 ± 1.1 g/kg) or 
preference ratio (control: 0.93 ± 0.05; URB597: 0.96 ± 0.03). 
1.6. Single, acute URB597 (0.5 mg/kg) increased saccharin preference ratio, 
but not intake in male mice. The specificity of the action of URB597 on alcohol intake 
was further tested on saccharin (non-caloric reinforcer) intake in mice. Like the 
sucrose experiments, after 3 weeks of chronic IA, the alcohol tube was switched to 
saccharin for 3 sessions over 6 days, and after stable intake observed, the male mice 
assigned to the vehicle-treated or URB597-treated groups had similar saccharin intake 
24 hours before the test day. For saccharin intake after 4 hours (Figure 1.3A), two-
way ANOVA revealed a significant effect of saccharin concentration [F (1, 20) = 86, 
p<0.00005] only. Post hoc analysis showed that with or without URB597 treatment, 
mice had more intake at 0.2% concentration than at 0.1% [p<0.01]. 
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Figure 1.3. Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) on 
0.1% or 0.2% saccharin intake (A) and preference ratio (B) in male mice (n=6) after 
3-week chronic intermittent access alcohol drinking. Saccharin and water intake 
values were recorded after 4 hours of saccharin access. *p<0.05 vs. vehicle control 
at the same saccharin concentration, and ++ p<0.01 vs. 0.1% saccharin. 
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For preference ratio (Figure 1.3B), two-way ANOVA revealed a significant 
effect of URB597 treatment only [F (1, 20) = 13, p<0.005]. Post hoc analysis showed 
that the URB597-treated mice had more preference than the control mice at both 0.1% 
and 0.2% concentrations [p<0.05 for both]. Furthermore, in alcohol-naïve male mice 
(n=6), there was no effect of 0.5 mg/kg URB597 on 0.1% saccharin intake (control 
mice: 0.15 ± 0.02 g/kg; URB597 mice: 0.13 ± 0.03 g/kg) or preference ratio (control: 
0.95 ± 0.02; URB597: 0.97 ± 0.02). 
2. Effect of single, acute or repeated administration of URB597 on ADE in both 
male and female mice. 
2.1. Single, acute URB597. In the single dose URB597 experiment, we tested 
the effect of URB597 at 0.5 mg/kg in both male and female mice, and found similar 
reducing effects on the ADE. As there were no significant sex differences in the 
effects of URB597, the data of each sex are presented separately (Figure 1.4). 
In males at 4 hours (Figure 1.4A), two-way ANOVA revealed a significant 
effect of URB597 treatment [F (1, 24) = 4.6, p<0.05], and a significant interaction 
between Session and Treatment [F (1, 24) = 4.5, p<0.05], and post hoc analysis 
showed that the URB597-treated males had less intake than the vehicle-treated ones in 
the ADE session [p<0.05]. To test our a priori hypothesis that there was an ADE, we 
included the post-hoc result showing that in the vehicle-treated mice, the ADE was 
significant after 4 hours [p<0.05], though 2-way ANOVA did not reveal any 
significant effect of Session after 4 hours (Figure 1.4A). There were no significant 
effects of ADE or acute URB597 after 8 or 24 hours (data not shown). 
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Figure 1.4. Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) on 
alcohol intake in an alcohol deprivation effect (ADE) model at 4 hours in male (A, 
n=7) and female (B, n=6-9) mice after 1 week of withdrawal from 3-week chronic 
intermittent access alcohol drinking. * p<0.05 vs. control baseline, and + p<0.05 
vs. ADE. 
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In females at 4 hours (Figure 1.4B), two-way ANOVA revealed a significant 
effect of Session [F (1, 26) = 4.3, p<0.05], and post hoc analysis showed that the 
females had more intake in the ADE session than the baseline [p<0.05]. Though 
overall Treatment difference was not significant, post hoc analysis showed that the 
URB597-treated females had less intake than the vehicle-treated ones in the ADE 
session [p<0.05] (Figure 1.4B). Similar to the male mice, there were no significant 
effects of ADE or acute URB597 treatment after 8 or 24 hours in females (data not 
shown). 
2.2. Repeated URB597.  In the repeated URB597 experiment, we tested the 
effect of URB597 at 0.5 mg/kg in both male and female mice, and found similar 
reducing effects on the ADE. As there were no significant sex differences in the 
effects of URB597, the data of each sex are presented separately (Figure 1.5). 
In males at 4 hours (Figure 1.5A), two-way ANOVA revealed a significant 
effect of URB597 treatment [F (1, 20) = 5.8, p<0.05], and a significant interaction 
between Session and Treatment [F (1, 20) = 5.9, p<0.05], and post hoc analysis 
showed that the URB597-treated males had less intake than the vehicle-treated ones in 
the ADE session [p<0.05]. To test our a priori hypothesis that there was an ADE, we 
included the post-hoc result showing that in the vehicle-treated mice, the ADE was 
significant after 4 hours [p<0.05] (Figure 1.5A), though 2-way ANOVA did not 
reveal any significant effect of Session. There were no significant effects of ADE or 
repeated URB597 after 8 or 24 hours (data not shown).  
In females at 4 hours (Figure 1.5B), two-way ANOVA revealed a significant 
effect of Session [F (1, 26) = 15.1, p<0.001] and post hoc analysis showed that the 
females had more intake in the ADE session than the baseline [p<0.01]. 
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Figure 1.5. Effects of five repeated administration of URB597 (URB, 0.5 mg/kg) on 
alcohol intake in an alcohol deprivation effect (ADE) model at 4 hours in male (A, 
n=6) and female (B, n=7-8) mice after 1 week of withdrawal from 3-week chronic 
intermittent access drinking. During the withdrawal, mice received five daily 
URB597 or vehicle injections with the last one 1 day before alcohol bottles were 
presented again. * p<0.05 vs. control baseline, and + p<0.05 vs. ADE. 
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However, there was no significant effect of the repeated URB597 treatment 
after 8 or 24 hours (data not shown). 
3. Acute (1 day) alcohol withdrawal transiently caused global brain eCB system 
dysregulation in male mice.  
3.1. Acute (1 day) withdrawal. Relative NAE abundances were detected in four 
mouse brain regions from male mice subjected to the chronic IA model following 1 
day alcohol withdrawal as well as from control (water) male mice. All four brain 
regions showed a significant increase in the NAEs (Figure 1.6, S1.1). AEA levels 
were increased the greatest, with a 3.1, 2.7, 2.1 and 1.9 -fold increase in the NAc, 
BLA, cerebellum and PFC, respectively (Figure 1.6A). Palmitoyl ethanolamide (PEA) 
and oleoyl ethanolamide (OEA) were similarly increased (Figures 1.6B, 1.6C, S1.1), 
as were other NAEs (data not shown). 
 3.2. Chronic IA and long-term withdrawal. Relative NAE abundances were 
further detected in the BLA of mice subjected to the chronic IA model as well as from 
that of control (water) mice in three groups: immediately after 3 week IA and long-
term (1- and 2-week) withdrawal. This was done in order to determine: (A) whether 
the increased NAEs after 1 day withdrawal were due to chronic alcohol drinking or 
due to acute withdrawal, and (B) if NAE elevation after acute withdrawal was a short-
term response to withdrawal or whether it persisted. Neither of these groups showed 
changed NAE levels, indicating that NAE elevation was a transient response to acute 
withdrawal (Figures 1.7A, S1.2). 
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Figure 1.6. Effects of 1-day withdrawal from 3-week chronic intermittent access (IA) 
alcohol drinking on brain NAE abundances in male mice (n=6). Test mice are labelled 
Alcohol and control mice are labelled Water. (A) Anandamide (AEA) abundances in 
four brain regions after 1 day alcohol withdrawal. (B) Palmitoyl ethanolamide (PEA) 
and oleoyl ethanolamide (OEA) abundances in the basolateral amygdala after 1 day 
alcohol withdrawal. Normalized, relative abundances are shown in all graphs. 
*p<0.05 **p<0.001 and ***p<0.0001 vs. control, error bars indicate standard error 
of the mean. 
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Figure 1.7. Anandamide (AEA) abundances after chronic 3-week chronic intermittent 
access (IA) alcohol drinking or long-term withdrawal in male mice. (A) AEA 
abundances after chronic IA (labelled “none”), 1-week or 2-week withdrawal; 
Alcohol naïve control mice labelled Water; (B) AEA abundances presented as fold 
change vs. control for each tested time point. Normalized, relative abundances are 
shown in all graphs. ***p<0.0001 vs. other time points, error bars indicate standard 
error of the mean. 
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Figure 1.8. No FAAH changes in male mice (n=6) after acute or long-term 
withdrawal from 3-week chronic intermittent access (IA) alcohol drinking.  A 
Western blot of FAAH at each time point and the corresponding intensity are 
shown. Control mice were given only water. Test mice were exposed to chronic 
IA alcohol (15%) drinking for 3 weeks and then 1 day, 1 week or 2 week of 
withdrawal. 
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As presented as fold change of AEA (Figure 1.7B), one-way ANOVA 
revealed a significant effect of time [F (3, 20) = 109, p<0.000001], and post hoc 
analysis showed that the 1-day (24 hours) withdrawal had higher ADE levels than 
other time points examined [p<0.0001].  
4. FAAH levels in the prefrontal cortex after withdrawal from chronic IA in male 
mice. Protein lysates prepared from the PFC of male mice were analyzed by Western 
Blotting. No difference in FAAH levels was detected after acute (1 day) or long-term 
(1 and 2 weeks) withdrawal, as compared to the water control (Figure 1.8). 
 
DISCUSSION 
 
Our first objective in the present study was to investigate the potential of an 
FAAH inhibitor, URB597, in reducing alcohol consumption in mice after acute (1 
day) withdrawal from chronic IA alcohol drinking.  Single acute administration of 
URB597 (a long-lasting inhibitor) significantly reduced 15% alcohol intake in mice in 
a dose-dependent manner (0.125-1 mg/kg) (Figure 1.2A). The URB597-induced 
reduction of alcohol intake was coupled with a full compensatory increase in water 
intake, resulting in no change in total fluid intake (Table S1.1). This indicates the 
absence of nonspecific sedative effects by this FAAH inhibitor. Consistently, URB597 
(0.125-1 mg/kg) produced a dose-dependent reduction in alcohol preference (Figure 
1.2B). In the present study, we further confirmed that URB597 reduced alcohol 
drinking in a CB1-dependent manner, as selective CB1 antagonist AM251 blocked the 
effects of URB597 (Table 1.6). It is unlikely that the effect of URB597 in reducing 
alcohol intake was secondary to a general suppression of appetitive (anhedonic effect) 
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or consumption behaviors, since URB597 at 0.5 mg/kg did not decrease sucrose 
(caloric reinforcer) (Table 1.7) or saccharin (non-caloric reinforcer) (Figure 1.3) 
intake. The present study also found a relatively long duration (4 hours) of the effect 
of single acute URB597 administration on alcohol drinking, which is likely due to its 
long-lasting bioactivity in vivo [Fegley et al. 2005; Basavarajappa et al. 2014]. 
Together, these results clearly demonstrate that the URB597-induced inhibition of 
FAAH plays a role in modulating alcohol drinking in mice. Therefore, the 
development of FAAH inhibitors with improved pharmacokinetics has the potential to 
yield useful compounds for the treatment of alcoholism and other drug addictions 
[Panlilio et al. 2013; Zhou & Kreek 2014]. 
Though URB597 does not produce any reward [Gobbi et al. 2005], repeated 
administration of URB597 has been found to correct the reduction in sucrose intake 
after chronic stress in both mice [Rademacher & Hillard, 2007] and rats [Bortolato et 
al. 2007]. Our results showed that single acute URB597 administration at 0.5 mg/kg 
(the most effective dose tested for reducing alcohol intake) had no effect on sucrose or 
saccharin preference in alcohol naïve mice, but increased saccharin preference in mice 
after 1-week alcohol withdrawal (Figure 1.3). Consistently, previous work has found 
that URB597 does not affect saccharin or sucrose drinking in stress-naïve animals (not 
rewarding) [Basavarajappa et al. 2006; Blednov et al. 2007; Manwell et al. 2009], but 
increases sucrose preference and/or intake in stress exposed animals due to “anti-
depression” properties [Rademacher & Hillard, 2007; Bortolato et al. 2007]. Together, 
our data suggest that the enhanced eCB activity resulting from the FAAH inhibitor can 
modulate sensitivity to saccharin reward during alcohol withdrawal.  Alternatively, 
URB597 as an indirect eCB agonist may increase preference for more palatable 
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reinforcers, such as saccharin (Figure 1.3) and sucrose (slight, but not significant, 
increases at 2% [Table 1.7A]), with decreased preferences for less palatable 
reinforcers (15% and 30 % alcohol), though URB597 itself is not rewarding [Gobbi et 
al. 2005]. 
With low alcohol intake models, previous studies tested the FAAH inhibitor 
URB597 on alcohol-related behaviors: [1] on reinstatements of alcohol-seeking 
behavior, no effect was found after acute URB597 administration in rats with alcohol 
intake < 2 g/kg during 1 hour of alcohol access [Cippitelli et al. 2008]; and [2] 
URB597 was reported to increase alcohol drinking in mice with alcohol intake < 4 
g/kg/day during 24 hours of alcohol access [Blednov et al. 2007]. In contrast to mice 
in the 4-hour limited-access DID paradigm, which had low alcohol intake (<5-6 
g/kg/day) [Rhodes et al. 2007], mice in the chronic IA paradigm showed “heavy” 
drinking with 15-20 g/kg/day in males and 20-25 g/kg/day in females [Hwa et al. 
2011; Zhou et al. 2017]. For these reasons, we purposely compared the effects of 
URB597 on chronic IA with DID, and found that single acute URB597 administration 
at 0.5 mg/kg reduced alcohol drinking after 1 day withdrawal from chronic IA (Figure 
1.2), with no effect after 1 day withdrawal from chronic DID (SI section, Results 
S1.1). When tested in other alcohol concentrations, we observed that single acute 
administration of URB597 at 0.5 mg/kg reduced high levels of alcohol intake with 
30% alcohol, but had no effect on low levels of alcohol intake with 7.5% alcohol 
(Table 1.5), consistent with the above notion. Together, our results demonstrate that 
URB597 modulates alcohol drinking in mice with long-access and chronic exposure to 
high levels of alcohol intake, but not with either limited access (like DID) or low 
levels of alcohol intake at 7.5% concentration. In accord with previous research, our 
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data further indicate that the protective role of the eCBs becomes effective as the 
withdrawal from “heavy” alcohol drinking is pronounced [Morena et al. 2016]. Drug 
escalation to high level intake is widely considered a hallmark of the transition from 
alcohol abuse to drug dependence in humans. Thus, our preclinical study may provide 
new information about the medical potential of URB597 in the treatment of 
alcoholism.  
Our second main objective was to investigate the potential of URB597 in 
reducing relapse-like drinking in mice after long-term withdrawal.  The phenomenon 
of a transient increase in alcohol consumption after a period of imposed abstinence has 
been termed the alcohol deprivation effect (ADE). It can be regarded as an animal 
model of relapse behavior and craving with good predictive validity [Vengeliene et al. 
2014]. In the present study, mice of both sexes displayed the ADE with increased 
alcohol intake after 1 week of withdrawal (Figures 1.4, 1.5). In contrast, the mice 
pretreated with single acute URB597 administration at 0.5 mg/kg had a blunted ADE 
in both sexes (Figure 1.4), suggesting the involvement of FAAH activity in the 
relapse-like drinking behavior. This finding with alcohol would constitute an 
interesting extension to the anti-relapse properties of URB597 observed in cocaine 
[Chauvet et al. 2014], nicotine [Scherma et al. 2008] or opiate seeking behaviors 
[Manwell et al. 2009]. One concern about the use of URB597 is that its FAAH 
inhibitory activity after repeated administration could result in the development of 
tolerance. Therefore, we tested the effectiveness of the multiple-dosing regimen (5 
daily injections before the ADE during the 1-week withdrawal) to mimic the multiple-
dosing treatment in the clinic. Like the effect of single acute URB597 administration 
at 0.5 mg/kg on reducing the ADE in both sexes (Figure 1.4), the repeated 
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pretreatments of URB597 at the same dose during the withdrawal week efficiently 
prevented the ADE drinking in mice (Figure 1.5), showing no tolerance development 
after this multiple-dosing regimen. It is worth mentioning that the prevention of the 
ADE by this multiple-dosing regimen occurred with the last URB597 administration 1 
day before alcohol re-exposure ADE. Thus, our findings show promising in vivo data 
indicating that the long-lasting FAAH inhibitor URB597 may shows therapeutic 
potential in alcoholism treatment models. 
Previous lines of experimental evidence have suggested chronic alcohol-
exposed rats and mice as an animal model of alcohol withdrawal-induced “anxiety” 
and “depression”. These emotional states, and the search for the anxiolytic and 
antidepressant-like effects of alcohol, might in turn contribute to promoting the high 
levels of alcohol intake and preference that characterize the escalation drinking 
observed in the present study in mice [Colombo et al. 1995; Koob and Volkow 2010]. 
The stress-response eCB system is critically involved in “anxiety”-related behaviors 
[Dincheva et al. 2015; Parsons & Hurd 2015; Pardini et al et al. 2012; Spagnolo et al. 
2016], and FAAH inhibition reverses enhanced anxiety-like behavior present during 
alcohol withdrawal [Cippitelli et al. 2008]. Our mouse escalation model suggests a 
role for FAAH activity in the alcohol withdrawal-induced tendency of mice towards 
“anxiety”- and “depression”- like states. Thus, the increased AEA/CB1 activity after 
URB597 administration, by inhibiting FAAH activity [Basavarajappa et al. 2014], 
could be partially responsible for the anxiolytic action of the FAAH inhibitor and 
subsequent reduction in alcohol intake after acute withdrawal in both male and female 
mice (Figure 1.1). In support of this concept, CB1 knockout mice with higher 
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“anxiety”-like behavior [Bowers & Ressler 2016] display higher alcohol consumption 
than the wild-type littermates during the first days [Racz et al. 2003]. 
Therefore, we sought to determine the effects of chronic high alcohol intake 
and subsequent alcohol withdrawal on the eCB system at a molecular level to better 
understand the dynamic changes in different brain regions. We used a targeted mass 
spectrometry method to quantify the relative abundance of NAE family of eCBs in the 
NAc, BLA, PFC and cerebellum of mice. Interestingly, after acute 1-day withdrawal 
from 3-week chronic IA alcohol drinking, all four brain regions showed significant 
increases in the AEA, OEA and PEA, with the NAc and BLA displaying the largest 
changes (Figure 1.6). As previous studies showed alterations of AEA levels in the 
amygdala and other brain regions of rats after chronic alcohol or withdrawal [Rubio et 
al. 2008; Robinson et al. 2016; Henricks et al. 2017], we further determined dynamic 
profiles of relative abundances of NAEs in the BLA following chronic IA drinking (no 
withdrawal) and after one and two weeks of alcohol withdrawal, all of which showed 
no change compared to control (Figure 1.7A, S1.2). Together, this indicates that 
global NAE dysregulation occurs as a response to acute alcohol withdrawal only. This 
transient increase may be due to decreased FAAH activity, as found in the rats after 1-
day alcohol withdrawal [Serrano et al. 2012], but not the FAAH expression level as 
observed in the present study (Figure 1.8). To our knowledge, this is the first 
description of global NAE dysregulation, both in terms of multi-localization and 
number of endogenous substrates (AEA, OEA, and PEA), in response to acute alcohol 
withdrawal, and indicates that a strong eCB response may act as an important 
molecular coping mechanism in acute alcohol withdrawal, thereby allowing the mice 
to better cope with alcohol withdrawal stress. As a possible allostatic process, the 
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AEA surges may be resultant from the absence of an AEA release during 1-day acute 
withdrawal. Indeed, a recent study has found that the AEA release in the rat nucleus 
accumbens is observed only after acute alcohol, but not chronic alcohol or chronic 
withdrawal [Ceccarini et al. 2013], though other reports showed that acute alcohol 
decreases [Ferrer et al. 2007] or did not change AEA release in this region [Alvarez-
Jaimes et al. 2009].  AEA and other NAE elevations were detected at 1-day 
withdrawal, whereas behavioral responses to the FAAH inhibitor URB597 (inhibition 
of alcohol drinking) were apparent at both 1-day and 1-week withdrawal time points. 
With the available data, the best explanation of this phenomenon is that naturally or 
pharmacologically elevated NAEs are protective from alcohol withdrawal stress. 
Naturally, this response (observed in tissue content, but not release) occurs only 
transiently as an acute response to withdrawal and does not persist after a week. 
However, after one week of alcohol withdrawal, pharmacological elevation of NAEs 
with an FAAH inhibitor still provides the same anti-stress protection, leading to 
reduce “relapse” drinking.  As the role of eCBs is complicated by their involvement in 
modulation of alcohol escalation and “relapse” drinking, two other possible 
explanations should be considered. The AEA changes in other brain regions rather 
than the four areas tested could be correlated to alcohol withdrawal. Alternatively, our 
data suggest that the CB1 binding and/or function, and the downstream effects of CB1 
receptor signaling can be more involved in the behavioral effects of the FAAH 
inhibition. Further study to elucidate these findings is warranted. In summary: In line 
with previous studies on cocaine, nicotine and opiate seeking behaviour [Panlilio et al. 
2013], our findings show initial, promising in vivo data indicating that 
  
77 
 
 
 
pharmacological FAAH inhibition decreases alcohol escalation and “relapse” drinking 
in mice. 
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SUPPLEMENTARY INFORMATION 
 
Results S1.1. No effect of single, acute administration of URB597 (0.25 or 0.5 mg/kg) 
on 15% alcohol intake after 3-week drinking-in-dark (DID) model. To assess the 
effect of URB597 on the short-access “binge” alcohol drinking, the mice (n = 6/per 
group) received URB597 at 0, 0.25 or 0.5 mg/kg after 3 weeks of DID. There was no 
effect on alcohol intake after 4 hours (control mice: 4.3 ± 0.27 g; 0.25 mg/kg URB597 
mice: 3.7 ± 0.39 g; 0.5 mg/kg URB597 mice: 3.9 ± 0.44 g). 
 
Table S1.1. No effects of single, acute administration of URB 597 (URB, 0.5mg/kg) on 
total fluid intake in male mice after 1 day of withdrawal from 3-week chronic 
intermittent access (IA) alcohol drinking. 
Total fluid intake, ml Vehicle (n = 7) 0.5 mg/kg URB (n = 6)  
4h  1.7 ± 0.2 1.6 ± 0.1  
8h  1.1 ± 0.3 1.3 ± 0.5 
24h  2.9 ± 0.3 2.8 ± 0.3 
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 Male female 
 Vehicle  
(n = 8) 
0.5 mg/kg URB 
(n = 7) 
Vehicle  
(n = 6) 
0.5 mg/kg 
URB 
(n = 6) 
Intake, g/kg 6.0± 0.35  2.8 ± 0.40 *  9.7 ± 1.1 
+ 
5.6 ± 1.0 ** 
Preference ratio 0.74 ± 0.06 0.48 ± 0.10 * 0.84 ± 
0.04 
0.56 ± 0.05 * 
 
  
Table S1.2. Effects of single, acute administration of URB597 (URB, 0.5 mg/kg) 
on 15% alcohol intake and preference ratio in both male (presented in Figure 1) 
and female (presented in Figure S1) mice after 1 day of withdrawal from 3-week 
chronic intermittent access (IA) alcohol drinking at 4 hours. Statistical analysis 
was run for both male and female mice together. For intake, two-way ANOVA 
revealed a significant effect of URB597 treatment [F (1, 27) = 24.5, p<0.00005] 
and a significant effect of sex [F (1, 27) = 9.4, p<0.01], with no significant 
interaction between URB597 treatment and sex.  Post hoc analysis showed that: 
(1) the vehicle-treated females had more intake than the vehicle-treated males 
(p<0.05); and (2) both the URB597-treated males and females had less intake 
than the vehicle-treated ones at 4 hours [p<0.05 and p<0.01, respectively]. For 
preference ratio, two two-way ANOVA revealed a significant effect of URB597 
treatment [F (1, 27) = 18, p<0.0005], with no significant interaction between 
URB597 treatment and sex. Post hoc analysis showed that both the URB597-
treated males and females had less preference than the vehicle-treated ones at 4 
hours [p<0.05 for both]. * p<0.05 and **p<0.01 vs. vehicle control in the same 
sex; + p<0.05 vs. male. 
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Figure S1.1. Effects of 1-day withdrawal from 3-week chronic intermittent access (IA) 
alcohol drinking on brain NAE abundances. Test male mice (labelled Alcohol, n = 6, 
each n is combined brain regions from 2 mice) were exposed to chronic IA alcohol 
(15%) drinking for 3 weeks and then 1 day of withdrawal. Control mice (labelled 
Water, n = 6, each n is combined brain regions from 2 mice) were given only water. 
NAEs were then extracted and quantified from four brain regions on an LC-MS 
system. The family of NAEs is generally elevated globally after 1 day alcohol 
withdrawal, as shown by AEA (shown in Figure 6), palmitoyl ethanolamide (PEA) and 
oleoyl ethanolamide (OEA) abundances in the basolateral amygdala (shown in Figure 
6), nucleus accumbens, cerebellum, and prefrontal cortex. Normalized, relative 
abundances are shown in all graphs. *p<0.05 **p<0.001 and ***p<0.0001 vs. 
control, error bars indicate standard error of the mean. 
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Figure S1.2. No NAE changes after chronic IA or long-term withdrawal.  Test male 
mice (n = 6, each n is combined brain regions from 2 mice) were exposed to chronic 
IA alcohol (15%) drinking for 3 weeks and then 1 week or 2 weeks of alcohol 
withdrawal. Control mice (labelled Water, n = 12, each n is combined brain regions 
from 2 mice) were given only water. NAEs were then extracted from the basolateral 
amygdala and quantified on an LC-MS system. Palmitoyl ethanolamide (PEA) and 
oleoyl ethanolamide (OEA) abundances were unchanged after chronic IA, 1-week or 
2-week withdrawal. Normalized, relative abundances are shown in all graphs. Error 
bars indicate standard error of the mean. 
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CHAPTER TWO† 
 
IDENTIFICATION OF A DISTINCT METABOLOMIC 
SUBTYPE OF SPORADIC ALS PATIENTS 
 
INTRODUCTION 
 
Sporadic amyotrophic lateral sclerosis (sALS) is a debilitating 
neurodegenerative disease for which effective therapeutic options are essentially non-
existent [Kiernan et al. 2011]. With a clinical presentation involving gradual failure of 
motor neurons all around the body, average survival from diagnosis is 2-5 years 
[Wijesekera et al. 2009]. Our understanding of sALS at a molecular level is severely 
lacking. To date, no clinically useful biomarkers of the disease exist and the molecular 
basis for disease pathogenesis is yet to be discovered [Turner et al. 2013]. 
A number of studies looking at metabolic abnormalities in blood plasma and 
cerebral spinal fluid of ALS patients suggest that ALS is closely linked with 
dysregulated metabolism [Lawton et al. 2012; Wuolikainen et al. 2012; Wuolikainen 
et al. 2011; Wuolikainen et al. 2016; Blasco et al. 2010; Blasco et al. 2013; Kumar et 
al. 2010]. However, these prior metabolomics studies have focused on familial ALS 
and consideration of these abnormalities in sALS are hindered by the fact that these 
studies have been limited to post-mortem tissues and biological fluids, rather than 
living cells. The ALS Stratification Prize - Using the Power of Big Data and 
Crowdsourcing for Catalyzing Breakthroughs in ALS aims to work towards 
                                                          
† Adapted from Chen et al. Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients. 
bioRxiv preprint. 2018. 
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understanding heterogeneity in ALS. Several clinical parameters have been identified, 
such as plasma uric acid, creatinine and blood pressure [Kuffner et al. 2015]. 
However, disease mechanism-relevant metabolic abnormalities would be more useful 
in understanding and interpreting patient heterogeneity. In support of cellular 
metabolism being integral to sALS, our collaborator recently showed that sALS 
patient-derived skin fibroblasts display bioenergetics abnormalities, including 
increased mitochondrial membrane potential (MMP), increased oxygen consumption 
rate (OCR), and increased extracellular acidification rate (ECAR) [Kirk et al. 2014]. In 
sum, it seems that the study of small metabolites offers a new vantage point to 
possibly uncover pivotal molecular mechanisms that are relevant to sALS disease. 
Identification of molecular biomarkers would potentially allow for 
stratification of sALS patients into subgroups, providing an opportunity for attempts at 
more personalized therapeutic approaches. A knowledge of quantifiable sALS disease 
biomarkers, as opposed to only long-term clinical outcomes, and a recognition of 
distinct mechanistic subtypes of sALS for patient stratification, would predictably 
allow for faster and more targeted clinical trials (i.e. using drugs efficacious in specific 
subgroups), leading to accelerated clinical advances. Finally, an understanding of 
molecular mechanisms and metabolic pathways involved in disease initiation and/or 
progression would provide new therapeutic targets for development of successful 
pharmaceutical interventions.  
 For highly relevant results, the metabolism-centered study of sALS should be 
done using live, metabolically active patient-derived cells. For this purpose, skin 
fibroblasts can be obtained with a minimally invasive punch biopsy and cultured until 
metabolite extraction and analysis [Vangipuram et al. 2013]. Because these cells share 
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the genetic make-up of motor neurons, if sALS has a genetic or epigenetic basis, they 
offer readily accessible disease-relevant insights. Notably, skin abnormalities in ALS, 
such as reduced elasticity and a delayed return phenomenon, indicate that fibroblasts 
are also affected by the disease [Ono et al. 1988]. ALS patient skin samples have also 
been found to display changes in ALS-associated proteins and metabolites, such as 
FUS [Oketa et al. 2013], TDP-43 [Suzuki et al. 2010], VCP [Ishikawa et al. 2012], 
VEGF [Suzuki et al. 2009], ubiquitin [Watanabe et al. 2010], MMP-2, MMP-9 [Fang 
et al. 2009; Fang et al. 2010], TNF-α [Fukazawa et al. 2013], IL-6 [Ono et al. 2001], 
angiogenin [Higashida et al. 2013], hyaluronic acid [Ono et al. 2000], and collagen 
[Ono et al. 2000]. Finally, astrocytes generated from ALS fibroblasts have been shown 
to be toxic to motor neurons, similar to regular ALS astrocytes [Meyer et al. 2014]. In 
all, these facts make patient fibroblasts a suitable model for live-cell metabolomics 
studies of sALS. 
The following study was based on the hypothesis that subgroups of patient 
derived sALS skin fibroblasts would have a distinct pattern of metabolic abnormalities 
that is shared with motor neurons and that is a common hallmark of sALS. The 
innovation of this study is two-pronged. First, it focuses on live, human-derived cells, 
a complex system which has not yet been used in the study of sALS. This system 
allows for unprecedented disease relevance and coverage of small metabolites. 
Second, this project utilizes mass spectrometry based untargeted global metabolite 
profiling, an extremely powerful analytical technique, whose full capabilities have not 
been exercised in pursuing information about sALS. 
We first did a number of experiments aimed at the characterization of 
metabolic profiles of sALS vs. control fibroblasts in order to identify subgroups of 
  
93 
 
 
 
sALS patients based on a shared ‘metabotype.’ We identified an sALS subgroup 
defined by increased abundance of homocysteine and other compounds related to the 
trans-sulfuration pathway in the largest such study to date (77 patient-derived dermal 
fibroblast lines and 45 age- and sex-matched controls). We next worked to validate 
these results and further characterize this subgroup using stable isotope tracing, 
untargeted metabolite profiling of plasma from these patients, and a multi-omics 
analysis including mRNAs and microRNAs from the patient fibroblasts. In all, this 
study highlights the possibility of stratification of sALS patients based on small 
molecule metabolites, which could lead to a better understanding of the disease and 
contribute to the development of personalized therapies. 
 
MATERIALS AND METHODS 
 
Reagents. LC-MS grade acetonitrile (ACN), isopropanol (IPA) and methanol (MeOH) 
were purchased from Fischer Scientific. High purity deionized water (ddH2O) was 
filtered from Millipore (18 OMG). OmniTrace glacial acetic acid and ammonium 
hydroxide were obtained from EMD Chemicals. [U-13C] glucose, [2,3,3-2H]-serine 
were purchased from Cambridge Isotope Laboratory. Ammonium acetate and all other 
chemicals and standards were obtained from Sigma Aldrich in the best available 
grade. 
Cell culture: A total of 77 sALS and 45 control fibroblast cell lines were obtained 
from cases and propogated as previously described [Konrad et al. 2017]. 75,000 
cells/well for each line were plated in duplicate 6-well plates and cultured in DMEM 
medium containing 5 mM glucose and 4 mM glutamine, 10% FBS, 1% of 100X 
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antibiotic/antimycotic (Ab+F; which contains sterile-filtered 10,000 units penicillin, 
10 mg streptomycin and 25 μg amphotericin B per mL, and 2.5 µg/ml Plasmocin). 
Cells were harvested at 80% confluency and metabolites extracted for LC/MS 
metabolomic analysis. 
Metabolite extraction: Each cell line was cultured and initially extracted as two 
biological replicates, for independent LC/MS metabolomic data acquisition. Cells 
were washed rapidly twice with ice-cold PBS and twice with ice-cold water, followed 
by metabolite extraction using -70ºC 80:20 methanol:water (LC-MS grade methanol, 
Fisher Scientific). The tissue–methanol mixture was subjected to multiple episodes of 
vortexing or were bead-beaten for 45 sec using a Tissuelyser cell disrupter (Qiagen). 
Extracts were centrifuged for 5 min at 5,000 rpm to pellet insoluble material and 
supernatants were transferred to clean tubes. The extraction procedure was repeated 
two additional times and all three supernatants were pooled, dried in a Vacufuge 
(Eppendorf) and stored at -80ºC until analysis. The methanol-insoluble protein pellet 
was solubilized in 0.2 M NaOH at 95ºC for 20 min and protein was quantified using a 
BioRad DC assay. On the day of metabolite analysis, dried cell extracts were 
reconstituted in 70% acetonitrile at a relative protein concentration of 1 µg/ml, and 4 
µl of this reconstituted extract was injected for LC/MS-based untargeted metabolite 
profiling.  
These 244 patient-derived skin fibroblast extracts (122 samples with 2 
biological replicates) were analyzed by LC-QTOF metabolomics profiling in random 
sequence. To adjust for day-to-day and batch-to-batch LC/MS instrument drift, 
metabolite stability, and other experimental factors that may contribute to systematic 
error, metabolite measurements were normalized to one another using flanking quality 
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control (QC) samples run at intervals of every 6 injections. These QC samples were 
prepared from a pool of all samples and this normalization procedure enabled the 
comparative analysis of data acquired over a 1-month collection period. 
Plasma metabolites were extracted by 1:20 dilution of plasma in 70% 
acetonitrile in ddH2O (vol:vol). The mixture was briefly vortexed and then 
centrifuged for 5 min at 16,000 × g to pellet precipitated proteins. An aliquot of the 
resulting extract (3 μl) was subjected to untargeted metabolite profiling using, 
applying both positive and negative ion monitoring MS. 
Untargeted metabolite profiling by LC/MS: Cell extracts were analyzed by LC/MS as 
described previously [Chen et al. 2012; Ismailoglu et al. 2014], using a platform 
comprised of an Agilent Model 1290 Infinity II liquid chromatography system coupled 
to an Agilent 6550 iFunnel time-of-flight MS analyzer. Chromatography of 
metabolites utilized aqueous normal phase (ANP) chromatography on a Diamond 
Hydride column (Microsolv). Mobile phases consisted of: (A) 50% isopropanol, 
containing 0.025% acetic acid, and (B) 90% acetonitrile containing 5 mM ammonium 
acetate. To eliminate the interference of metal ions on chromatographic peak integrity 
and electrospray ionization, EDTA was added to the mobile phase at a final 
concentration of 6 µM. The following gradient was applied: 0-1.0 min, 99% B; 1.0-
15.0 min, to 20% B; 15.0 to 29.0, 0% B; 29.1 to 37min, 99% B.  Raw data were 
analyzed using MassHunter Profinder 8.0 and MassProfiler Professional (MPP) 14.9.1 
software (Agilent technologies). Mann Whitney t-tests (p<0.05) were performed to 
identify significant differences between groups.   
Metabolite Structure Specification To ascertain the identities of differentially 
expressed metabolites (P<0.05), LC/MS data was searched against an in-house 
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annotated metabolite database created using MassHunter PCDL manager 7.0 (Agilent 
Technologies), based on monoisotopic neutral masses (<5 ppm mass accuracy) and 
chromatographic retention times. A molecular formula generator (MFG) algorithm in 
MPP was used to generate and score empirical molecular formulae, based on a 
weighted consideration of monoisotopic mass accuracy, isotope abundance ratios, and 
spacing between isotope peaks. A tentative compound ID was assigned when PCDL 
database and MFG scores concurred for a given candidate molecule. Tentatively 
assigned molecules were verified based on a match of LC retention times and/or 
MS/MS fragmentation spectra for pure molecule standards. 
Stable isotope tracing of [U-13C] glucose and [2,3,3-2H] serine: An in-house 
untargeted stable isotope tracing (USIT) workflow was employed using Agilent 
metabolite profiling software MassHunter Qualitative Analysis 7.0, MassProfinder 8.0 
and MPP 14.9.1. Labelled metabolites were identified on the basis of differential 
abundance in cells cultured with supplemental heavy isotope-labelled metabolite vs. 
natural (light) isotope, as described previously [Leung et al. 2017; Chen et al. 2018]. 
Selected metabolites were identified on the basis of previously curated isotopologues. 
Notably, the USIT workflow calculates and corrects for the natural abundance of 13C 
and 2H isotope in samples. 
Microarray analysis:  Total RNA (combined mRNA and miRNA) from skin 
fibroblasts was extracted from 27 sALS patients and 27 controls using Trizol agent 
(Invitrogen). Total RNA was further extracted using the Agilent Absolutely RNA 
miRNA Kit. The total RNA concentration and RNA sample integrity were verified by 
a Bio-Analyzer 2100 (Agilent Technologies, Waldbronn, Germany). The quality of 
isolated RNA was determined using an Agilent 2200 TapeStation system and 
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Bioanalyzer with mRNA labeling and microarray processing were performed 
according to the manufacturer’s recommendations. miRNA labeling was done using 
an Agilent miRNA Complete Labeling and Hyb Kit with gene expression and miRNA 
data extracted using Agilent Feature Extraction Software. 
Extracted mRNA and miRNA data were analyzed using the respective 
workflows in GeneSpring GX 14.9.1 (Agilent Technologies, CA). Signal intensities 
for each mRNA probe was normalized to 75th percentile values with baseline 
transformation for gene expression analysis. Separately, miRNA data was normalized 
to 90th percentile and baseline transformed for miRNA analysis. The differential 
miRNA list (P<0.05, FC>1.2) was used to identify the gene targets based on a target 
prediction database incorporated in GeneSpring GX (e.g. TargetScan, PicTar, 
microRNA.org). The differentially expression mRNA was combined with validated 
miRNA targets and metabolites for integrated multi-Omics pathway analysis using 
databases linked to KEGG, Wiki pathways and Biocyc.   
Statistics: All values are averages of at least three independent measurements. Error 
bars indicate standard deviation (S.D.) or standard error of the mean (S.E.M.). 
Statistically significant differences between two groups were estimated by unpaired 
two-tailed Student’s test with significance set at p<0.05.   
 
RESULTS 
 
Untargeted metabolite profiling of human skin fibroblasts identifies an sALS 
subgroup.  Metabolite profiling was performed on cultured skin fibroblasts obtained 
from 77 sALS patients and 45 healthy controls (age and sex matched). 507 of 1172 
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detected features were differentially abundant in sALS vs control (non-parametric 
Mann-Whitney test (P<0.05)) (Figure 2.1A). Principal component analysis (PCA) 
using these metabolite abundances highlighted a distinct subgroup of 18 sALS 
(‘sALS-1’) cell lines that clustered along PC1 (33.9% variance), revealing a subgroup 
with a distinct ‘metabotype’ (Figure 2.1B). 
We repeated metabolic profiling on these 18 sALS cell lines (cells were re-
thawed, grown and metabolites extracted) and a randomly selected group of 18 control 
cell lines. 41 metabolites were differentially abundant in both experiments when the 
sALS-1 was compared to all control lines (Figure S2.1), including significant 
increases for 2-hydroxybutyrate, taurine, and C3-C5 carnitines and significant 
decreases in creatinine, ATP and several amino acid (Figure 2.1E). The taurine and 
hypotaurine pathway was identified as the most significantly impacted in a pathway 
enrichment and topology analysis (Figure 2.1C).  
We generated a 4-metabolite linear support vector machine (SVM) model 
(using 2-hydroxybutyrate, taurine, propionylcarnitine and creatinine) that predicted the 
sALS-1 group with an accuracy of 97% in the original group (with 1/45 false-positives 
and 1/18 false-negatives; Figure 2.1D) and 90.9% accuracy in the repeat analysis. 
These metabolites are related through the methionine cycle, methylation and trans-
sulfuration pathways (Figure 2.1F) and these metabolite profiling results indicate 
abnormalities in these pathways in the sALS-1 subgroup. Homocysteine can enter the 
trans-sulfuration pathway as a precursor for cystathionine. Cystathionine cleavage 
produces 2-ketobutyrate, which can be reduced to 2-hydroxybutyrate or added to 
propionylcarnitine for -oxidation in mitochondria. 
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Figure 2.1. Mass spectrometry-based untargeted metabolite profiling of patient 
fibroblast cell lines reveals an sALS subgroup. A) Mass and retention time (RT) 
scatterplot of 1165 features detected in skin fibroblasts. Metabolites with >70% 
frequency in one group were included. B) Principal component analysis plot of 77 
sALS (red) and 45 control (yellow circles) cell lines based on metabolite abundances. 
A subgroup of >18 sALS patients (dashed red oval) clearly separates form other cell 
lines (yellow oval). C) An enrichment and pathway topology analysis of metabolites of 
interest. Taurine and hypotaurine are identified as the most significantly affected 
pathways in sALS-1. D) An ROC curve from the support vector machine model based 
on 4 metabolites. The AUC for sALS-1 prediction (i.e. the overall accuracy, specificity 
and sensitivity) is 97.5%. The inset is the ROC curve and AUC for the repeat 
experiment. E) Detected ion abundance of 4 metabolites of interest. *, P<0.05 (2-
tailed Student t-test). F) Schematic representation of the methionine cycle, methylation 
and trans-sulfuration pathways. Met, methionine; Hcy: homocystieine; Sam: S-
adenosylmethionine; Sah: S-adenosylhomocysteine; Cyst: cystathionine; Sa: 
sulfoalanine; 3-SP: 3-sulfopyruvate. The enzyme name abbreviations were adapted 
from KEGG pathway. MAT: methionine adenosyltransferase; MS: methionine 
synthase; SAHH: S-adenosylhomocysteine hydrolase; MTase: methyltransferase; 
CBS: cstathionine beta synthase; CSE: cystathionine gamma lyase; GCL: glutamate 
cysteine ligase; GS: GSH synthase; CDO: cysteine dioxygenase; LDH: lactate 
dehydrogenase; COAS: propionylCoA synthetase; CA: carnitine acyltransferase; 
GAD1: glutamate decarboxylase 1; GGT: Gamma-glutamyltransferase; GOT1: 
glutamic-oxaloacetic transaminase 1; SO:  sulfite oxidase; Spon1, Spon2 and Spon3 
refer to non-enzymatic spontaneous degradation process. 
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Creatine, which is synthesized by methylation of guanidinoacetate [Wyss et al. 
2000], and can spontaneously degrade to creatinine. A lower abundance of creatinine 
indicates reduced S-adenosylmethionine (SAM) mediated methylation. 
 
The sALS-1 subgroup has increased serine incorporation into glutathione. In order 
to further characterize the trans-sulfuration related abnormality in sALS-1 fibroblasts, 
we performed stable isotope tracing with deuterated serine. The goal was to assess if 
these fibroblasts display increased glutathione production from serine-derived glycine. 
sALS-1 (3 cell lines with high  intracellular 2-hydroxyglutarate) and control 
fibroblasts (3 randomly selected) were grown in 2 mM [2,3,3-2H]-serine supplemented 
medium. sALS-1 fibroblasts indeed displayed increased serine flux to into GSH and 
GSSG (Figure 2.2A, B, C, D). 
Surprisingly, we did not detect any serine incorporation into cystathionine, 
indicating that trans-sulfuration from homocysteine to de novo synthesized cysteine 
was insignificant. Serine, together with homocysteine, is a precursor for cystathionine 
(Figure 2.1F). Deuterium incorporated into cystathionine can therefore indicate the 
activity of the trans-sulfuration pathway. It is possible that cystine in the culture 
medium was at a high enough concentration to support GSH production. To test this, 
we cultured cells with deuterated serine for a longer time (48h), when cystine is 
significantly decreased in the media. Increased serine-derived GSH (Figure 2.2E, F) 
and cystathionine (Figure 2.2G-H) was indeed observed in the sALS-1 group vs. 
control at this time point. The cystathionine gamma-lyase/hydrogen sulfide system 
was previously shown to be essential for maintaining cellular glutathione status [Lee 
et al. 2014].  
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Figure 2.2. Serine tracing shows increased GSH, GSSG and cystathionine synthesis 
in the sALS-1 subgroup. A) isotope enrichment and B) total ion abundance of GSH in 
sALS-1 and control fibroblasts after growth with [2,3,3-2H]-serine for indicated 
durations. C) isotope enrichment and D) total ion abundance of GSSG in sALS-1 and 
control fibroblasts after growth with [2,3,3-2H]-serine for indicated durations. E) 
isotope enrichment and F) total ion abundance of GSH in sALS-1 and control 
fibroblasts after growth with [2,3,3-2H]-serine for 48h. G) isotope enrichment and H) 
total ion abundance of cystathionine in sALS-1 and control fibroblasts after growth 
with [2,3,3-2H]-serine for 48h. 3 sALS-1 and 3 control cell lines were used. Error 
bars are mean ± S.D. *, P<0.05 (2-tailed Student t-test). 
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The minor incorporation into GSH observed here suggests that the cysteine is 
primarily used toward oxidation to taurine and reduction to hydrogen sulfide to 
maintain current GSH supply, as a possible mechanism for protection against 
oxidative stress. 
 
The sALS-1 subgroup has increased glucose incorporation into glutathione and 
TCA cycle intermediates. Next, we studied the flux of glucose carbon atoms to GSH, 
which provides information about the contribution of glutamate to GSH production. 
Through TCA cycle-derived alpha ketoglutarate, glucose carbons are incorporated into 
glutamate. We traced glucose carbons in 3 sALS-1 and 3 control fibroblast cell lines 
by adding 5 mM [U-13C]-glucose to cell culture media and metabolites were extracted 
after 1h, 5h, 24h and 48h time points. Incorporation of glucose into glutamate was 
observed at all time points (Figure 2.3A-B). sALS-1 fibroblasts had significantly 
increased GSH incorporation from glutamate (M+2) at 24h and 48h time points 
(Figure 2.3C, E). Increased glutamate-derived GSH but unchanged total GSH 
abundance (Figure 2.3D, F) in the sALS-1 subgroup indicates increased GSH 
consumption, which is supported by increased 13C labeled GSSG and total GSSG 
(Figure 2.3G, H). This may be explained as accelerated GSH oxidation to GSSG to 
provide more antioxidant defense in the sALS-1 group. We also analyzed these 
samples to determine if the sALS-1 subgroup displayed an overall increased metabolic 
rate, by looking at the glucose-derived metabolite abundances of intermediates in 
glycolysis, the TCA cycle, and other metabolic pathways. 
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Figure 2.3. Glucose tracing shows increased glutamate, GSH, and GSSG synthesis in 
the sALS-1 subgroup. A) and B) isotope enrichment of glutamate in sALS-1 and 
control fibroblasts after growth with [U-13C]-glucose for indicated durations. C) and 
E) isotope enrichment and D) and F) total ion abundance of GSH in sALS-1 and 
control fibroblasts after growth with [U-13C]-glucose for indicated durations. G) 
isotope enrichment and H) total ion abundance of GSSG in sALS-1 and control 
fibroblasts after growth with [U-13C]-glucose for 48h. 3 sALS-1 and 3 control cell 
lines were used. Error bars are mean ± S.D. *, P<0.05 (2-tailed Student t-test). 
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sALS-1 fibroblasts had increased incorporation of glucose into lactate, TCA 
cycle intermediates, amino acids (aspartate and alanine), and C2 and C4 acyl-
carnitines (Figure 2.4A-F and Figure 2.5A-D). These differences indicate an 
accelerated TCA cycle flux in the sALS-1 subgroup, supportive of increased energy 
metabolism as has been previously described in sALS fibroblasts [Konrad et al. 2017; 
Kirk et al. 2014]. 
 
sALS-1 subgroup transcriptomic changes support the metabolomic findings.  mRNA 
and microRNA microarray analysis was performed on 27 sALS (11 sALS-1 subgroup 
& 16 other sALS (sALS-2)) and 27 control cell lines to determine whether the 
metabolic pathway peculiarities described above in the sALS-1 subgroup were 
manifest in transcriptional changes. We curated the searchable database to include 
potential candidate gene sets based on previously published sALS studies, then 
identified genes based on differentially-expressed transcripts and microRNA targets in 
sALS subgroups. Using the curated database, Gene Set Enrichment analysis (GSA) 
identified significantly increased expression of genes involved in the regulation of 
catabolic processes, apoptosis, and epigenetic regulation by H3K4Me2 in sALS-1 vs. 
sALS-2 fibroblasts (Figure S2.2). Epigenetic regulation of senescence was suppressed 
in both sALS groups compared to control. 
For a multiomic interpretation, we integrated transcriptome, microRNAome 
and metabolome data into metabolic pathways queried by KEGG, Wiki-pathways and 
BioCyc. The super-trans-sulfuration pathway was among the top enriched in sALS-1 
(P<2.3e-4 by Fischer’s exact test, Figure 2.6A).  
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Figure 2.4. Glucose tracing shows increased incorporation into A) lactate and TCA 
cycle intermediates (B) citrate, C) oxoglutarate, D) succinate, E) fumarate and 
F)malate) in the sALS-1 subgroup fibroblasts. Fibroblasts were cultured for the 
designated duration with [U-13C]-glucose. Time points where significantly increased 
incorporation was observed are designated for each metabolite. 3 sALS-1 and 3 
control cell lines were used. Error bars are mean ± S.D. *, P<0.05 (2-tailed Student 
t-test). Note: Due to the overlapping of succinate M+2 with the reference ion (m/z 
119.03) used for mass accuracy correction, the calculated M+2 incorporation in 
succinate is much smaller than the actual incorporated value. 
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Figure 2.5. Glucose tracing shows increased incorporation into amino acids (A) 
alanine and B) aspartate) and acylcarnitines (C) acetylcarnitine and D) 
Butyrylcarnitine) in the sALS-1 subgroup fibroblasts. Fibroblasts were cultured for 
the designated duration with [U-13C]-glucose. Time points where significantly 
increased incorporation was observed are designated for each metabolite. 3 sALS-1 
and 3 control cell lines were used. Error bars are mean ± S.D. *, P<0.05 (2-tailed 
Student t-test). 
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Figure 2.6. An integrated analysis of transcriptomic (microarray) and metabolomics 
data reveal common pathways that are perturbed in sALS-1 fibroblasts. A) 
Enrichment analysis of multiomic data identifies the super-transsulfuration pathway 
as the most significantly different in sALS-1 compared to control group (sALS-2 
similarly shows this pathway as significant, but less so than sALS-1) (p<0.05, 
Fisher’s exact test). Analysis is based on differentially-abundant (metabolites or 
transcripts) targets from each ‘omic experiement. The metabolic pathways used for 
mapping were obtained from KEGG, Wiki-pathways and Biocyc and imported into 
Agilent GeneSpring 14.9.1 for pathway analysis. B) Schematic representation of the 
affected pathways with differentially expressed mRNA (cyan with purple boxes), 
miRNA (cyan without purple boxes) and metabolites (yellow) indicated. Charts next 
to entities represent normalized abundance in control (left bar) and sALS-1 (right 
bar). Transcript abundances of C) SLC7A11, the cystine-glutamate antiporter D) 
SLC1A3 , the glutamate aspartate transporter and E) glutathione peroxidase 6 
(GPX6) show differential expression in sALS-1 fibroblasts vs. control fibroblasts and 
highlight the manifestation of the perturbed transsulfuration pathway in sALS-1 
subgroup at the transcript level. *, P<0.05 (2-tailed Student t-test). 
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Figure 2.6B is a visualization of both the metabolomic and transcriptomic 
changes related to the trans-sulfuration pathway and highlights the overlap/support of 
the multiomic findings (sALS-1 fibroblasts vs. control). Differentially-expressed 
mRNA transcripts and microRNA targets were related to the methionine cycle, 
homocysteine to cysteine trans-sulfuration, and glutathione and cysteine metabolism. 
The sALS-1 subgroup showed significant transcriptional changes related to 
glutathione synthesis and oxidation, such as a decrease in SLC25A11 and an increase 
in SLC1A3 and GPX6 transcripts (Figure 2.6C-E). SLC7A11 is the cystine/glutamate 
antiporter (system xc-) and is of great interest in ALS, as it is linked to both oxidative 
stress and excitotoxicity. Cystine transport into the cell is critical for GSH generation, 
whereas glutamate release can potentially lead to excitotoxicity. SLC7A11 has been 
shown to be dysregulated in both ALS patients and animal models [Mesci et al. 2015; 
Albano et al. 2013; Figuera-Losada et al. 2017]. SLC1A3 is the glutamate/aspartate 
antiporter and transports glutamate into cells or mitochondria. Upregulation possibly 
indicates increased malate-aspartate shuttle, which is consistent with the increased 
TCA cycle flux found observed above. GPX6 is an isoform of glutathione peroxidase, 
which is involved in the oxidation of GSH to GSSG and the upregulation in this 
transcript is consistent with the accumulation of trans-sulfuration pathway metabolites. 
 
sALS-1 subgroup plasma displays altered trans-sulfuration pathway 
metabolites. Metabolite profiling of plasma from the same 18 sALS-1 subgroup 
patients and 20 control subjects was performed. >1000 metabolite features were 
detected, with 85 differentially-abundant in sALS-1 vs. control (Figure 2.7A, B). 
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Figure 2.7. Untargeted metabolite profiling of plasma reveals differentially abundant 
metabolites for sALS-1 subgroup vs. control that support the multiomic results from 
the same patients’ fibroblast cell lines (abnormal trans-sulfuration related 
metabolites). A) A heatmap of metabolites found to be significantly different in sALS-
1 subgroup plasma compared to control plasma. Increased (red) and decreased 
(blue) metabolites related to altered taurine and trans-sulfuration pathway, amino 
acids, lipid metabolism and purine nucleosides are indicated. sALS drug Riluzole and 
its drug metabolite hydroxyriluzole glucuronide are also highlighted. B) A principal 
component analysis plot using 88 differentially abundant plasma metabolites shows a 
clear separation of the sALS-1 subgroup (yellow) from control (red). C) Metabolite 
pathway enrichment analysis (KEGG pathways, MetaboAnalyst 3.0) highlights the 
Taurine/Hypotaurine pathway metabolites as the most significantly different in sALS-
1 plasma. 
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Decreased abundance of glutamine, glutamate, methionine, tyrosine and creatinine 
were observed in sALS-1 samples. Increased metabolites in these samples included 
taurine, glutamyl-taurine, bile acids, 2-hydroxybutyrate, purine metabolites, 
phospholipids, ceramides and fatty acid amides. The taurine/hypotaurine pathway was 
identified as the most significantly different (Figure 2.7C). These results are consistent 
with the metabolic perturbations identified in fibroblasts and suggest potential for the 
use of plasma biomarkers for clinical recognition of patients belonging to the sALS-1 
subgroup. 
 
DISCUSSION 
 
Our goal was to utilize mass spectrometry-based untargeted metabolite 
profiling to identify metabolic abnormalities in sALS patient-derived fibroblasts and 
to attempt to identify sALS subgroups based on these biomarkers. We successfully 
identified a subgroup of sALS fibroblasts characterized by increased trans-sulfuration 
pathway activity, displaying increased GSH synthesis and accelerated glucose 
metabolism. In a multiomic approach, we also found evidence of abnormal trans-
sulfuration pathway in fibroblast mRNAs and microRNA. This metabotype was 
supported by plasma metabolites from the same patients, indicating the possibility of 
usable plasma (easy to obtain) biomarkers for clinical subgrouping. 
Hypermetabolism in ALS has been described before. In fact, we (the Manfredi 
lab) previously showed that these sALS skin fibroblasts display abnormal 
mitochondrial bioenergetics, with increased mitochondrial membrane potential 
(MMP) and MMP to mitochondrial mass (MMP:MM ratio) [Konrad et al. 2017]. 
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Additionally, some ALS patient brains have 10% elevated resting energy expenditure 
[Cistaro et al. 2012; Weijs et al. 2011; Desport et al. 2001]. On average, the presence 
of hypermetabolism in ALS results in a worse prognosis [Vucic et al. 2017; Jesus et al. 
2017]. Clinically, 18F-FDG-PET imaging has been used to assess differences in 
glucose uptake in ALS patients, with increased uptake being associated with worse 
cognitive deficiency [Cistaro et al. 2012; Canosa et al. 2016; Turner et al. 2000]. 
Notably, an analysis of our previous bioenergetics data from these fibroblasts revealed 
that the sALS-1 subgroup fibroblasts showed higher MMP and lower MM compared 
to other ALS patients and controls (Figure S2.3). Our findings suggest that the 
increased antioxidants in the sALS-1 subgroup may be a protective response to the 
consequences of hypermetabolism associated with the disease. 
 Using untargeted mass spectrometry methods, we showed that sALS patients 
can be subgrouped based on fibroblast metabotype. The identified subgroup displayed 
increased GSH synthesis, glucose metabolism, and 2-hydroxybutyrate and taurine 
abundances. We hypothesize that, in about 25% of sALS patients (18/77), increased 
glucose metabolism leads to greater production of ROS spurring antioxidant GSH 
synthesis as a defense. Recently, van Weehaeghe et al. demonstrated using PET 
imaging that stages of ALS disease correlate with regional brain glucose metabolism, 
disease duration and forced vital capacity [van Weehaeghe et al. 2017]. This indicates 
that the sALS-1 subgroup may also fall along a spectrum of glucose hypermetabolism 
with a common metabotype resulting from a cysteine-dependent antioxidant response. 
Our findings are supported by the fact that changes in plasma levels 2-
hydroxybutyrate, taurine, amino acids and creatinine have been previously reported in 
ALS patients, with oxidative stress being credited for many of these changes 
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[Wuolikainen et al. 2016; Lawton et al. 2014; Lawton et al. 2012; Patel et al. 2013]. 
Decreased plasma creatinine has previously been suggested as an ALS risk factor [van 
Eijk et al. 2017; Chio et al. 2014].  The fact that metabolites of interest are observed in 
both fibroblasts and plasma suggests the possibility of plasma metabolomics for 
clinical stratification of ALS patients.  
In the current study, bile acids and bile acid conjugates, known to play a 
protective role in neurodegenerative disorders [Ackerman et al. 2016], were also 
increased in the sALS-1 subgroup (Figure 2.7A). There are two primary bile acids 
produced by the liver: cholic acid and chenodeoxycholic acid, which undergo 
conjugation with glycine (glycocholic acid and glycochenodeoxycholic acid) or 
taurine (taurocholic acid and taurochenodeoxycholic acid) prior to secretion in the 
bile. Increased plasma abundances of taurine and taurocholic acid may also be part of 
an oxidative stress defense mechanism. 
In summary, we described the first application of mass spectrometry-based 
untargeted metabolite profiling and stable isotope tracing as a means to stratify, 
predict and characterize a subgroup of sALS patients using metabolically active skin 
fibroblasts. Our work also highlights the utility of a multiomic approach to support 
initial findings and more comprehensively characterize results. We identified a distinct 
sALS metabotype displaying an increase in trans-sulfuration and glucose 
hypermetabolism. The presence of these changes in patient plasma indicates the 
possibility of easy clinical stratification of sALS patients using plasma metabolite 
profiling. As an example, the sASL-1 subtype patients could be identified for yet-
undiscovered, targeted anti-oxidant therapies. We hypothesize that the upregulation of 
the trans-sulfuration pathway arises as an adaptation to limiting cysteine and hence 
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GSH, potentially triggered by hypermetabolism that accelerates GSH oxidation. The 
knowledge obtained from metabotypic stratification sALS patients may provide a 
much-needed first step toward developing metabotype-personalized therapy.  
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SUPPLEMENTARY INFORMATION 
Figure S2.1. Heatmap of metabolites found to be 
differentially abundant in both the original and repeat 
fibroblast metabolite profiling experiments. Unknown 
metabolites were expressed as accurate mass@retention time. 
Blue denotes downregulation and red denotes upregulation. 
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Figure S2.2. Gene Set Enrichment analysis (GSA) identified 
significantly different transcript levels of genes involved in the 
regulation of catabolic processes, apoptosis and epigenetic 
regulations in sALS-1 compared to sALS-2 and control groups. 
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Figure S2.3. The sALS-1 subgroup showed increased mitochondria membrane 
potential and mitochondria membrane potential to mass ratio compared to control 
and non-stratified (sALS-2) patients. The Y axis for A) and B) are relative 
fluorescence units for the respective dyes used to measure mitochondrial mass (MM) 
and mitochondrial membrane potential (MMP). Data was obtained as previously 
described [Konrad et al. 2017]. The numbers of sALS-1, sALS-2 and control cell lines 
are 18, 58 and 43, respectively. *, P<0.05 (2-tailed Student t-test). 
  
123 
 
 
 
REFERENCES 
Ackerman HD, and Gerhard GS. Bile Acids in Neurodegenerative Disorders. Front 
Aging Neurosci. 2016;8(263. 
Albano R, Liu X, and Lobner D. Regulation of system x(c)- in the SOD1-G93A 
mouse model of ALS. Exp Neurol. 2013;250(69-73. 
Blasco H, Corcia P, Moreau C, et al. 1H-NMR-based metabolomic profiling of CSF in 
early amyotrophic lateral sclerosis. PLoS One. 2010;5(10):e13223. 
Blasco H, Corcia P, Pradat P-F, et al. Metabolomics in cerebrospinal fluid of patients 
with amyotrophic lateral sclerosis: an untargeted approach via high-resolution 
mass spectrometry. J Proteome Res. 2013;12(8):3746-3754. 
Canosa A, Pagani M, Cistaro A, Montuschi A, et al. 18F-FDG-PET correlates of 
cognitive impairment in ALS. Neurology. 2016;86(1):44-9. 
Chen Q, Park HC, Goligorsky MS, Chander P, et al. Untargeted plasma metabolite 
profiling reveals the broad systemic consequences of xanthine oxidoreductase 
inactivation in mice. PLoS One. 2012;7(6):e37149. 
Chen Q, Kirk K, Shurubor YI, Zhao D, et al. Rewiring of Glutamine Metabolism Is a 
Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations. 
Cell Metab. 2018. 
Chio A, Calvo A, Bovio G, Canosa A, et al. Amyotrophic lateral sclerosis outcome 
measures and the role of albumin and creatinine: a population-based study. 
JAMA Neurol. 2014;71(9):1134-42. 
Cistaro A, Valentini MC, Chio A, Nobili F, et al. Brain hypermetabolism in 
amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar 
onset. Eur J Nucl Med Mol Imaging. 2012;39(2):251-9. 
  
124 
 
 
 
Desport JC, Preux PM, Magy L, Boirie Y, et al. Factors correlated with 
hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin 
Nutr. 2001;74(3):328-34. 
Fang L, Huber-Abel F, Teuchert M, et al. Linking neuron and skin: Matrix 
metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 
2009;285(1-2):62-66. 
Fang L, Teuchert M, Huber-Abel F, et al. MMP-2 and MMP-9 are elevated in spinal 
cord and skin in a mouse model of ALS. J Neurol Sci. 2010;294(1-2):51-56. 
Figuera-Losada M, Thomas AG, Stathis M, Stockwell BR, et al. Development of a 
primary microglia screening assay and its use to characterize inhibition of 
system xc(-) by erastin and its analogs. Biochem Biophys Rep. 2017;9(266-72. 
Fukazawa H, Tsukie T, Higashida K, Fujikura M, Ono S. An immunohistochemical 
study of increased tumor necrosis factor-α in the skin of patients with 
amyotrophic lateral sclerosis. J Clin Neurosci. 2013;20(10):1371-1376. 
Higashida K, Tsukie T, Fukazawa H, Fujikura M, Ono S. Immunohistochemical 
studies of angiogenin in the skin of patients with amyotrophic lateral sclerosis. 
J Neurol Sci. 2013;326(1-2):18-23. 
Ishikawa H, Yasui K, Oketa Y, Suzuki M, Ono S. Increased expression of valosin-
containing protein in the skin of patients with amyotrophic lateral sclerosis. J 
Clin Neurosci. 2012;19(4):522-526. 
Ismailoglu I, Chen Q, Popowski M, Yang L, et al. Huntingtin protein is essential for 
mitochondrial metabolism, bioenergetics and structure in murine embryonic 
stem cells. Dev Biol. 2014;391(2):230-40. 
Jesus P, Fayemendy P, Nicol M, Lautrette G, et al. Hypermetabolism is a deleterious 
prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 
2017. 
  
125 
 
 
 
Kiernan MC, Vucic S, Cheah BC, Turner MR, et al. Amyotrophic lateral sclerosis. 
Lancet. 2011;377(9769):942-55. 
Kirk K, Gennings C, Hupf JC, Tadesse S, et al. Bioenergetic markers in skin 
fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral 
sclerosis patients. Ann Neurol. 2014;76(4):620-4. 
Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, et al. Fibroblast bioenergetics to 
classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 
2017;12(1):76. 
Kuffner R, Zach N, Norel R, Hawe J, et al. Crowdsourced analysis of clinical trial data 
to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 
2015;33(1):51-7. 
Kumar A, Bala L, Kalita J, et al. Metabolomic analysis of serum by (1) H NMR 
spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta. 2010;411(7-
8):563-567. 
Lawton KA, Cudkowicz ME, Brown MV, Alexander D, et al. Biochemical alterations 
associated with ALS. Amyotroph Lateral Scler. 2012;13(1):110-8. 
Lawton KA, Brown MV, Alexander D, Li Z,  et al. Plasma metabolomic biomarker 
panel to distinguish patients with amyotrophic lateral sclerosis from disease 
mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5-6):362-
70. 
Lee ZW, Low YL, Huang S, Wang T, et al. The cystathionine gamma-lyase/hydrogen 
sulfide system maintains cellular glutathione status. Biochem J. 
2014;460(3):425-35. 
Leung KY, Pai YJ, Chen Q, Santos C, et al. Partitioning of One-Carbon Units in 
Folate and Methionine Metabolism Is Essential for Neural Tube Closure. Cell 
Rep. 2017;21(7):1795-808. 
  
126 
 
 
 
Liu X, Rush T, Zapata J, and Lobner D. beta-N-methylamino-l-alanine induces 
oxidative stress and glutamate release through action on system Xc(-). Exp 
Neurol. 2009;217(2):429-33. 
Mesci P, Zaidi S, Lobsiger CS, et al. System xC- is a mediator of microglial function 
and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain. 
2015;138(Pt 1):53-68. 
Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts 
demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in 
familial and sporadic ALS. Proc Natl Acad Sci U S A. 2014;111(2):829-832. 
Oketa Y, Higashida K, Fukasawa H, Tsukie T, Ono S. Abundant FUS-
immunoreactive pathology in the skin of sporadic amyotrophic lateral 
sclerosis. Acta Neurol Scand. 2013;128(4):257-264. 
Ono S, Imai T, Shimizu N, Nakayama M, Yamano T, Tsumura M. Serum markers of 
type I collagen synthesis and degradation in amyotrophic lateral sclerosis. Eur 
Neurol. 2000;44(1):49-56. 
Ono S, Imai T, Tsumura M, et al. Increased serum hyaluronic acid in amyotrophic 
lateral sclerosis: relation to its skin content. Amyotroph Lateral Scler Other 
Motor Neuron Disord. 2000;1(3):213-218. 
Ono S, Toyokura Y, Mannen T, Ishibashi Y. “Delayed return phenomenon” in 
amyotrophic lateral sclerosis. Acta Neurol Scand. 1988;77(2):102-107. 
Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and 
serum in amyotrophic lateral sclerosis. J Neurol Sci. 2001;187(1-2):27-34. 
Patel SS, Molnar MZ, Tayek JA, Ix JH, et al. Serum creatinine as a marker of muscle 
mass in chronic kidney disease: results of a cross-sectional study and review of 
literature. J Cachexia Sarcopenia Muscle. 2013;4(1):19-29. 
Suzuki M, Mikami H, Watanabe T, et al. Increased expression of TDP-43 in the skin 
of amyotrophic lateral sclerosis. Acta Neurol Scand. 2010;122(5):367-372. 
  
127 
 
 
 
Suzuki M, Watanabe T, Mikami H, et al. Immunohistochemical studies of vascular 
endothelial growth factor in skin of patients with amyotrophic lateral sclerosis. 
J Neurol Sci. 2009;285(1-2):125-129. 
Turner MR, Bowser R, Bruijn L, et al. Mechanisms, models and biomarkers in 
amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal 
Degener. 2013;14 Suppl 1:19-32. 
Turner MR, and Leigh PN. Positron emission tomography (PET)--its potential to 
provide surrogate markers in ALS. Amyotroph Lateral Scler Other Motor 
Neuron Disord. 2000;1 Suppl 2(S17-22. 
van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, et al. Monitoring 
disease progression with plasma creatinine in amyotrophic lateral sclerosis 
clinical trials. J Neurol Neurosurg Psychiatry. 2017. 
van Weehaeghe D, Ceccarini J, Willekens SM, de Vocht J,et al. Is there a glucose 
metabolic signature of spreading TDP-43 pathology in Amyotrophic Lateral 
Sclerosis? Q J Nucl Med Mol Imaging. 2017. 
Vangipuram M, Ting D, Kim S, Diaz R, Schüle B. Skin punch biopsy explant culture 
for derivation of primary human fibroblasts. J Vis Exp. 2013;(77):e3779. 
Vucic S. Hypermetabolism appears to be an adverse prognostic biomarker in 
amyotrophic lateral sclerosis: a potential for therapeutic intervention? Eur J 
Neurol. 2017. 
Watanabe T, Okeda Y, Yamano T, Ono S. An immunohistochemical study of 
ubiquitin in the skin of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 
2010;298(1-2):52-56. 
Weijs PJ. Hypermetabolism, is it real? The example of amyotrophic lateral sclerosis. J 
Am Diet Assoc. 2011;111(11):1670-3. 
Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 
2009;4:3 
  
128 
 
 
 
Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H. ALS patients with 
mutations in the SOD1 gene have an unique metabolomic profile in the 
cerebrospinal fluid compared with ALS patients without mutations. Mol Genet 
Metab. 2012;105(3):472-478. 
Wuolikainen A, Jonsson P, Ahnlund M, Antti H, et al. Multi-platform mass 
spectrometry analysis of the CSF and plasma metabolomes of rigorously 
matched amyotrophic lateral sclerosis, Parkinson's disease and control 
subjects. Mol Biosyst. 2016;12(4):1287-98. 
Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related 
changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis 
detected by GC/TOFMS. PLoS One. 2011;6(4):e17947. 
Wyss M, and Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 
2000;80(3):1107-213. 
  
  
129 
 
 
 
CHAPTER THREE 
 
TOWARDS CHARACTERIZING SLC25 FAMILY 
MITOCHONDRIAL TRANSPORTERS WITH MASS 
SPECTROMETRY-BASED METABOLOMICS 
 
INTRODUCTION 
 
The solute carrier SLC25 family of proteins is a group of sequence-
homologous proteins that localize to the inner mitochondrial membrane and serve to 
transport a diverse array of small molecule metabolites in and out of the mitochondria. 
In humans, there are 53 SLC25 genes, which are considered to be integral for 
physiological metabolism [Palmieri et al. 2016]. Mutation or interruption of normal 
function for many of these proteins have been associated with disease [Palmieri 2014]. 
For example, SLC25A8, an uncoupling protein and carboxylate transporter, has been 
linked to obesity and type 2 diabetes [Zhang et al. 2001; Zhang et al. 2006], and 
mutations of SLC25A38, the glycine transporter, have been shown to compromise 
transport function and give rise to congenital sideroblastic anemia [Guernsey et al. 
2009]. Reciprocally, upregulation of SLC25A38 was observed to occur in acute 
lymphoblastic leukemia cases [Chen et al. 2014]. SLC25 family proteins alternatively 
employ antiport (most common), symport or uniport as a fundamental modes of 
transport. Transport is energy-independent, driven by the trans-membrane 
concentration gradients of cognate substrates, and is sometimes impacted by the 
chemical or electrical potentials across the mitochondrial membrane [Palmieri 2013]. 
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Understanding the function of these transporters is integral to our 
understanding of cellular metabolism in health and disease. However, many of these 
transporters remain either uncharacterized, with no known substrates, or incompletely 
characterized, with a few identified substrates but the potential to transport additional 
substrates [Palmieri 2013]. Similarly, we know of many compounds with integral 
metabolic or pathologic roles which must traverse the mitochondrial membrane with 
transporter assistance (charged/polar compounds), but for which no transporter has yet 
been discovered, such as formate, 2-hydroxyglutarate and, until recently, serine. 
In this study, we were specifically interested in identifying the mitochondrial 
2-hydroxyglutarate and serine transporters. While during the course of this 
investigation a mitochondrial serine transporter was identified, it is notable that this 
did not prove to be an SLC25 family member [Kory et al. 2018]. Notwithstanding, we 
hypothesize that there may also be an SLC transporter family member that contributes 
to serine transport. 
D-2-hydroxyglutarate is an oncometabolite that is produced at high levels in 
gliomas and acute myeloid leukemia from the precursor 2-oxoglutarate by mutations 
causing hyperactivity of mitocondrial isocitrate dehydrogenase (IDH2) [Xu et al. 
2011]. IDH-1 is the cytosolic form of this enzyme that, when mutated, can also 
provide an oncogenic source [Achouri et al. 2004; Dang et al. 2017]. Additionally, L-
2-hydroxyglutarate is an oncometabolite that can be produced under some 
circumstances by malate dehydrogenase (MDH1 in the cytosol or MDH2 in the 
mitochondria) or the cytosolic enzyme lactate dehydrogenase A (LDHA) [Rzem et al. 
2006; Ye et al. 2018]. Both the L and D forms of 2-hydroxyglutarate are metabolized 
by mitochondria-localized enzymes, L-2-hydroxyglutarate dehydrogenase or D-2-
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hydroxyglutarate dehydrogenase, respectively [Dang et al. 2017; Ye et al. 2018]. 
Notably, although it is appreciated that cytosol produced 2-hydroxyglutarate (from 
IDH1 or LDHA) must be transported from cytosol to mitochondria for metabolic 
consumption/detoxification, the relevant mitochondrial transporter has eluded 
discovery [Engqvist et al. 2014]. 
In the case of serine, multiple important physiological roles are recognized, 
including function as a precursor for glycine and methylene tetrahydrofolate (THF) 
formation, ultimately providing the one carbon donor for synthesis of purines, 
thymidine, phospholipids, and methylation reactions involving DNA, proteins and 
small molecules [Locasale 2013]. At the start of this work, no mitochondrial serine 
transporter was recognized, although a novel transporter was recently found [Kory et 
al. 2018]. 
Whereas the specific cargo of current “orphan” SLC25 family transporters is 
unknown, general class functions can be inferred based on homology to known SLC25 
family members (such as ‘amino acid’ or ‘carboxylate’ transporters (see Figure 3.1, 
from [Palmieri 2013])). 
Studies were performed focusing on functional characterization of SLC25A38, 
a presumed glycine transporter, which has not been fully characterized in terms of its 
cargo. Importantly, SLC25A38 has been presumed, without experimental proof, to 
additionally transport (or antiport) serine [Guernsey et al. 2009; Fernández-Murray et 
al. 2016]. We also selected the homologous amino acid transporters SLC25A39, 
SLC25A40 and SLC25A44 as alternative mitochondrial serine transporter candidates. 
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Figure 3.1. Reproduced from [Palmieri 2013]. Phylogenetic tree of human SLC25 
family mitochondrial transporters. Homologous transporters can be broken down into 
subgroups based on substrates (likely to be) transported, such as carboxylates and 
amino acids. ‘Carboxylate’ and ‘UCP’ transporters are relatively homologous and 
transporters from both groups have been shown to transport carboxylates.  
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It should be noted that although we had a specific interest in identifying the 
mitochondrial serine transporter as a critical source of support for folate-mediated one-
carbon reactions, we further sought to characterize these transporters as potential 
carriers for other amino acids. We also selected 12 SLC family transporters with the 
closest structural homology to known carboxylate and uncoupling protein (UCP) 
carriers as candidates for the 2-hydroxyglutarate transporter. Although most of these 
proteins are not fully characterized, some of the uncoupling protein transporters have 
been shown to carry carboxylate species, including aspartate, malate and 2-
oxoglutarate [Vozza et al. 2014; Monné et al. 2018]. SLC25A11 and SLC25A21 were 
of particular interest as they were shown to transport 2-oxoglutarate, the direct 
metabolic precursor to 2-hydroxyglutarate [Indiveri et al. 1987; Monné et al. 2013; 
Palmieri et al. 2001; Fiermonte et al. 2001]. In fact, 2-hydroxyglutarate was shown to 
competitively inhibit 2-oxoglutarate transport into rat liver mitochondria even before 
the isolation and characterization of SLC25A11 or other 2-oxoglutarate transporters, 
evidence of interaction with the transporter’s active sight [Palmieri et al. 1972]. 
Similarly, 2-hydroxyglutarate was found to inhibit 2-oxoglutarate transport by yeast 
SLC25A21 in reconstituted proteoliposomes [Palmieri et al. 2001]. 
We initially set out to assess function of SLC25 transporters in the MDA-MB-
468 human breast cancer cell line using CRISPR-Cas9 knockouts. The rationale for 
this approach was that loss of transporter function could cause significant metabolic 
abnormalities in the knockout cell lines compared to control, which could be detected 
in an unbiased manner by untargeted metabolite profiling. Profound changes in 
metabolite abundances could be used to generate a hypothesis as to the substrate of the 
knocked-out transporter, which could then be confirmed by various methods, such as 
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stable isotope tracing and studying isolated mitochondria or purified proteins. The 
underlying assumption for studies of SLC25 family CRISPR KO cell lines was that 
these transporters are important enough for their absence to cause metabolic 
perturbations, but not essential so knockout cell lines would be viable. The disruption 
of important transporter function may directly impact metabolite abundances (such as 
elevated levels of a compound that is metabolized in the mitochondria) or lead to 
detectable metabolic compensation mechanisms that indirectly inform on cargos for a 
given transporter. However, due to findings considered below, we later shifted to a 
simpler and more targeted discovery approach that involved study of heterologous 
protein expression in Lactococcus Lactis bacteria. 
Lactococcus Lactis is a gram-positive bacteria that has been used for 
heterologous protein expression of functional membrane proteins. There are a number 
of features that make this bacterium attractive for membrane protein expression. First, 
membrane proteins, even eukaryotic mitochondrial transporters, have been found to 
fold properly and localize to the bacterial membrane, with little or no formation of 
inclusion bodies. The expressed proteins can be inducibly expressed by taking 
advantage of a nisin promoter that resides in the pNZ8048 expression plasmid. Nisin 
is an anti-bacterial peptide that can be administered at very low concentrations to drive 
protein expression, allowing for controlled levels of over-expression (this may be 
important for toxic proteins) [Kunji et al. 2003; Seigneurin-Berny et al. 2016]. In the 
past, this system has been used to express membrane proteins that were subsequently 
reconstituted into proteoliposomes to enable radioligand transport studies. However, 
there have also been reports of studies demonstrating functional membrane transport 
activity in intact L. lactis bacteria (also using radioisotopes) [Janvilisri et al. 2003; 
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Kunji et al. 2003; Burgess et al. 2006; Frelet-Barrand et al. 2010; Linares et al. 2010; 
Herzig et al. 2012; Mifsud et al. 2012; Seigneurin-Berny et al. 2016]. 
We reasoned that the study of SLC25 protein function in intact bacteria 
coupled with mass spectrometric detection of substrates would save significant time 
compared to studying the reconstituted proteins in liposomes and would open the 
possibility for more rapid study or even screening experiments. The use of heavy 
stable isotope-labelled substrates for transport assays and LC/MS-based detection 
affords a number of advantages over studies involving radioisotopes. First, with stable 
isotope studies radioactive contamination and safety is not a concern, which 
significantly reduces the hassle of working with the samples and equipment. Second, 
unlike radioisotopes, stable isotopes can enable reliable metabolic fate-tracing. 
Finally, mass spectrometry can easily distinguish between different labeled 
compounds and potentially enable the screening of transporters for activity with 
multiple compounds at one time, facilitating the comprehensive study of 
uncharacterized transporters. We therefore set out to establish a whole cell 
Lactococcus Lactis protocol for studying small molecule membrane protein transport 
using mass spectrometry, and to assess the feasibility of using Lactococcus Lactis to 
study the human SLC25 family of transporters. 
 
MATERIALS AND METHODS 
1. Reagents. LC-MS grade acetonitrile (ACN), isopropanol (IPA) and methanol 
(MeOH) were purchased from Fischer Scientific. High purity deionized water 
(ddH2O) was filtered from Millipore (18 OMG). OmniTrace glacial acetic acid and 
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ammonium hydroxide were obtained from EMD Chemicals. 9D-Choline, 6D-2-
oxoglutarate, 13C-glycine, and 15N-aspartate were purchased from Cambridge Isotope 
Laboratory. 
 
2. CRISPR knockout cell line production. 
2.1 Plasmid construction for CRISPR genome editing (eSpCas9). Double-
stranded oligomers were synthesized commercially and cloned into BbsI restricted 
eSpCas9(1.1) vector (Addgene, Cat.# 71814). The vector was transformed into NEB 
Stable chemically competent E. coli (NEB) and positive clones were identified and 
DNA sequenced using standard methods. The eSpCas9 constructs used for this study  
were produce with the following gRNA sequences, targeting the genomic DNA near 
endogenous restriction enzyme cut sites: 
GGTAGAGCAGGTCCCACTGA (SLC25A38 KO1), 
ACTCTTGAAGGTGGTTCGCA (SLC25A38 KO2), 
GGACACCATTGCAATACAGG (SLC25A39), 
GCAGGTAAAATAAATAACTG (SLC25A40), 
GAGTAACACAGTCAAATCAC (SLC25A44). 
2.2 Generation of knockout cell lines. eSpCas9 constructs were transiently 
transfected into MDA-MB-468 triple-negative breast cancer cells using 
lipofectamine3000 (Invitrogen, CA) and selected for cell uptake based on viability in 
puromycin media for 3 days. Viable cells were seeded at low density (~750 cells per 
100 mm dish), then individual colonies (clones) were selected and transferred to 24-
well plates for clonal expansion.  
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2.3 Cut-site screening. Genomic DNA was harvested from each clonal line for 
genotyping. Colonies were screened by PCR amplification of the target region and 
endonuclease restriction digestion to identify edits in the restriction site near the target 
CRISPR cut site (restriction resistant PCR products indicate edited genomic DNA). 
The PCR bands with modified restriction-sites were sequenced by TA-cloning, as 
follows. Purified PCR products were cloned into the pGEM-T Easy vector (Promega, 
WI), and transformed into NEB Stable E.coli. Plasmid DNA was isolated from 
individual bacterial colonies and sequenced using the T7(+) primer. Sufficient 
colonies were screened to obtain sequence information for both alleles (Figure 3.2). 
 
2. Protein reinsertion cell line production. 
2.1 Plasmid construction for gene reinsertion. Gene sequences with either N-
terminal FLAG or C-terminal EGFP and the appropriate restriction sites were PCR 
amplified. Purified PCR products were cloned into pcDNA3.1 vector (Invitrogen) and 
transformed into bacteria. Positive clones were identified using standard bacterial 
screening and confirmed by DNA sequencing. 
2.2 Generation of reinsertion cell lines. We transiently introduced the 
constructs into the appropriate MDA-MB-468 triple-negative breast cancer knockout 
cell line using lipofectamine3000 (Invitrogen, CA) and selected for neomycin 
resistance of cells during a 7 day treatment. We then seeded the cells at low density 
(~750 cells per 100 mm dish) to obtain clonal lines. Individual colonies were selected 
under a microscope and transferred to 24-well plates for clonal expansion. EGFP 
positive cell lines were confirmed under a fluorescent microscope and later imaged by 
confocal microscopy. 
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Figure 3.2. Sequence alignment of knockout cell line alleles with wild-type 
sequence for two cell lines for SLC25A38, SLC25A39 and SLC25A40. Top 
sequences of each alignment indicate the wild-type sequence (lower case). Bottom 
sequences indicate sequence obtained from genotyping alleles by TA cloning (two 
sequences) or by directly sequencing the PCR product (one sequence). Each 
edited allele has an insertion or deletion that causes a frame-shift. The gRNA 
target sequence (green line), Protospacer adjacent motif (PAM), and cut site 
(black arrow) are indicated for each CRISPR design. 
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3. MDA-MB-468 derived cell line metabolite profiling. 
3.1 Cell culture. 150,000 cells/well were plated in 6-well plates and cultured in 
DMEM medium containing 25 mM glucose, 10% FBS, and 1% HEPES for 48 hours. 
Cells were harvested at 80% confluency and extracted for LC/MS metabolomic 
analysis. 
3.2 Metabolite extraction. One plate was extracted at a time. Cells in each 
individual well (samples) were harvested one-by-one, rapidly washed twice with ice-
cold PBS, then twice with ice-cold water, followed by addition of -70ºC 80:20 
methanol:water (LC-MS grade methanol, Fisher Scientific). Cells were scraped and 
transferred to an Eppendorf tube. For quantitative recovery of metabolite extracts, an 
additional 400uL of 80% methanol was added to cell culture wells 2 additional times 
and pooled with the initial extract. Cells suspensions/extracts were vortexed for 15 
seconds before being placed on dry ice and stored overnight at -80 ºC. On the 
following day, extracts were thawed on ice, vortexed, and then centrifuged at 16,000 
RPM for 10 min to pellet insoluble material (protein/nucleotides). Supernatants were 
transferred to clean tubes, dried in a Vacufuge (Eppendorf), and stored at -80ºC until 
metabolomic analysis by LC/MS. The methanol-insoluble protein pellet was 
solubilized in 0.2 M NaOH at 95ºC for 20 min and protein content was quantified 
using a BioRad DC assay and findings were used to normalize the volume of extracts 
for metabolite profiling. On the day of metabolite analysis, dried cell extracts were 
reconstituted in 70% acetonitrile at a relative protein concentration of 3 µg/ml, and 4 
µl of this reconstituted extract was injected for LC/MS-based untargeted metabolite 
profiling. Samples were analyzed on an LC-QTOF system in an alternating sequence 
(i.e, test, control, test, control etc.). 
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3.3 Untargeted metabolite profiling by LC/MS. Cell extracts were analyzed by 
LC/MS as described previously [Chen et al. 2012; Ismailoglu et al. 2014], using a 
platform comprised of an Agilent Model 1290 Infinity II liquid chromatography 
system coupled to an Agilent 6550 iFunnel time-of-flight MS analyzer (Agilent 
Technologies). Chromatography of metabolites utilized aqueous normal phase (ANP) 
chromatography on a Diamond Hydride column (Microsolv). Mobile phases consisted 
of: (A) 50% isopropanol, containing 0.025% acetic acid, and (B) 90% acetonitrile 
containing 5 mM ammonium acetate. To eliminate the interference of metal ions on 
chromatographic peak integrity and electrospray ionization, EDTA was added to the 
mobile phase at a final concentration of 6 µM. The following gradient was applied: 0-
1.0 min, 99% B; 1.0-15.0 min, to 20% B; 15.0 to 29.0, 0% B; 29.1 to 37min, 99% B.  
Raw data were analyzed using MassHunter Profinder 8.0 and Mass Profiler 
Professional (MPP) 14.9.1 software (Agilent Technologies). 
3.4 Metabolite structure specification. To ascertain the identities of unknown 
compounds, LC/MS data was searched against an in-house annotated metabolite 
database created using MassHunter PCDL manager 7.0 (Agilent Technologies), based 
on monoisotopic neutral masses (<5 ppm mass accuracy) and chromatographic 
retention times. A molecular formula generator (MFG) algorithm in MPP was used to 
generate and score empirical molecular formulae, based on a weighted consideration 
of monoisotopic mass accuracy, isotope abundance ratios, and spacing between 
isotope peaks. A tentative compound ID was assigned when PCDL database and MFG 
scores concurred for a given candidate molecule. Tentatively assigned molecules were 
verified based on a match of LC retention times and/or MS/MS fragmentation spectra 
for pure molecule standards. 
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3.5 Stable isotope tracing. Deuterated choline (6D) was added to choline free 
DMEM and added to cells at specific times prior to harvest (1, 5 and 24 hours). 
Metabolites were harvested and LC-MS metabolomics was performed as described 
above. A database of predicted m/z values for deuterium-labeled choline-derived 
metabolites was produced based on retention times from our in-house database and 
used in MassProfinder 8.0 to quantify metabolite abundance data. 
 
4. Next-Generation Amplicon Sequencing of SLC25 knockout cell line mRNAs. 
mRNA was reverse transcribed using random hexamer primers to produce cDNA from 
two knockout cell lines per protein (SLC25A38, SLC25A39, SLC25A40). cDNA 
were PCR amplified using primers spanning the CRISPR target site (~200bp on either 
side) for the respective gene. Primers were designed based on exon sequences 
(processed mRNA) and spanned known intron splice sites so that amplified DNA at 
the predicted size (~400bp) could not be due to genomic DNA contamination. PCR 
products were sequenced by Next-Generation Amplicon Sequencing (GENEWIZ). 
Alignment to the wild-type reference sequence for each protein (based on the most 
common NCBI transcript sequence) was performed using the CRISPRESSO 2.0 web 
tool. 
 
5. Transporter overexpression in Lactococcus Lactis. 
5.1 Electrocompetent Lactococcus Lactis production. Overnight cultures (~8 
mL) of Lactococcus Lactis grown in M17 were diluted into 200 mL SGGM17 (M17 
broth containing 0.5M sucrose, 0.5% glucose and 2.5%) and grown to an O.D. of 0.3-
0.4 at 600 nm. Cells were pelleted by centrifugation at 6,000 x g at 4°C for 8 min. 
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Cells were resuspended in 100 mL of 0.5M sucrose/10% glycerol solution and pelleted 
again. Cells were then resuspended in 100mL 0.5M sucrose/10% glycerol with 50mM 
EDTA pH 8.0 and placed on ice for 15 minutes and pelleted at 6,500 x g for 12 min, 
then twice resuspended/pelleted in 125mL 0.5M sucrose/10% glycerol solution. 
Finally, cells pellets were resuspended in 1 mL of 0.5M sucrose/10% glycerol, flash 
frozen in 40uL aliquots, and stored at -80°C until analysis.  
5.2 Plasmid construction for gene reinsertion. Gene sequences were PCR 
amplified from endogenous homo sapiens sequences, for SLC25A40 and SLC25A44, 
or from Lactococcus Lactis ‘codon context’ optimized sequences for SLC25A38, 
SLC25A39, carboxylate transporters (optimized using Codon Optimization On-Line 
(COOL) tool, gene fragments from GenScript)) with the appropriate restriction sites 
and with or without a C-terminus FLAG tag sequence. Generally, BbsI/KpnI 
endonuclease sites were used for cloning into the NcoI/KpnI restricted pnZ8048 vector 
backbone. Vectors were precipitated by addition of sodium acetate pH 5.2 and 100% 
EtOH, followed by incubation at -20°C for at least 1 hour. DNA was pelleted by 
centrifugation, washed 3 times with 70% EtOH, dried (not to completion) and 
dissolved in 5 µL water. A 1 µl volume of the resulting vector solution was 
electroporated into electrocompetent Lactococcus Lactis using a 0.2 cm cuvette (2,000 
V, 25 μF, 200 Ω), incubated in recovery media (M17 broth containing 0.5 M sucrose 
0.5% glucose, 20 mM MgCl2 and 2 mM CaCl2) at 30°C for 1.5 hours, plated on M17 
agar plates containing 0.5% glucose and 10 ug/mL chloramphenicol and incubated at 
30°C for 2 days. Positive clones were identified using standard bacterial screening 
(cells were incubated in a ‘resuspension buffer’ (10 mM Tris pH 8.0, 50 mM NaCl, 10 
mM EDTA, 20% sucrose, 10 mg/mL lysozyme (added fresh)) for 20 minutes at 55°C, 
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before continuing at the lysis buffer step using a DNA Miniprep Kit (Sigma).  
Construct sequences were confirmed by DNA sequencing. 
5.3 Transporter overexpression. Overnight cultures of Lactococcus Lactis that 
express pnZ8048 vector with an incorporated a gene of interest, were diluted 10-fold 
in M17 broth containing 0.5% glucose and 5 ug/mL chloramphenicol. Cells were 
grown at 30°C to an OD of 0.6 at 600nm (~1 hour). Protein expression was induced by 
addition of 1 ng/µL nisin (Sigma) and bacteria were allowed to grow for 3 h until use. 
5.4 Western blot and dot-blot for FLAG tagged transporters. 2 mL of M17 
broth was inoculated with Lactococcus Lactis and transporter expression was induced 
as described above. Bacteria were harvested by centrifugation, resuspended in a 50 
mM Tris pH 8.0, 200 mM NaCl, 5 mg/mL lysozyme (added fresh) solution and 
incubated at 55°C for 20 min. Cells were pelleted and the supernatant removed. The 
pellet was suspended in an 8 M urea, 50 mM Tris-HCl pH 6.8, 10 mM EDTA, 50 mM 
DTT solution and incubated at room temperature for 10 min. The debris was pelleted 
and 10 µL of the resulting supernatant was added to 10 µL 10% glycerol/bromophenol 
blue loading dye. Samples were loaded on an 8-16% tris-glycine gel and run at 120V 
for 1.5 hr. Protein was transferred onto an activated PVDF membrane, blocked with 
2.5% milk in TBS-T, then treated with monoclonal anti-flag-M2 antibody (1:1000 
dilution; Sigma) overnight. For the dot blots, PVDF membranes were dried, blocked 
and then treated the same as the western blots. Membranes were washed in TBS-T, 
treated for 1 hour with secondary anti-mouse antibody, washed and then imaged by 
chemilumiescence after treatment with the SuperSignal ‘Pico’ or ‘Femto’ 
chemiluminescent reagent (ThermoFisher). 
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6. Metabolite profiling of Lactococcus Lactis. 
 6.1 Initial metabolite extraction protocol. Lactococcus Lactis cell lines were 
cultured and transporter expression induced with nisin as described above (2 mL M17 
broth inoculated with 200 uL overnight culture). Cells were isolated by centrifugation 
and at 12,000 x g for 1 min and resuspended in phosphate buffered saline (PBS) pH 
7.4. Cell were pelleted again at 18,000 x g. Wash steps were repeated 2 times in iced 
PBS and then ddH2O. After the final wash, 1 mL -70°C 80% MeOH was added to 
extract metabolites and samples were frozen on dry ice. Samples were subsequently 
subjected to bead-beating using a TissueLyser II bead beater (Qiagen) and stainless 
steel beads for 2.5 minutes, then centrifuged at 16,000 x g for 5 minutes and placed on 
dry ice. This process was continued until the samples were bead-beaten 4 times. 
Samples were then placed at -80°C overnight. After thawing the following day, 
samples were spun a final time and supernatants were transferred to new Eppendorf 
tubes followed by drying in a vacufuge and storage at -80°C until analysis. Remaining 
protein in cell pellets (after metabolite extraction) was dried under vacuum in a 
vacufuge, solubilized in 0.2 N NaOH at 95°C, then protein was quantified using a Bio-
Rad Bradford protein assay. On the day of analysis, metabolites were reconstituted to 
the equivalent of 1 µL 70% ACN per 3 µg protein to normalize for sample differences 
in bacteria quantity. 
6.2 Improved metabolite extraction protocol. Lactococcus Lactis cell lines 
were cultured and transporter expression was induced as described above (in 35 mL 
M17 broth/chloramphenicol inoculated with 3.5 mL overnight culture, 2 times per cell 
line for 12 samples, 4 times for 24 samples). Cells were collected at 6,000 x g for 10 
min at 4°C and washed with ice-cold 50 mM potassium phosphate buffer pH 7.0. 
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Pellets were respun and washed a second time. After a final spin (20 min), pellets were 
resuspended in 7 mL potassium phosphate buffer (14 mL for 24 samples) and stored 
on ice. Aliquots of bacterial suspensions (500 µL) were added to 5 mL culture tubes. 
The test transport substrate of interest was added to the incubation solution and the 
bacteria were maintained in a 30°C water bath for the desired time interval. Samples 
were simultaneously harvested on glass fiber filter paper (GF/B, Brandel) and rapidly 
washed with water 4 times (3 seconds/wash) using a Brandel M-24T cell harvester. 
Filter discs were punched out of the glass fiber sheet by hand, and added to 2 mL 
round bottom Eppendorf tubes on dry ice. A 1.8 ml volume of methanol:ddH2O 
(80:20; -70°C) was added to each sample. Samples were bead-beaten for 2.5 minutes, 
centrifuged at 16,000 x g for 10 min at 4°C and then refrozen on dry ice. This 
extraction procedure was repeated until each sample was beaten 4 times in total (with 
a final 5 min extraction). Samples were stored overnight at -80°C. On the following 
day, samples were bead-beaten (5 min, then 10 min), centrifuged and frozen two 
additional times. Finally, samples were centrifuged at 16000 x g for 30 min at 15°C. 
Small squares of no lint cotton (Agilent Technologies) were pushed into p200 pipette 
tips to create a filter.  Supernatant (750 µL) was pushed through these filters into a 
clean Eppendorf tube using a p1000 pipette in order to remove glass fibers that were 
too fine to spin down. Samples were dried in a vacuum centrifuge and stored at -80°C 
overnight until analysis. On the day of analysis, potential transported substrates were 
suspended in 70% ACN (at specified volumes; 40 µl, 80 µl or 300 µl, depending on 
compound of interest). 
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RESULTS 
Untargeted metabolite profiling of an MDA-MB-468 SLC25A38 knockout cell 
line reveals modest metabolite changes compared to parental control. Untargeted 
metabolite profiling was performed on an MDA-MB-468 SLC25A38 knockout clonal 
cell line, compared to the parental control cell line (n=12). Cells were grown for 48h, 
followed by metabolite extraction and untargeted profiling as described above. 
Unbiased data was acquired and analysis was performed in a targeted manner (with 
reference to an in-house retention time and mass-annotated database) and also 
considering structurally-unidentified compounds. Notably, no unidentified compounds 
were found to exhibit sufficient differential expression and significance to warrant the 
effort of structure elucidation. However, there were multiple statistically significant 
identified compounds, although also showing only modest metabolite changes in KO 
cells compared to control (Table 3.1). It should be noted that these identities are 
tentative and confident assignment of some would require MS/MS fragmentation for 
definitive assignment by comparison with reference standards. A feature matching the 
retention time and m/z of an N-acetylglycine acetic acid adduct (acetic acid is present 
in the mobile phase) was the most significant change, with a nearly 2-fold decrease in 
SLC25A38 KO cells (Figure 3.3). Due to the fact that SLC25A38 was reported to 
transport glycine and increases in other acetylated amino acids were concomitantly 
observed, N-acetylglycine was a focus of follow-up experiments. 
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Table 3.1. Statistically significant, differentially abundant features of an 
unbiased metabolomics experiment of SLC25A38 KO cells compared to 
parental control cells. Tentative molecular identities were assigned with 
reference to an in-house database. N-acetylglycine, the most significant 
compound of interest is highlighted. P-values are Benjamini-Hochberg false 
discovery rate corrected. Features from each ionization mode are corrected 
independently). 
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Figure 3.3. Comparison of the abundance of N-acetylglycine in 
SLC25A38 KO cells compared to control cells. A38 KO cells have 
significantly reduce abundance, possibly due to reduced glycine 
transport into the mitochondria.  
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Metabolite profiling validation using a second SLC25A38 knockout cell line 
shows a less significant decrease in N-acetylglycine. Untargeted metabolite profiling 
was performed on a second MDA-MB-468 SLC25A38 knockout clonal cell line 
produced with different guide RNA (in order to control for off target effects), using 
the parental cell line as a control (n=12). Cells were grown for 48 h, followed by 
metabolite extraction and untargeted profiling as described above. Unbiased data 
analysis was performed in a targeted manner, using an in-house retention time and 
mass-annotated database as well as in an untargeted mode. As shown in Figure 3.4, 
abundance of the N-acetylglycine feature was found to be only modestly reduced. 
Additionally, other features of statistical significance showed no overlap with those 
from the first knockout cell line, suggesting that observed differences arose primarily 
as clonal peculiarities, off target CRISPR effects or were cell culture condition 
dependent (Table 3.2). No shared features were promising enough to follow up on. 
Untargeted metabolite profiling of an MDA-MB-468 SLC25A40 knockout cell 
line reveals modest metabolite changes compared to parental control. Untargeted 
metabolite profiling was performed on an MDA-MB-468 SLC25A40 knockout clonal 
cell line, compared to the parental control cell line (n=12). Cells were grown for 48h, 
followed by metabolite extraction and untargeted profiling as described above. 
Unbiased data was acquired and analysis was performed in a targeted manner (with 
reference to an in-house retention time and mass-annotated database) and also 
considering structurally-unidentified compounds. Notably, no unidentified compounds 
were found to exhibit sufficient differential expression and significance to warrant the 
effort of structure elucidation. 
 
  
151 
 
 
 
  
P a r e n ta l S L C 2 5 A3 8  K O 2
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
N -a c e ty lg ly c in e  in  S L C 2 5 A 3 8  K O 2
N
-a
c
e
ty
lg
ly
c
in
e
 i
o
n
 c
o
u
n
ts
Figure 3.4. Comparison of the abundance of N-acetylglycine in 
SLC25A38 KO cells compared to control cells. A38 KO cells 
have mildly reduced abundance of unconvincing importance to 
the study of the knockout protein. 
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Table 3.2. Statistically significant, differentially abundant features of an 
unbiased metabolomics experiment of a second SLC25A38 KO cell line 
compared to parental control cells. Tentative identities were assigned based on 
an in-house database. No interesting compounds shared between the two 
knockout cell lines were identified. P values are Benjamini-Hochberg false 
discovery rate corrected (features from each ionization mode corrected 
separately). 
  
153 
 
 
 
However, there were multiple statistically significant identified compounds, although 
also showing only modest metabolite changes in KO cells compared to control (Table 
3.3). It should be noted that these identities are tentative and confident assignment of 
some would require MS/MS fragmentation for definitive assignment by comparison 
with reference standards. A feature matching the retention time and m/z of betaine was 
one of the most significant differentially abundant compounds, with a 1.73 fold 
decrease in SLC25A40 KO cells (Figure 3.5). As a compound produced exclusively in 
the mitochondria from a choline precursor, this generated the hypothesis that 
SLC25A40 could be a mitochondrial choline transporter. 
MS/MS fragmentation confirms betaine identity. MS/MS fragmentation was 
performed on the 118.08 m/z (positive mode) feature, the putative betaine compound, 
using collision energies of 0, 10, 20 and 40 (Figure 3.6). Comparison to the Metlin 
fragmentation database confirmed the compounds identity as betaine (Figure 3.7). 
Heavy isotope labeled (9 deuterated) choline tracing confirms decreased choline-
derived betaine in the SLC25A40 knockout cell line. Mass spectrometry based 
stable isotope tracing was performed using deuterated choline (9 deuterium) in 
SLC25A40 KO cells and parental control cells. 
Cell culture media was exchanged at 24h, 5h or 1h time points before metabolite 
extraction for media containing 9D choline (n=6). Metabolite abundances for betaine, 
choline and other choline-derived compounds were analyzed (Figure 3.8A-F). 
Reduced choline-derived betaine (deuterated) was observed in SLC25A40 KO cells 
(Figure 3.8B), further indicating that choline mitochondrial transport is reduced in 
these cells.  
  
154 
 
 
 
  
Table 3.3. Statistically significant, differentially abundant features of an 
unbiased metabolomics experiment of SLC25A40 KO cells compared to 
parental control cells. Tentative identities were assigned based on an in-house 
database. Betaine, the most significant and primary compound of interest is 
highlighted. P values are Benjamini-Hochberg false discovery rate corrected 
(features from each ionization mode corrected separately). 
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Figure 3.5. Comparison of the abundance of betaine in 
SLC25A40 KO cells compared to control cells. A40 KO cells 
have significantly reduce abundance, possibly due to reduced 
choline transport into the mitochondria.  
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Figure 3.6. MS/MS fragmentation spectra of m/z 118.08 at collision energies of 0 
(top panel), 40 (2nd panel), 20 (3rd panel) and 10 (bottom panel). Images is cropped in 
the middle (where no significant peaks are present) for visibility. 
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Figure 3.7. Comparison of the MS/MS fragmentation of m/z 118.08 (pos, 
bottom panel) to the Metlin fragmentation database for betaine (top panel) 
confirms the compound’s identity as betaine. The middle panel shows the direct 
comparison of both spectra. 
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Figure 3.8. Choline tracing reveals reduced choline-derived betaine in SLC25A40 KO 
cells. A) Unlabeled betaine abundance is initially different between the cell lines. At 
later time points the abundances even out, as betaine is no longer being derived from 
unlabeled choline. B) Choline-derived betaine is significantly reduced in A40 KO cells 
at all time points. C), E) Choline and phosphocholine abundances are the same at all 
time point. D) Total cellular deuterated choline uptake and F) extramitochondrial 
produced metabolites, such as phosphocline, are unchanged, implicating a 
mitochondria related defect in the reduced betaine production (enhanced betaine 
degeration could aslo be possible). 
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Importantly, overall cellular choline uptake and choline-derived compounds produced 
outside the mitochondria, such as phosphocholine were unchanged (Figure 3.8D, F). 
Choline tracing of additional SLC25A40 knockout cell lines shows unchanged 
choline-derived betaine abundance. 24h choline tracing was performed on a second, 
third and fourth MDA-MB-468 SLC25A40 knockout clonal cell line produced with the 
same guide RNA (this approach does not control for CRISPR off target effects, but as 
a first pass should arguably be more likely to be similar to the initial knockout cell 
line) and on the parental cell line as a control (n=6). Unfortunately, the original A40 
KO cell line did not grow properly when plating for this experiment and is therefore 
not included in the comparison. The abundance of choline-derived betaine was not 
found to be affected in any of the other cell lines (Figure 3.9). Additionally, other 
features of statistical significance showed no overlap with those from the first 
knockout cell line, indicating again that differences were merely clonal peculiarities, 
cell culture condition dependent, or off-target CRISPR effects. 
Untargeted metabolite profiling of an MDA-MB-468 SLC25A39 knockout cell 
line reveals highly reproducible metabolite changes compared to parental 
control. Untargeted metabolite profiling was performed on an MDA-MB-468 
SLC25A39 knockout clonal cell line, compared to the parental control cell line (n=12). 
Cells were grown for 48h, followed by metabolite extraction and untargeted profiling 
as described above. Unbiased data was acquired and analysis was performed in a 
targeted manner (with reference to an in-house retention time and mass-annotated 
database) and also considering structurally-unidentified compounds.   
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Figure 3.9. Comparison of the abundance of deuterated betaine 
in SLC25A40 KO cells compared to control cells. The three 
other A40 KO clonal cell lines have unchanged betaine, 
indicating that the above observations were not SLC25A40 
related. 
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A number of unidentified compounds were differentially abundant, but tentative IDs 
could not be assigned and, given the clonal nature of changes observed in other 
experiments, structural elucidation was not pursued. There were a number of 
statistically significant identified compounds showing >2 fold change in KO cells 
compared to control (Table 3.4). It should be noted that these identities are tentative 
and confident assignment of some would require MS/MS fragmentation for definitive 
assignment by comparison with reference standards. A feature matching the retention 
time and m/z of guanidinoacetate was one of the most significant changes, with a 2.7-
fold decrease in SLC25A39 KO cells (Figure 3.10A, B). Guanidinoacetate is a 
compound produced in the mitochondria from the precursors glycine and arginine and 
this suggested that A39 may serve to transport either of these compounds. Due to the 
fact that A39 is homologous A38, a presumed glycine transporter, this compound was 
the focus of follow-up experiments.  
This experiment was repeated (n=6) with highly similar results (Table 3.4, 
Figure 3.10A, B), confirming these metabolite differences in this cell line and 
highlighting the robustness of the metabolite extraction protocol. 
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Table 3.4. Statistically significant, differentially abundant features of two 
unbiased metabolomics experiment of SLC25A39 KO cells compared to parental 
control cells. Tentative identities were assigned based on an in-house database. 
guanidinoacetate, one of the most significant and primary compound of interest is 
highlighted. P values are Benjamini-Hochberg false discovery rate corrected. 
Only positive mode features are shown for clarity. On the left are the results of the 
original experiment. On the right, the repeat experiment shows strikingly similar 
results for these compounds. 
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Figure 3.10. Comparison of the abundance of guanidinoacetic acid in SLC25A39 KO 
cells compared to control cells. A) A39 KO cells have significantly reduce 
abundance, possibly due to diminished glycine or arginine transport into the 
mitochondria. B) Similar results were obtained in a repeat experiment, confirming 
this difference as a feature of this cell line and highlighting the reliability of the 
experimental protocol. 
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Metabolite profiling of additional SLC25A39 knockout cell lines show no 
profound shared metabolite changes and unchanged guanidinoacetate 
abundance. Metabolite profiling of the original knockout cell line alongside a second 
and third MDA-MB-468 SLC25A39 knockout clonal cell line produced with the same 
guide RNA (does not control for CRISPR off target effects, but as a first pass should 
arguably be more likely to be similar to the initial knockout cell line) and on the 
parental cell line as a control (n=6). The abundance of the putative guanidinoacetate 
compound was not found to be affected in any of the other cell lines (Figure 3.11). 
Additionally, other features of statistical significance showed no overlap with those 
from the first knockout cell line, indicating again that differences were clonal 
peculiarities, cell culture condition dependent, or off-target CRISPR effects. No shared 
features were promising enough to follow-up on. 
Metabolite profiling of SLC25A39 EGFP tagged reinsertion cell lines do not 
rescue the observed metabolic perturbations. Metabolite profiling of the original 
knockout cell line alongside two clonal cell lines in which the SLC25A39-EGFP 
tagged gene was reinserted (constitutively overexpressed, Figure 3.12) and on the 
parental cell line as a control (n=6). The abundance of guanidinoacetate was not found 
to be rescued with in the reinsertion lines in any of the other cell lines (Figure 3.13). 
No shared changes within the reinsertion cell lines and compared to the knockout cell 
line were promising enough to follow up on. 
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Figure 3.11. Comparison of the abundance of guanidinoacetate in 
SLC25A39 KO cells compared to control cells. Although the 
original cell line once again shows a profound depletion of 
guanidinoacetate, the two other A39 KO clonal cell lines have 
unchanged abundance, suggesting that the above observations 
were not SLC25A39 related. 
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Figure 3.12. Representative confocal fluorescent image of SLC25A39-EGFP 
expressing cells. Perinuclear, punctate staining consistent with mitochondrial 
localization of the reinserted protein. 
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Figure 3.13. Comparison of the abundance of guanidinoacetate in SLC25A39 KO 
cells compared to A39-EGFP reinsertion clonal lines. The reinsertion cell lines do not 
show rescue of guanidinoactate abundance, further indicating that the above 
observations were not SLC25A39 related. 
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Untargeted metabolite profiling of an MDA-MB-468 SLC25A44 knockout cell 
line reveals highly reproducible unidentified metabolite changes compared to 
parental control. Untargeted metabolite profiling was performed on an MDA-MB-
468 SLC25A44 knockout clonal cell line, compared to the parental control cell line 
(n=12). Cells were grown for 48h, followed by metabolite extraction and untargeted 
profiling as described above. Unbiased data was acquired and analysis was performed 
in a targeted manner (with reference to an in-house retention time and mass-annotated 
database) and also considering structurally-unidentified compounds. A number of 
unidentified compounds were differentially abundant, but tentative IDs were not 
confidently assigned (some matched the predicted m/z of polypeptides). Molecular 
structure elucidation based on MS/MS fragmentation was attempted, but abundances 
were insufficient to obtain informative spectra, data not shown. 
Next-generation sequencing of SLC25 knockout cell line mRNAs shows no 
indication of expression of additional alleles but reveals presence of alternate 
transcript splice variants. mRNA was reverse transcribed to produce cDNA from 
two knockout cell lines per protein (SLC25A38, SLC25A39, SLC25A40). cDNA 
were PCR amplified using primers spanning the CRISPR target site (~200bp on either 
side). PCR products were sequenced using Next-Generation Amplicon Sequencing, 
which resulted in ~30,000 – 90,000 reads per sample. Alignment to the wild-type 
reference sequence for each protein (based on the most common NCBI transcript 
sequence) confirmed the two allele edits identified using TA-cloning (shown in Figure 
3.2) and showed no indication of additional wild-type (Figure 3.14). Evidence of an 
additional edited allele sequence was absent or minimal (Table 3.5).  
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Figure 3.14. Next-Generation Amplicon Sequencing of knockout cell line mRNA 
supports ‘TA-cloning’ genotyping results but reveals high prevalence of alternate 
splicing. Displayed are graphical overviews of amplicon sequence alignment to 
wild-type sequence (most common isoform on based on NCBI AceView) indicating 
the percent of total sequencing reads for which each position on the amplicon is 
deleted, substituted or has an insertion. Visible CRISPR-mediated insertions and 
deletions (blue text) and prominent splice sites (‘SS’, black text) are indicated. 
Splice sites detected in the SLC25A38 and SLC25A40 genes have not been 
previously reported. 
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Table 3.5. Overview of most prevalent ‘other’ sequences detected with Next-Generation 
Amplicon Sequencing. This analysis was done to address the question of if there are 
additional alleles present. ‘Other’ sequences are defined as those which have a 
sequences varying form the wild-type sequence at the CRISPR target site. * indicates 
sequence deviation that is most likely due to splicing, as a region is removed that spans 
exactly to an exon start site. A38KO2 and A39KO1 are unlikely to represent an 
additional allele, given the low percent of representation and the absence of detection 
in ‘TA-cloning’ genotyping. More likely explanations for these sequences are described 
in the discussion. 
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There are a number of explanations for these ‘other’ sequences of minor 
representation in the A38 KO2 and A40 KO1, which are discussed below. However, 
sequence alignments revealed the presence of transcript variants for all genes. For 
A39, the 3 primary splice sites detected have been reported previously (NCBI). For 
A38 and A40 KO cell lines transcript variants that were detected have not been 
previously described or predicted (based on NCBI, AceView, Ensembl, and ASPicDB 
databases). These variants include complete exon skipping and removal of portions of 
predicted exons. 
For SLC25A38 KO1 the targeted exon can be skipped entirely but still results 
in a frame-shift (122bp). >99% of transcript reads indicate a frame-shift (overview of 
frame-shift analysis for all cell lines shown in Table 3.6). For SLC25A38 KO2 the 
targeted region can be skipped in two separate variants (skipping 91bp or 38bp). ~97% 
of detected sequences maintain a frame-shift, with a splice variant representing ~1.5% 
of reads resulting in an in-frame transcript (with 48bp being skipped). 
For SLC25A39, 3 splice variants are observed which do not overlap with the 
CRISPR target site. For KO1 ~97.5% of detected sequences maintain a frame-shift, 
with another sequence representing ~1.85% of reads that, combine with the dominant 
splice variant, results in an in-frame transcript. For KO2 the combination of splice 
variant 2, CRISPR mediated deletion and splice variant 3 cause the transcript to be in-
frame. This represents ~14% of transcript reads. 
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Table 3.6. Overview of in-frame sequence read percentage detected with Next-
Generation Amplicon Sequencing. 
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For SLC25A40, one splice variant is observed which does not overlap with the 
CRISPR target site. For KO1 the combination of the splice variant and one allele edit 
cause the transcript to be in-frame. This transcript represents ~80% of the reads. For 
KO2 all significantly represented reads maintain a frame-shift, with only ~1.5% of 
reads in-frame (likely PCR or sequencing artifact). 
Human SLC25A38, SLC25A39, SLC25A40 and SLC25A44 are successfully 
expressed in Lactococcus Lactis bacteria. SLC25A38, SLC25A39, SLC25A40 and 
SLC25A44 with C-terminal FLAG tags were inducibly expressed in Lactococcus 
Lactis bacteria, as shown by western blot (Figures 3.15A, B). Nisin was used to induce 
protein expression from the pnZ8048 plasmid containing the gene sequences. 
 Untargeted metabolite profiling of SLC25A38, SLC25A39, SLC25A40 and 
SLC25A44 (both FLAG and non-FLAG tagged) expressing Lactococcus Lactis 
shows metabolites with strongly increased abundance in specific bacterial lines, 
likely protein related peptides. Untargeted metabolite profiling was performed on 
SLC25A38, SLC25A39, SLC25A40 and SLC25A44 clonal knockout cell line and on 
the parental cell line as a control (n=8). 
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Figure 3.15. Western blots showing expression of SLC25A38, SLC25A39, 
SLC25A40 and SLC25A44 with C-terminal FLAG tags. A) Inducible 
expression of A40 and A44. + or – indicate presence or absence of the inducer 
nisin, respectively. B) A38 and A39 expression are also detectable, albeit at 
relatively lower levels. 
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Bacteria were grown from dilution of an overnight culture until induction at O.D. 
600nm of 0.6, followed by an additional 3 hours of proliferation and protein 
expression. For this experiment, cells were washed with a series of PBS and water 
washes with intermittent centrifugation to remove the wash media (initial extraction 
protocol). Untargeted profiling was done as described above. Unbiased data analysis 
was performed in an untargeted (unknown compound ID, data not shown) and targeted 
manner (using an in-house retention time and mass annotated database). Due to 
massively different metabotypes which would lead to hundreds of differentially 
abundant compounds if compared to control (which would be uninterpretable), groups 
were compared to all the others in order to highlight only the most significant 
differences that were unique to bacteria with a specific SLC25 transporter expression. 
This analysis highlighted a number of untargeted compounds that were greatly more 
abundant with expression of a given protein (these were shown to not be clonal, as the 
same results were found in both FLAG and non-FLAG tag protein expressing clones) 
(Figure 3.16). Many of these unknowns matched the predicted m/z of polypeptides 
and may be degradant peptides of the overexpressed protein. Most of these compounds 
were not detectable in the bacteria culture media, indicating that it was not being 
transported into the bacteria (i.e. not the expressed protein’s substrate). Coupled with 
these possibilities, concerns related to the extraction protocol (metabolite leakage due 
to extensive time spent in wash steps) led us to forgo follow-up on these compounds 
and to rather develop a superior extraction methodology and a more targeted analytical 
approach. 
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Figure 3.16. Examples of metabolites that were greatly increased in one of the 
protein expressing lines compared to the others. A) A coumpound with mass 441.27 
at retention time 7.5 min was very abundant in SLC25A44 expressing Lactococcus 
Lactis compared to all the other cell lines. B) A coumpound with mass 453.29 at 
retention time 23.04 min was very abundant in SLC25A40 expressing Lactococcus 
Lactis compared to all the other cell lines. 
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Most human SLC25A family carboxylate transporters are successfully expressed 
in Lactococcus Lactis bacteria. SLC25A7, 8, 9, 10, 11, 14, 21, 27, 30, 34, and 35 
with C-terminal FLAG tags were successfully inducibly expressed in Lactococcus 
Lactis bacteria, as shown by western blot (Figures 3.17 A, B). Nisin was used to 
induce protein expression from the pnZ8048 plasmid containing the gene sequences. 
Proteins were expressed with highly varying abundances. SLC25A10 showed a faint 
band on the western blot but a dot blot of the same samples indicates that the low 
detection may be due to a technical issue (e.g. inefficient transfer to the membrane) 
(Figure 3.17C). SLC25A35 shows significant degradation and is likely not a good 
candidate for study/expression in these bacteria. SLC25A1 shows no conspicuous 
expression, although the dot blot suggets very low expression. As the homologs of this 
protein from other species have been expressed before in this system, it may be 
possible with varying nisin concentration. In all, 10 out of 12 proteins were found to 
be clearly expressed without significant degradation. 
Transport assays with SLC25A11 expressing bacteria (with and without FLAG 
tag) fail to show increased 2-oxoglutarate transport with protein expression. 
Initial transport assays were attempted with unlabeled 2-oxoglutarate in order to get a 
sense for the proper conditions, such as concentration and time, and in order to 
confirm that the metabolite extraction protocol was effective. First, 2-oxoglutaric acid 
(200 µM) was assessed for transport during a 30 min interval using the assay 
described above. Both SLC25A11 overexpressing bacteria and empty vector control 
did not reveal significant transport over this time course (Figure 3.18A, B). 
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Figure 3.17. Protein expression of most of the SLC25A family carboxylate 
transporters. A) Western blot showing expression of SLC25A9, 14, 27, 30, 10. A1 may 
have a very faint band or may not be expressed. B) Western blot showing expression 
of SLC25A11, 34, 35, 7, 8 and 21. A35 shows significant degradation. C) Dot blot of 
the samples shown in B, indicating possible expression of A10 and A1. 
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Figure 3.18. SLC25A11-FLAG OE and empty vector Lactococcus Lactis 30 min 
time course transport assay. 2-oxoglutarate was used in a transportation assay at a 
concentration of 200 µM with A) SLC25A11 overexpressing Lactococcus Lactis and 
B) empty vector Lactococcus Lactis. No indication of transport was observed. 
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This may have been caused by an ineffective choice of substrate concentration, so an 
additional experiment was performed to test the potential impact of substrate 
concentration on uptake. Malate transport was also attempted, as SLC25A11 was 
reported to exchange malate for 2-oxoglutarate (and possibly other carboxylates). 
Although no concentration of either substrate showed clear evidence of SLC25A11-
selective transport, 2mM 2-oxoglutrate was markedly increased in 2/3 samples (Figure 
3.19A, B). Although this is now believed to have been protocol or compound related 
variation (error), this concentration was used for all future experiments. 
This concentration/time point was repeated, this time with an empty vector 
control to check for increased transport with SLC25A11 overexpression. A difference 
between the substrate treated and untreated groups was observed, but the data 
variation within groups was excessive (Figure 3.20). We reasoned that this may be due 
to substrate carry-over due to insufficient washing of the bacteria. To evaluate this 
possibility, an experiment was performed to assess the effect of repeated 3-sec wash 
steps on substrate detection levels. Toward this end, the bacteria were gently vortexed 
to break up clumps and aspirated along with the 1st wash (as opposed to before) to 
facilitate uniform distribution over the filter membrane. As shown in Figure 3.21, a 
single additional wash step was sufficient to remove unbound substrate and at least 4 
more wash steps did not lead to bacteria-associated substrate leakage. This protocol 
(including careful vortex and aspiration steps) was used to repeat the SLC25A11 
overexpression vs. empty vector control experiment. 2-oxoglutarate was increased in 
subtrate treated vs. untreated groups, suggesting uptake into the bacteria, but increased 
uptake with A11 expression was not clear (comparison of A11 2-OG group vs. empty 
vector 2-OG group) (Figure 3.22). 
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Figure 3.19. SLC25A11-FLAG OE Lactococcus Lactis substrate concentration test. 
Various concntrations of A) 2-oxoglutarate and B) malate were tested for transport in 
SLC25A11 overexpressing Lactococcus Lactis during a 30 min time interval. 2mM 2-
oxoglutarate showed the most promising results. 
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Figure 3.20. SLC25A11-FLAG OE and empty vector Lactococcus Lactis 30 min 
transport assay. 2-oxoglutarate was used in a transportation assay at a concentration 
of 2mM with SLC25A11 overexpressing Lactococcus Lactis and an empty vector 
control. Indication of transport with substrate vs. without was observed. However, 
significant data variation was also present. 
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Figure 3.21. Various numbers of 3 second washes were tested to determine the 
optimal number of washes to remove excess external substrate without internal 
substrate leakage. Any number of washes 2 or greater appear sufficient. No 
significant leakage was observed with up to 6 washes. 
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Figure 3.22. SLC25A11-FLAG OE and empty vector Lactococcus Lactis 30 min 
transport assay. 2-oxoglutarate was used in a transportat assay at a concentration of 
2 mM with SLC25A11 overexpressing Lactococcus Lactis and an empty vector 
control. Indication of transport with substrate vs. without was observed, but 
SLC25A11 mediated transport was not clear (comparison of A11 2-OG group vs. 
empty vector 2-OG group). 
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Now that the protocol was established and transport (at least endogenous) of 2-
oxoglutarate was indicated, experiments with heavy isotope labeled substrate, which 
has no background signal, were performed. The time frame was reduced, as possible 
transport saturation could cause the difference between overexpression and control to 
be masked. [6D]-2-oxoglutarate was transported at 5 min and 14 min time points 
(Figure 3.23). Although substrate was observed to be associated with bacteria 
(consistent with transport), no difference was seen between the groups. Surprisingly, 
no time-dependent difference was observed, possibly indicating rapid saturation. 
Because the addition of a FLAG-tag could potentially perturb transporter function, a 
follow-up experiment was performed using non-tagged SLC25A11 overexpressing 
bacteria and very brief time points (2min/5min) (Figure 3.24). At 2 min, SLC25A11 
overexpression trended towards increased [6D]-2-oxoglutarate abundance, but sample 
number was too low to be conclusive. Again, however, no increase was observed from 
2 min to 5 min. Therefore, the experiment was repeated with a 1 min time point and 
more samples per group. This experiment was also inconclusive, as data variation was 
once again too high (Figure 3.25). This level of variation seen in some experiements 
was only ever observed with 2-oxoglutarate and may indicate that this compound is, 
for unknown reasons, not a good candidate for this transport assay setup.  
Transport assays with FLAG tagged SLC25A21 expressing bacteria fail to show 
increased 2-oxoglutarate transport. SLC25A21 is an oxoadipate/oxoglutarate 
exchanger and was tested (with a FLAG tag) for its ability to increase 2-oxoglutarate 
transport compared to an empty vector control. As shown in Fig 23, SLC25A21 
expression was not associated with increased transport. 
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Figure 3.23. SLC25A11-FLAG OE and empty vector Lactococcus Lactis transport 
assay. [6D]-2-oxoglutarate was studied at a concentration of 2mM with SLC25A11 
overexpressing Lactococcus Lactis and an empty vector control at 5 min and 14 min 
time points. [6D]-2-oxoglutarate is clearly entering the cells, but no difference 
between groups and no increase from 5 min to 14 min were observed. 
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Figure 3.24. SLC25A11 OE and empty vector Lactococcus Lactis transport assay. 
6D 2-oxoglutarate was used in a transportation assay at a concentration of 2mM with 
SLC25A11 (no tag) overexpressing Lactococcus Lactis and an empty vector control 
at 2min and 5min time points. [6D]-2-oxoglutarate is clearly entering the cells, but 
no clear difference between groups was observed (although a possible increase with 
protein expression at 2 min). No increase from 2 min to 5 min was observed. 
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Figure 3.25. SLC25A11 OE and empty vector Lactococcus Lactis transport assay. 6D 
2-oxoglutarate was used in a transportation assay at a concentration of 2mM with 
SLC25A11 (no tag) overexpressing Lactococcus Lactis and an empty vector control 
at a 1min time point. [6D]-2-oxoglutarate is clearly entering the cells, but no clear 
difference between groups was observed. Again, significant data variation led to 
inconclusive results. 
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Transport assays with SLC25A38 expressing bacteria (with and without FLAG 
tag) fail to show increased glycine transport. SLC25A38 has been recognized as a 
glycine transporter and was also used in an attempt to show protein mediated transport 
in Lactococcus Lactis. Heavy isotope (13C labeled) glycine was used in the transport 
assay described above with both FLAG tagged (Figure 3.27A) and non-tagged (Figure 
3.27B) SLC25A38 overexpressing bacteria. Although endogenous transport was 
evident and replicate data were tight, no effect of SLC25A38 on glycine transport was 
observed. 
Transport assays with SLC25A40 expressing bacteria (with FLAG tag) fail to 
show increased glycine transport with protein expression. SLC25A40 is 
homologous to the SLC25A38 glycine transporter and showed robust protein 
expression in Lactococcus Lactis. Therefore, it was tested whether glycine may be a 
substrate for transport by SLC25A40 in Lactococcus Lactis. For this purpose, [13C]-
glycine was studied for uptake into SLC25A40-FLAG overexpressing bacteria (Figure 
3.28). Although endogenous transport was evident and replicate data very tight, no 
effect of transporter expression on relative uptake was observed. 
Transport assays with SLC25A8 expressing bacteria (without FLAG tag) fail to 
show increased aspartate transport with protein expression. SLC25A8 is 
recognized as an aspartate transporter and was also used in an attempt to demonstrate 
protein mediated transport in Lactococcus Lactis – notably, robust protein expression 
was observed (Figure 3.17B). Heavy isotope labeled aspartate (15N) was used in the 
transport assay described above with SLC25A8 (no tag) overexpressing bacteria. 
Although endogenous transport was clear and replicate data very tight, no effect of 
protein expression was observed (Figure 3.29).   
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Figure 3.26. SLC25A21-FLAG OE and empty vector Lactococcus Lactis 30 min time 
course transport assay. 2-oxoglutarate was used in a transportation assay at a 
concentration of 200 µM with SLC25A21 overexpressing Lactococcus Lactis and 
empty vector Lactococcus Lactis. Although endogenous transport was indicated, no 
indication of SLC25A21 transport was observed. 
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Figure 3.27. SLC25A38 OE and empty vector Lactococcus Lactis transport assays. 
13C glycine was used in a transport assay at a concentration of 2mM with A) 
SLC25A38-FLAG overexpressing Lactococcus Lactis and an empty vector control at 
2min, 6min and 18min time points and B) SLC25A38 (no tag) overexpressing 
Lactococcus Lactis and an empty vector control at 3min and 9min time points. Linear 
endogenous transport and highly reproducible data is observed, but there is no 
indication of SLC25A38 mediated transport. 
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Figure 3.28. SLC25A40-FLAG OE and empty vector Lactococcus Lactis transport 
assays. 13C glycine was used in a transportation assay at a concentration of 2mM 
with SLC25A40-FLAG overexpressing Lactococcus Lactis and an empty vector 
control at 5min and 14min time points. Linear endogenous transport and highly 
reproducible data is observed, but there is no indication of SLC25A40 mediated 
transport. 
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Figure 3.29. SLC25A8 OE and empty vector Lactococcus Lactis transport assays. 
15N aspartate was used in a transportation assay at a concentration of 2mM with 
SLC25A8 (no tag) overexpressing Lactococcus Lactis and an empty vector control at 
2min and 6min time points. Linear endogenous transport and highly reproducible 
data is observed, but there is no indication of SLC25A8 mediated transport. 
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DISCUSSION 
Initially, our primary goal was to identify the substrates transported by orphan 
mitochondrial transporters from the SLC25 family of proteins. Specifically, we focus 
on SLC25A39, SLC25A40 and SLC25A44, which have high homology to 
SLC25A38, a putative glycine transporter (Figure 3.1, from [Palmieri 2013]). Our 
hypothesis was that these transporters may transport glycine, glycine-like compounds, 
such as serine (SLC25A38 has been hypothesized to be a glycine/serine antiporter 
[Guernsey et al. 2009; Fernández-Murray et al. 2016]), and/or other amino acids. We 
included SLC25A38 in our study, which has not yet been fully characterized. 
We produced monoclonal homozygous knockout cell lines for each individual 
protein of interest in MDA-MB-468 triple negative breast cancer cells with the idea 
that the cells could then be probed for profound abnormalities in metabolism that 
could be traced back to the lost function of an SLC25-type transporter protein. Due to 
the lack of characterized western blot antibodies for these SLC25 transporter proteins, 
homozygous knockout was confirmed using a PCR-based screen for genome edits, 
followed by allele sequencing by TA cloning. Cell lines with a confirmed frameshift-
causing edit in both alleles were used for the experiments. 
In a first experiment, untargeted metabolite profiling was performed with one 
SLC25A38 KO cell line, one SLC25A40 KO cell line and the parental MDA-MB-468 
as the control cell line for each. Metabolic changes compared to control were found to 
be overall modest (fold change < 2) for both cell lines (Tables 3.1 and 3.3). 
 
 
  
200 
 
 
 
SLC25A38 
For the SLC25A38 KO cell line features possibly corresponding to 
acetylglycine (an acetic acid adduct), acetylleucine and acetylserine (based on mass 
and retention time matches to an in-house reference database) were among the most 
potentially relevant changes (Table 3.1). The relatively diminished level of 
acetylglycine (Figure 3.3) may be explained by reduced glycine import into the 
mitochondria, where it can be acetylated by the mitochondrial localized protein 
glycine-N-acyltransferase [Nandi et al. 1979]. The reduction in acetylglycine 
production could lead to diversion of acyl-CoA towards other products, including 
acetylleucine and acetylserine, explaining the increased abundances of these 
compounds. 
In attempt to reproduce these results, an experiment was performed using a 
second SLC25A38 KO cell line made with a different guide RNA (controlling for 
potential off-target CRISPR effects or clonal peculiarities). Acetylglycine abundance 
was less severely decreased in this follow-up experiment (1.3 fold; Figure 3.4). Taken 
together, these experiments suggest further validation of SLC25A38 as the glycine 
transporter. The most profound changes from both targeted and untargeted analyses of 
both experiments were compared, but the levels of no other compounds of interest 
were significantly changed in both cell lines (Tables 3.1 and 3.2). 
Worthy of note, sorbitol was increased significantly in the knockout cell lines 
for many of the mitochondrial proteins. This change may be a response to CRIPSR 
gene editing and we therefore did not further pursue it. However, it could also be a 
true metabolic perturbation due to the loss of the function of these transporters, which 
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would possibly suggest overlapping metabolism among these transporters, and could 
be worthy of further scrutiny. 
SLC25A40 
With regard to SLC25A40, as mentioned above, metabolic changes in the 
knockout compared to control were modest (fold change < 2; Table 3.3). One of the 
most significant changes was a reduction in betaine in the knockout cell line (1.73 fold 
change; Figure 3.5). Betaine’s identity was initially based on comparison to our in-
house database and then confirmed by MS/MS fragmentation followed by matching to 
the METLIN fragmentation database (Figure 3.6 and Figure 3.7). Betaine is produced 
exclusively in the mitochondria via a two-step enzymatic process from its precursor, 
choline. Importantly, betaine can be used in one carbon trafficking and thereby 
contribute to purine salvage [Ueland et al. 2015; Obeid 2013] as well as other one-
carbon donor fates. Therefore, we hypothesized that SLC25A40 could function as a 
choline transporter, with KO resulting in diminished choline import into the 
mitochondria, explaining the observed decrease in cell betaine. Notably, no 
mitochondria-specific choline transporter has yet been identified, although the plasma 
membrane choline transporter has been shown to also localize to the mitochondria 
[Michel, et al. 2009].  
Surprisingly, in a follow-up experiment the same cell line showed only a mild 
decrease in betaine (data not shown). However, confidence in the decreased betaine in 
the original SLC25A40 knockout cell line was restored in a choline tracing experiment. 
Indeed, we traced deuterated choline ([9D]-choline) supplied to the cells in the 
cell culture media to assess whether SLC25A40 KO cells do indeed exhibit a decrease 
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in choline-derived betaine (Figure 3.8B). Diminished [9D]-choline-derived betaine 
was confirmed at 1, 5 and 24 hrs. Importantly, total deuterated choline in cells was not 
different between the SLC25A40 KO and control cell lines, indicating that overall 
choline uptake from the media by both cell lines was indistinguishable (Figure 3.8D). 
Also, the abundance of extramitochondrial-produced deuterated choline-derived 
compounds, such as phosphocholine and phosphatidylcholines, were not different 
between the two cell lines, further indicating that the perturbation observed with 
regard to betaine could be due to reduced choline import into the mitochondria (Figure 
3.8F). 
In attempt to validate this conclusion, deuterated betaine uptake was quantified 
in four other knockout cell lines produced from the same guide RNA (two of these had 
only a single sequencing read, suggesting an identical edit on both alleles and a high 
likelihood of being a homozygous knockout). This was a first pass at validation before 
endeavoring to engineer knockout cell lines using an alternative guide RNA. Cell lines 
produced with the same guide RNA would be expected to show a similar phenotype if 
the observed metabolic changes observed were indeed due to the function of the 
knocked out transporter. Surprisingly, none of the other knockout cell lines had 
decreased betaine production compared to the control cell line, suggesting that the 
reduced betaine in the original cell line may be growth state-dependent, or a clone-
specific metabolic peculiarity that is unrelated to SLC25A40 function (Figure 3.9). 
SLC25A39 
We performed a similar experiment for SLC25A39, comparing metabolite 
abundances for an SLC25A39 knockout cell line to the control parental line. Here, 
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there were a few profound metabolite changes (>2 fold) in the knockout compared to 
control, such as compounds with tentative identifications of guanidinoacetic acid and 
CDP-choline, as well as unidentified features from untargeted analyses (Table 3.4 left 
side, Figure 3.10A). These changes were highly reproducible in this cell line in a 
repeat experiment (Table 3.4, Figure 3.10B), validating the reliability of the cell 
growth conditions and metabolite extraction protocol. In fact, guanidinoacetate was 
found to be severely depleted in this cell line in every follow-up experiment. 
Guanidinoacetate is produced from the precursors glycine and arginine by the 
mitochondrial protein arginine:glycine amidinotransferase [Humm et al. 1997], which 
led to the hypothesis that SLC25A39 could be an arginine or glycine transporter. 
However, similar to findings with SLC25A40, this metabolic perturbation was 
not observed in other SLC25A39 KO clonal cell lines produced with the same guide 
RNA, indicating again that reduced guanidinoacetate may be cell growth-state 
dependent or arise as a clonal specific peculiarity unrelated to the transporter (Figure 
3.11). In support of this interpretation, reinsertion of EGFP tagged SLC25A39 into the 
knockout cell line was unable to rescue this phenotype (Figure 3.12; Figure 3.13). 
SLC25A44 
We performed a similar experiment for SLC25A44, comparing metabolite 
abundances for an SLC25A44 knockout cell line to the control parental line. Here, 
there were also a few profoundly differentially abundant features (>2 fold) in the 
knockout compared to control in an untargeted analysis. These changes were highly 
reproducible in this cell line in a repeat experiment. However, the identity of these 
features could not be established by MS/MS analysis due to relatively low species 
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abundance and poor fragmentation spectra obtained. Considering the prevalence of 
what may be clonal peculiarities, based on our analysis of other SLC25 transporter 
knockout cell lines, the molecular identities of these species and relevance of their 
changing levels was not pursued further (data not shown). 
Suitability of knockout cell lines as a system for untargeted mitochondrial 
transporter studies 
In all, these experiments highlight a number of challenges and considerations 
for studying mitochondrial transporters in knockout eukaryotic cell lines. Apparent 
clone-specific metabolite abundances and inability to confirm findings were a major 
pitfall of this study. These could be caused by off-target CRISPR edits, genetic 
variation in the cancer cell line, epigenetic variation, or growth state-dependent 
metabolism. In the first possibility, the occurrence of off-target CRISPR-mediated 
genome edits in some knockout clones and not others could lead to metabolic variation 
that would explain the observed metabotypic difference. Although the possibility of 
CRISPR off target effects were known at the beginning of the study [Zhang et al. 
2015], the likelihood/prevalence of this affecting metabolism may not have been 
adequately appreciated.  
In terms of genetics or epigenetics, it is possible that there is a wide array of 
metabolite variation within a multi-clonal population of parental cell lines. This 
variation in metabolite abundances among clones would likely fall along a normal 
distribution for each metabolite. Conceivably, certain metabolites would have larger 
variation in abundance than others. Selecting one clone from among a population of 
clones and then performing metabolite profiling, surveying thousands of compounds, 
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would have a high likelihood of finding one or more metabolites for which that clone 
has an abundance that deviates markedly from average. 
In support of this possibility, Zong et al. showed genetic variation in a single 
cell selected from SW480 colon cancer cell line compared to the population average 
[Zong et al. 2012]. Specifically, they detected distinct copy number variation (CNV) 
and single nucleotide variation (SNV) in single cell genome sequencing. CNVs were 
detected in single cells selected from the population of SW480 cells obtained from 
American Type Culture Collection (ATCC). Importantly, for SNV they first expanded 
a single cell into a colony in order to ensure a single genetic origin and grew for 20 
generations before selecting 1 cell for comparison to the bulk. They estimate that 49 
mutation occurred during the 20 generations, indicating a mutation rate of 2.5 
nucleotides per generation (in addition to detectable copy number variation). This 
highlight the possibility of genetic variation among cultured cells, which could 
conceivably cause metabotypic variation. It also exemplifies that heterogeneity is 
present in human tumor cell lines, even when obtained from repositories. The authors 
estimate that SW480 cells have been cultured for at least 150 generations; the MDA-
MB-468 cell line used in the present study was established around the same time 
(1977) as the SW480 cell line and has likely undergone comparable expansion. 
Notably, these cell lines are established from a tumor bulk that is generally assumed to 
be syngeneic. However, clonal genome, genetic and phenotypic variation is well 
known within solid tumors and derived cell lines [Enger et al. 1986; Nistér et al. 1986; 
Meyer et al. 2015; Greaves et al. 2012; Marusyk et al. 2010; McGranahan et al. 2017; 
Hastings et al. 1983]. Other studies have also shown variation among individual cells 
from a cultured population, such as in the growth rate of T lymphoblastoid Molt3 
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clones selected from a population obtained from ATCC [Tomelleri at al. 2008] and in 
various phenotypes of MCF-7 breast cancer line clones [Baguley et al. 2011]. 
Famously, HeLa cell lines (from a single origin) have been shown to display marked 
heterogeneity across different labs even when cultured side-by-side [Frattini et al. 
2015; Liu et al. 2018]. Indeed, Stockholm et al. described the emergence of 
phenotypic heterogeneity in cultured, clonal mammalian cells as “a rule rather than 
exception” [Stockholm et al. 2007]. 
Furthermore, Xu et al. showed significant chromosomal variation in single cell 
clones selected from a parental MDA-MB-468 population, the same cell line used for 
this study [Xu et al. 2008]. In the karyotyping of 27 cells, they found a range 45-65 
chromosomes, including significant chromosomal aberrations. Importantly, these 
numbers varied from previous reports, which they interpreted as an indication of 
genomic instability in this cell line. Notably, the ATCC listing for MDA-MB-468 
recognizes the presence of karyotype variation among the population. Abdallah et al. 
show that cell lines exhibiting genomic instability can vary in a short time frame (1-2 
months) and emphasize that in these cases considering an average of a heterogeneous 
population can be misleading [Abdallah et al. 2013]. Conceivably, genomic instability 
and the common occurrence of chromosomal variation in clones from MDA-MB-468 
could lead to cell-specific metabotypes. 
The fact that MDA-MB-468 is aneuploid provides another possible 
explanation for clonal variation. Initially, we assume that there would be two copies of 
each gene of interest and therefore performed TA cloning until 2 allele sequences were 
confirmed. However, should the gene be present additional times in certain clones of 
this cell line, there could be remaining yet-undetected wild-type or edited but in-frame 
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alleles of the protein in some cell lines. Should one cell line be a true knockout and the 
comparison lines contain a functional allele, metabolic differences would be expected. 
We therefore explored this possibility using Next-Generation Amplicon 
Sequencing of a PCR amplification of cDNA that is reverse transcribed from cell line-
derived RNA (to obtain mRNA sequences). This sequencing revealed that for all cell 
lines there were no or minimal sequencing reads that could be considered a third allele 
(Table 3.5). The very minor representation of sequence deviations in SLC25A40 KO 
cell lines are most likely due to splicing, as in each case a region is removed that spans 
exactly to an exon start site. The other sequences in SLC25A38 KO2 and SLC25A39 
KO1 are unlikely to be due to a third allele, considering the very low representation in 
mRNA sequencing reads and the lack of detection by TA cloning. There are a number 
of other explanations for these findings, such as RNA splicing, PCR or sequencing 
artifacts, minor contamination with another cell line (clonal selection error) and 
continued CRISPR-mediated cutting during clonal colony growth. The latter 
possibility is supported by the fact that these two cell lines are the only two where a 
frame-shift edit is a 1bp insertion. This could leave sufficient homology to the original 
gRNA recognition site for a second editing event if Cas9 was still expressed during 
growth of the clonal colonies. This would cause a minor subpopulation of cells in that 
colony to have the re-edited allele. 
More importantly, this mRNA sequencing revealed prevalent mRNA splicing 
as an unexpected consideration. For each gene, alternative splice sites were identified 
(Figure 3.14). With the exception of those for SLC25A39, these splice sites have not 
been previously reported. In the case of SLC25A38, both cut sites sit on top of 
possible splice regions. However, in this case, these splice variants overwhelmingly 
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result in out-of-frame sequences, which should not affect the validity of the knockout. 
However, in two cell lines (SLC25A39 KO2 and SLC25A40 KO1), the combination 
of the splice variants and the CRISPR edit results in in-frame sequences that are 
significantly represented in the mRNA (Table 3.6). As these could possibly lead to 
functional (albeit edited) transporter, the validity of these two knockout cell lines are 
questionable. 
In the case of SLC25A39, this prospect of functional protein in KO2 is a 
possible explanation for the irreproducibility of results seen in SLC25A39 KO1 
(mRNA from KO3 could potentially be sequenced to further assess this possibility). 
For SLC25A40, if it is assumed that KO1 has functional protein, the metabolic 
variation from the parental population is a concern (as the observed decrease in 
betaine would not be due to protein knockout). On the other hand, if this KO clone 
does not have functional protein, the irreproducibility in KO2 remains an issue. 
Additionally, the metabolic variation observed in the case of the SLC25A38 KO cell 
lines is not explained by the sequencing results, as sequence data indicates both cell 
lines to be knockouts. Therefore, in the end, the issue of clonal metabolic variation 
unrelated to the function of the protein of interest persists. 
A possible solution to the issue of comparing a single cell-derived cell line to 
the original population average would be to select a single clone to expand before 
producing knockout cell lines. This strategy would allow for a comparison of a 
knockout clone to a syngeneic control rather than to a population average of clonal 
variants. This would ensure that the knockout and control cell line would be as similar 
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as possible (fewer passages between splitting the lineages), providing for a ‘cleaner’ 
comparison. 
Another possible explanation for the differences detected between clonal cell 
lines stems from differences in compensation for the loss of transporter function. 
Conceivably, knockout of very important proteins would force cells to compensate 
metabolically for the loss in order to live, likely by altering the expression of other 
proteins [El-Brolosy et al. 2017]. Should there be multiple compensatory mechanisms 
that enable survival of a given SLC25 knockout cell line, one would anticipate the 
selection of multiple clonal variants with marked differences in metabolite 
abundances. Regardless of the cause, this study highlights that two independently 
produced CRISPR knockout cell lines should always be analyzed initially to avoid 
being misled by knockout-independent phenotypic differences.  
The goal of studying knockout cell lines was to observe profound metabolite 
changes due to the knockout that could be traced back to aberrations in mitochondrial 
transporter function. Part of the problem in achieving this goal was that, for the most 
part, metabolite changes in the knockout cell lines were small. This leads to low 
confidence in the metabolite changes being due to loss of the transporter protein and 
difficulty in selecting high-confidence species to focus on for follow-up experiments. 
Conceivably, the SLC25 transporter proteins studied may be non-essential due to 
functional redundancy, compensation, or cell type-specific metabolism that make a 
given knockout cell lines a poor system for de-orphanizing mitochondrial transporters. 
Notably, the selection of study cell type could be a key issue, as certain transporters 
can be critically important in some cell types, while completely dispensable in others. 
As an example, betaine is an important osmoregulator kidney cells [Grunewald et al. 
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1995], but may have little role in the breast cancer epithelial cells, such as the MDA-
MB-468 line studied herein.  Therefore, a choline mitochondrial transporter knockout 
would predictably have more profound metabolic effects in kidney cells than breast 
cancer cells. Unfortunately, when studying transporters of unknown function it is 
impossible to know which cell type the transporter is most functionally relevant to. An 
educated guess should be made based on information known about homologous 
transporters or the suspected class of the substrate. 
Another challenge highlighted by this study is that of investigating the function 
of mitochondrial proteins within the context of whole cell metabolism. This challenge 
is compounded by the generic problem of studying a protein with unknown function in 
an untargeted manner. Although untargeted metabolite profiling can be a powerful 
tool, the combination of so many unknowns in a complex system (i.e., global cellular 
metabolism) will predictably lead to difficult-to-interpret results. The issue with 
studying mitochondrial transporters in a whole cell context is that even if profound 
metabolic changes are observed, they could be significantly downstream metabolic 
effects that would be very difficult to trace to a specific substrate for a given SLC25 
transporter. Instead, studying short-term transport in isolated mitochondria from 
knockout cells could be considered as an alternative approach that affords more 
readily interpretable results.  However, this strategy would engender new 
methodological challenges for rapid isolation of large numbers of functional 
mitochondria or mitochondria that retain their metabolite profiles despite extensive 
purification procedures. 
As previously mentioned, during the course of this study SFXN1 was reported 
to serve as a mitochondrial serine transporter [Kory et al. 2018]. Importantly, this 
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report recognized the possibility of functional redundancy and there may indeed be an 
SLC25 family transporter involved in serine transport. In this paper, the investigators 
took a more tailored approach towards identifying the serine transporter. Assuming 
that the serine transporter would display synthetic lethality in the absence of serine 
hydroxymethyl transfrase-1 (SHMT1), the authors performed a CRISPR knockout 
screen targeting 3000 proteins in SHMT1 knockout cells to identify candidate 
proteins. Additionally, in order to reduce possible confounding effects of redundant 
mechanisms, they depleted serine from the media, thereby sensitizing cells to the 
knockout of a potential serine transporter. This strategic approach led to successful 
identification of a serine transporter and reveals the benefit of a more targeted 
knowledge-driven discovery approach for identifying transport proteins with a specific 
function. 
Lactococcus Lactis transporter expression studies 
 Due to the challenges with eukaryotic cell studies, we sought a simpler and 
more confident model system for establishment of SLC25-type transporter functions. 
In this regard, we became aware that the bacteria Lactococcus Lactis has previously 
been found to be a suitable host for the inducible expression of functional membrane 
proteins. In fact, functional mitochondrial transporters have been expressed a number 
of times in these bacteria, with very little degradation and no detectable inclusion body 
formation. Monné et al. showed expression of 11 functional yeast SLC25 family 
mitochondrial transporters [Monné et el. 2005]. Included in this study were the 
homologs of SLC25A1, SLC25A10 and SLC2511, three of the carboxylate 
transporters, which were demonstrated to be functional in proteoliposome-based 
transport studies. Human SLC25A10 and SLC25A11 have also been previously 
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expressed in Lactoccoccus Lactis and were functional in proteoliposomes [Booty et al. 
2015]. Due to the fact that bacteria do not have mitochondria, these transporters are 
localized to the bacterial outer cell membrane. This membrane protein localization 
obviates the challenge of studying mitochondrial metabolism within the context of an 
intact eukaryotic cell. 
Although transport assays using Lactococcus Lactis-expressed membrane 
proteins have previously been done with isolated proteins resuspended in artificial 
liposomes, a number of reports have successfully shown transport into intact bacteria 
cells. Most notably, the mouse mitochondrial pyruvate carrier (MPC) complex (co-
expression of MPC1 and MPC2 proteins) [Herzig et al. 2012] and the human 
mitochondrial ADP/ATP carrier (SLC25A4) were characterized in intact L. Lactis 
transport studies [Mifsud et al. 2013]. Similarly, transport assays with intact bacteria 
were also successfully used to study the riboflavin transport protein (RibU) [Burgess 
et al. 2006], the Arabidopsis ATP/ADP translocator (AtAATP1) [Frelet-Barrand], the 
L. Lactis di- and tripeptide transport protein (DtpT) [Hagting et al. 1994], sterol 
transport by the Human Breast Cancer Protein (BRCP) [Janvilisri et al. 2003], a yeast 
mitochondrial ATP/ADP carrier (AAC3), the Neocallimastix hydrogenosomal 
ADP/ATP carrier (AAChyd) [Kunji et al. 2003], the Streptococcus Thermophilus 
lactose transporter (LacS- ΔIIA) and L. Lactis branched-chain amino acid permease 
(BcaP) [Linares et al. 2010]. Due to the simplicity of this system, and the conspicuous 
advantages it affords for study of mitochondrial transporters, we set out to use this 
model system in combination with mass spectrometry as a novel platform to assess 
function for the SLC25A family of mitochondrial transporters. 
  
213 
 
 
 
Initially, Lactococcus Lactis were engineered to express a pNZ8048 plasmid 
that encodes SLC25A38, SLC25A39, SLC25A40 or SLC25A44. Later, bacterial lines 
containing FLAG-tagged version of these proteins were also produced in to facilitate 
the detection of nisin-induced transporter expression. Expression of all four proteins 
were detected by anti-FLAG western blot analysis. Whereas, SLC25A40 and 
SLC25A44 showed robust expression, levels of SLC25A38 and SLC25A39 were 
relatively lower (Figure 3.15). An untargeted metabolite profiling experiment was 
performed on bacterial metabolite extracts collected after 3 hours of SLC25 protein 
expression of each of the above proteins (and an empty vector control). These cell 
lines displayed profoundly different metabotypes and generally appeared to fall into 
two groups. Surprisingly, this indicated that general metabolism for each cell line was 
distinct, possibly due to cell density (induction of protein expression can increase or 
decrease bacterial growth rate, leading to different densities/metabolic states). This 
meant that in comparison to the control cell line there could be hundreds of 
differentially-abundant metabolites for each protein overexpression line, challenging 
the interpretation of SLC25 cargo function. Therefore, in order to identify the most 
profound changes that were unique to each cell line, and therefore more likely due to 
transporter function, the metabolite abundances of each cell line were compared to the 
aggregate of all the others as reference “control” group. This indeed identified a 
number of untargeted features with extremely increased abundance in certain 
transporter-expressing cell lines (Figure 3.16). In experiments performed using both 
FLAG-tagged and non-tagged SLC25 transporter cell lines, identical features were 
differentially abundant, indicating that observed changes were indeed related to 
transporter protein expression. These features could indicate compounds that are 
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transported by the overexpressed protein, but may alternatively arise as peptide 
degradation products of the overexpressed protein. In support of the latter possibility, 
many of the m/z values for differentially-expressed features were found to match 
values predicted for polypeptides. Also, metabolite profiling of culture media in which 
these transporter expressing lines were grown indicated no change for these features 
(for the few that were detectable in the media) and many were not detectable in the 
media. This supports the possibility that the differentially-expressed features were not 
metabolites being transported, but rather other species that arose from SLC25 
overexpression (such as peptides). 
Moving forward, in order to avoid these confounding issues involved with 
studying uncharacterized transporters with untargeted profiling, we decided to take a 
more targeted approach. Here, in addition to the above transporters, we set our sights 
on the transporter of 2-hydroxyglutarate, a recognized cancer-driving metabolite 
(oncometabolite) produced from 2-oxoglutarate by several alternative enzymes [Dang 
et al. 2017; Ye et al. 2018]. Notably, 2-hydroxyglutarate is often synthesized in the 
cytosol and must be transported into mitochondria for metabolism, but the cognate 
mitochondrial transporter has not been identified [Engqvist et al. 2014]. Based on 
homology, there are 12 SLC25 family transporters that have been shown to or are 
likely to transport carboxylic acids (Figure 3.1, from [Palmieri 2013]). We 
hypothesized that one or more of these 12 transporters conducts 2-hydroxyglutarate. 
Gene fragments for each of these SLC25 proteins were codon optimized for 
Lactococcus Lactis expression and bacterial cell lines were produced for FLAG-
tagged versions of these transporter. Western blots showed successful protein 
expression for at least ten out of the twelve transporters (Figure 3.17). 
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Due to the fact that the previously employed extraction protocol required 
extensive wash time in phosphate-buffered saline (PBS) and water, an experimental 
approach was developed for more rapid extraction followed by targeted LC/MS-based 
analysis. 
In terms of experiment design, cells lines were grown in larger quantities for 
protein induction. Bacteria were then normalized to culture density, collected by 
centrifugation, washed, resuspended in HEPES buffer and split into multiple samples. 
The metabolite of interest would then be added to replicate bacterial aliquots and 
incubated for the desired time at 30°C, followed by cell harvesting and metabolite 
extraction.  After the desired incubation time, bacteria were simultaneously harvested 
on glass fiber filter paper and rapidly washed using a Brandel M-24T cell harvester. 
This harvesting methodology has traditionally been used for radiolabel-based studies. 
The goal for this approach was to avoid metabolite leakage during the bacterial wash 
steps, followed by bead-beating of bacteria on filter paper for metabolite extraction 
and analysis. Should this experiment design and metabolite extract protocol suffice for 
transport assays, this would provide a novel approach to study small molecule 
transport in a bacterial model system. As opposed to radioactivity based assays, 
LC/MS-based approach used would allow the possibility of simultaneously screening 
a multitude of compounds for transport. 
To establish this system for studying metabolite transport in Lactococcus 
Lactis, positive control experiments were attempted using transporters with known 
cargo, including: SLC25A11 (2-oxoglutarate transporter), SLC25A21 (2-oxoglutarate 
transporter), SLC25A38 (glycine transporter) and SLC25A8 (aspartate transporter). 
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SLC25A11 is an 2-oxoglutarate/malate antiporter, and due to the structural 
similarity between 2-oxoglutarate and 2-hydroxyglutarate, it was a candidate for 2-
hydroxyglutarate transport. In a first experiment, the time course of 2-oxoglutarate 
uptake was assessed using 200 µM 2-oxoglutarate added to the resuspended bacterial 
aliquots – an empty vector time course was performed concurrently as a negative 
control. Under these conditions, no evidence of 2-oxoglutarate transport was detected 
(Figure 3.18). To determine if there is an optimal concentration to detect transport, we 
did a follow up experiment at a 30 min time point where we screened a range of 2-
oxoglutarate concentrations for an indication of transport (2 µM, 20 µM, 200 µM, and 
2 mM). Various concentrations of malate were also tested for potential transport (20 
µM, 200 µM, and 2 mM). Although the results were not conclusive, there was an 
indication of 2-oxoglutarate transport when studied at its highest concentration (i.e., 2 
mM; Figure 3.19). Although this was later assumed to be due to washing inefficiency, 
2 mM substrate was used as concentration for all following experiments. 
2mM 2-oxoglutarate was tested again at a 30min time point with more 
replicates and a control cell line. The samples with added 2-oxoglutarate once again 
showed large variation, suggesting a potential issue with washing away the external 2-
oxoglutarate (Figure 3.20). Therefore, we tested using the effects of up to six 3-second 
washes on levels of quantified 2-oxoglutarate, potentially informing on either under-
washing (i.e., unincorporated metabolite) or over-washing (i.e., metabolite leakage). 
The findings suggested that 2 washes were sufficient, and that extensive washing did 
not cause significant additional substrate loss (Figure 3.21). Four washes were used in 
subsequent experiments. 
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The previous experiment with 2-oxoglutarate wash repeated with more careful 
attention to vortexing bacteria during wash steps (to break up clumps), vortexing after 
metabolite addition (to ensure adequate mixing), allowing cell harvester probes to only 
minimally submerge during washing (to avoid leakage from the probes during 
washing). Also, ice cold water was used for washes. Results indicated that 2-
oxoglutarate was indeed being transported into the bacteria, despite a lack of clear 
evidence that SLC25A11-FLAG overexpressing bacteria had increased transport 
(Figure 3.22). The same experiment done with SLC25A21-FLAG overexpressing 
bacteria showed no increased transport with protein expression (Figure 3.26). 
In these preliminary experiments, unlabeled 2-oxoglutarate was used. Ideally, 
heavy-isotope labeled substrate could be used to better differentiate transported 2-
oxoglutarate from endogenous sources of 2-oxoglutarate. Therefore, transport assays 
were done using deuterated [6D]-2-oxoglutarate. As a standard, this compound is 
primarily detected as [4D]-2-oxoglutarate due to the rapid exchange of two deuterium 
atoms. However, during the extraction and drying process, additional deuterium atoms 
can apparently be exchanged resulting in detection of both [2D] and [3D] forms of 2-
oxoglutarate. In general, [4D] and [3D] were the most abundant forms and their 
abundance generally follows the same pattern between the samples. Although 
transport of labeled 2-oxoglutarate was detectably present in the bacteria, at 5min and 
14min time points no differences was detected between SLC25AA11-FLAG 
overexpression bacteria and empty vector bacteria (Figure 3.23). Interestingly, no 
difference was observed between the time points, possibly indicating that transport 
reached steady-state saturation. 
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Similar experiments were attempted using SLC25A38-FLAG and SLC25A40-
FLAG overexpressing bacteria, studying the potential for uptake of [2-13C]-glycine. 
Note that SLC25A40 was tested for glycine transport because it is homologous to 
SLC25A38 and additionally exhibits far more robust expression in Lactococcus 
Lactis. These studies revealed no overexpression mediated transport by either SLC25 
carrier protein (Figure 3.27A, Figure 3.28). However, tight data and a linear increase 
in [2-13C]-glycine abundance validated the robustness of the extraction methodology 
and indicated that appropriate time points were being used (i.e. transport was not 
saturated), allowing detection of potential differences in glycine transport rate. 
Until this point, C-terminus FLAG tagged proteins were being expressed to 
enable convenient detection of transporter protein expression. However, the addition 
of a tag sequence could affect protein function or localization, contributing to the 
observed lack of expressed protein function. Therefore, we additionally engineered 
Lactococcus Lactis bacterial lines to express non-tagged forms of SLC25A11, 
SLC25A38 and SLC25A8, with the assumption that the removal of the 8 amino acid 
tag on the C-terminus would not detrimentally affect protein expression. SLC25A8 
was also included as it displayed robust protein expression by western blot and was 
shown to transport aspartate [Vozza et al. 2014], which is readily available as a heavy 
isotope-labelled species. 
In a first experiment with the SLC25A11 overexpressing bacterial line, there 
was a trend of increased [6D]-2-oxoglutarate transport at 2 min, although there were 
not enough samples per group to be convincing (Figure 3.24). Once again, no increase 
in 2-oxoglutarate was observed between 2 min and 5 min, possibly indicating rapid 
saturation of transport. Therefore, the experiment was repeated with a 1 min time point 
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and more replicates. However, this experiment was inconclusive, as there was 
seemingly samples that did not efficiently wash and the other samples showed wide 
variation (Figure 3.25). 
Transport assays with SLC25A38 and SLC25A8 overexpressing bacteria and 
glycine and aspartate, respectively, were performed. Once again, no protein function 
was detected although linear import and highly reliable replicates were observed in 
both cases (Figure 3.27B; Figure 3.29). 
In the end, Lactococcus Lactis seems to be a suitable system for the expression 
of many mitochondrial transporters, although it may not be suitable for intact bacteria 
functional assays. Expression of 11/12 carboxylate or UCP and 4/4 glycine-related 
SLC25 family transporters were detectable, albeit with varying levels of expression. 
Protein expression could likely be increased for some of the transporters by varying 
the concentration of the inducer, nisin. Also, low protein abundance may not be an 
issue for studying the proteins, depending on the assay sensitivity (protein 
transportation rate compared to noise). 
A transport assay protocol, including simultaneous, rapid, filter-based wash, 
followed by metabolite extraction for mass spectrometry was established. This assay 
was found to be reliable (despite the need to quickly normalize based on cell culture 
density, to remove salts and impurities for mass spectrometry and to extract 
metabolites from bacteria imbedded in a glass-fiber filter), as exemplified by the 
glycine and aspartate transport experiments, where replicates were tight, even across 
different cell lines, and linearly time-dependent. Of course, a high level of endogenous 
transport may mean that these compounds are not good candidates for study in these 
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bacteria. However, sufficient exogenous protein activity could possibly overcome this 
issue. 
2-oxoglutarate at times displayed a puzzling combination of compound-
specific highly variant data without evidence of time-dependent transport. Although 
this was initially taken to mean rapid saturation of transport, it may also indicate that 
2-oxoglutarate transport into the cells was not being observed at all. In this case, 
detected deuterated 2-oxglutarate would be a background signal. It unclear where this 
would come from, as the water washes seem to be sufficient and there is no 
background in samples not treated with deuterated 2-oxoglutarate. However, support 
for the view that no transport was being observed comes from Monné et el., where 
no/low background for 2-oxoglutarate was observed in proteoliposomes prepared from 
membrane isolates of control Lactoccous Lactis (which should retain endogenous 
transporters) [Monné et el. 2005]. 
In any case, expressed protein-mediated transport was, unfortunately, not 
detected, which may indicate that these transporters are not suitable for study in intact 
Lactococcus Lactis. There could be a number of explanations, such as insufficient 
abundance of internal substrates for antiport (seemingly unlikely due to detection of 
endogenous transport), improper transport conditions (e.g. pH, substrate concentration, 
membrane potential) insufficient protein abundance (e.g. SLC25A38), incorrect 
protein localization, or an unsuitable membrane lipid composition. This suggests that 
functional assessment of SLC25 transporters in reconstituted proteoliposomes, rather 
than intact bacteria, may be unavoidable. Although this would add significantly to 
assay complexity and diminish throughput, it could still lead to significant discovery 
and would be a worthwhile next step. In this regard, human SLC25A10 and 
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SLC25A11 have already been shown to be functional in proteoliposome studies. If the 
isolation and wash protocol described above can be suitably adapted to 
proteoliposomes, mass spectrometry centered studies may be more effectively used to 
characterize SLC25 mitochondrial transporters expressed in Lactococcus Lactis. 
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NEXT STEPS 
 
Chapter 1 
 The endocannabinoid system is an integral signaling system in mammals and 
contributes to a wide array of physiological and pathological topics, such as learning, 
memory, metabolism and hunger, depression, anxiety and drug addiction. Further 
research into the characterization of this important group of receptors and related 
ligands will shed light on the various roles of the endocannabinoid system and may 
allow the biomedical research community to take advantage of it for therapeutic gain. 
In our research, we showed that the endocannabinoid system is important in the acute 
metabolic response to alcohol withdrawal in mice. Future experiments to confirm 
results in human studies are warranted and further mouse-centered studies could focus 
on endocannabinoid fluctuations over the entire addiction time course (before, during 
and after alcohol addiction), as well as the mechanisms of potential alcohol-abuse 
therapeutics in relation to the endocannabinoid system. Further metabolic 
characterization of the endocannabinoid system in alcohol dependence and withdrawal 
using mass spectrometry-based metabolomics could provide mechanistic insights into 
addiction and withdrawal, and may be useful in developing novel therapies. Our 
research could also be expanded to survey endocannabinoid levels in response to use 
of and withdrawal from other drugs of addiction. Additionally, the endocannabinoid 
system is known to have an important actions in the periphery, in addition to the brain 
(e.g. immune cell function). Mass spectrometry-based studies of other cannabinoid-
regulated tissues would provide a more comprehensive understanding of the dynamics 
of cannabinoid receptor signaling in genetic mouse models and diseases. Other areas 
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of endocannabinoid research would benefit from the application of metabolite 
profiling to assist interpretation of behavioral data at a more granular, metabolic level, 
such as studies focused on the common human C385A fatty acid amide hydrolase 
polymorphism known to be related to stress and alcohol abuse tendency, the effects of 
cannabis on the endocannabinoid system or the dynamics of the endocannabinoid 
system during development. These topics could all be studied using the metabolomics 
methods discussed in our work. 
Chapter 2 
 Amyotrophic lateral sclerosis remains a poorly understood and devastating 
disease. Further metabolism-centered studies are warranted in attempt to gain insight 
into the molecular mechanisms of this disease and its apparent variants/subtypes. We 
showed that metabolic subgroups can be identified among sALS patients, specifically 
revealing the sALS-1 subgroup. Future research should focus on the continued 
characterization of sALS-1 patients, seeking to further validate our results in a 
separate cohort, using metabolomics to probe the mechanisms of disease in patient-
derived fibroblasts. These experiments will likely include surveying the cell lines in 
stress conditions for differential response in the sALS-1 subgroup, which could help in 
clarifying the source(s) of the metabolic perturbations. Metabolite profiling and stable 
isotope tracing would shed light on the metabolic effects causing the observed 
phenotype. Also, motor neurons could be produced from the patient fibroblasts using 
induced pluripotent stem cell technology and would provide the most disease-relevant 
system for metabolic characterization of the subgroup. This technology could also be 
used to determine if the causes of the metabotype are genetic or epigenetic by 
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reprogramming the motor neurons back into fibroblasts, as epigenetic markers are 
wiped during the conversion process. 
Generally, our work indicates that larger metabolite profiling studies are 
warranted to pursue other sALS subgroups. Importantly, machine learning-based 
subgrouping endeavors gain significant power with increased sample size. A larger, 
collaborative metabolic characterization of thousands of sALS patient-derived samples 
would likely reveal additional, less common subgroups exhibiting a shared 
metabotype. 
Chapter 3 
 Further work is needed to establish a system/methodology for the reliable 
characterization of SLC25 family mitochondrial transporters. In regard to the existing 
MDA-MB-468 human breast cancer knockout cell lines, cell culture scenarios could 
be screened to identify conditions in which the missing transporter becomes more 
important for cell function, predictably exacerbating metabolic abnormalities 
associated with the knockout metabotype. These conditions may be selected based on 
hypothesized transport cargo, such as testing for auxotrophic growth-dependence on 
the presence of serine and/or glycine in culture medium when trying to identify a 
suspected serine transporter. Ideally, a growth, cell morphology or other noticeable 
phenotype would be observed in knockout cells, compared to control, which would 
allow for rapid identification of conditions and pathways worth studying with a more 
focused metabolic profiling effort. This is an example of an approach to screen for 
protein knockout-related phenotypes or pathways of interest that could then be 
followed up with using metabolomics. These sorts of preliminary screen-type 
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experiments could help focus the study and avoid the confusion and misdirection that 
can come from untargeted metabolomics when used as a first approach. Another more 
focused discovery approach may include a CRISPR knockout screen specifically 
designed to identify transporter candidates for a specific compound, as was done in 
studies that identified SFXN1 as a serine transporter.  In any case, any further studies 
using knockout cell lines should include a second knockout cell line produced using a 
different guide RNA and a compensated knockout (reinsertion) cell line from the 
beginning. 
 The study of mitochondria isolated from these knockout cell lines could also 
be considered to remove the issue of studying mitochondrial metabolism within the 
background of cytosolic metabolites. However, this introduces significant 
consideration and would require careful protocol establishment and validation. There 
are two likely approaches to studying isolated mitochondria. The first would be to 
endeavor to study the endogenous metabolites present in the mitochondria. Here, 
mitochondria would have to isolated and washes rapidly to avoid leakage of 
metabolites of interest. The applicability of this approach would likely be metabolite 
dependent, as incubation times of at least 10 minutes (most protocols without 
specialized cell lines take more than 1 hour) in wash buffer are currently unavoidable, 
which could lead to metabolite leakage or continued metabolism. The second 
approach would be to isolate functional mitochondria and study metabolism in 
isolation. These could include either simple substrate transport assays or studying the 
small molecule content of mitochondria after a given period of time of active 
metabolism in a complex milieu of metabolic substrates. Again, a rapid wash protocol 
would have to be established (the one developed for L. Lactis studies could be 
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considered). Regardless of the approach, isolated mitochondria experiments are 
probably more amenable to targeted or semi-targeted experiments, as replicates will 
generally limited and the sensitive, specialized process will likely lead to more 
replicate data variation than cell metabolite extract replicates. 
 The production of new knockout cell lines in a different parental cell line 
should be considered. As discussed above, the MDA-MB-468 cell line may be 
genetically unstable and may exhibit clonal metabolic variation, which can be a 
confounding factor in this knockout cell line-based approach and may make it a poor 
choice of experimental system. Selection of a more stable cell type could mitigate 
some of these concerns. The detected prevalence of unreported splice variants 
suggests that a parental cell line’s mRNA should be sequenced before pursuing a 
knockout to check for cell line-specific splice variants that could confound knockout 
attempts. I would also recommend that clonal selection from the parental population 
before attempting knockout to establish the most homogenous and comparable control 
cell line possible. Other human cell line-based approaches could also be considered, 
such as the use of inducible hairpin knockdown cell lines or studying CRISPR 
knockout in a polyclonal population-based approach. 
 With regard to Lactococcus Lactis bacteria protein expression protocol, further 
work should focus on determining if there are conditions where intact bacteria could 
be used to generally characterize SLC25 family transporters. Numerous changes can 
be considered, such as attempting to increase protein expression (e.g. by increasing 
nisin concentration), varying pH, “preloading” bacteria with antiported substrate and 
de-energizing (with 2-deoxyglucose) and energizing bacteria (with glucose). Other 
carboxylate transport proteins could be tested for successful positive control transport, 
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such as the mitochondrial citrate transporter SLC25A1. Use of a transporter that has 
previously been shown to be functional in intact bacteria transport experiments, such 
as the human mitochondrial ADP/ATP carrier (SLC25A4), could be useful in 
establishing the validity of the protocol before troubleshooting proteins which have 
not previously been shown to be functional in whole L. Lactis. 
 Should intact bacteria experiments continue to fail to show overexpressed 
protein-mediated transport, the protocol should be adapted to reconstituted 
proteoliposome-based studies. Once again, these studies should first use transporters 
that have previously been shown to be active in identical experiments (albeit with 
radiolabeled substrates), such as human SLC25A10 or SLC25A11, as positive controls 
to establish the validity of the protocol. 
